ANNUAL PROGRESS REPORT

FY-92

VOLUME I

DEPARTMENT OF CLINICAL INVESTIGATION
WALTER REED ARMY MEDICAL CENTER
WASHINGTON, DC 20307-5001

CLINICAL INVESTIGATION PROGRAM
RCS MED-300(RI)
This report identifies approved clinical research activities conducted at Walter Reed Army Medical Center through protocols approved by the Clinical Investigation Committee, the Human Use Committee/Institutional Review Board, and/or the Animal Use Committee, as appropriate. This report includes a Detail Summary Sheet outlining the progress of each protocol during Fiscal Year 92. Also included is a list of all known presentations and publications related to approved studies, as well as those not related to approved clinical investigation protocols. All research was conducted under the provisions of AR 40-38 (Clinical Investigation Program), AR 40-7 (Use of Investigational Drugs in Humans and the Use of Schedule I Controlled Drug Substances), AR 70-25 (Use of Volunteers as Subjects of Research), HSC Reg 40-23 (Management of Clinical Investigations, Protocols, and Reports), and AR 70-18 (The Use of Animals in DOD Programs).
The Annual Progress Report (APR) documents the continuing review during FY-92 of research approved by the Clinical Investigation Committee (CIC), the Animal Use Committee (AUC), and the Human Use Committee/Institutional Review Board (HUC/IRB) of Walter Reed Army Medical Center (WRAMC). The review of each research protocol is initiated by the Department of Clinical Investigation (DCI) on the anniversary month of its approval. At that time, a request is sent to the principal investigator for submission of a progress report. The completed report consists of a detail summary sheet (DSS), a copy of the approved consent form, and a questionnaire regarding the continuing review of human subject participation or animal use. Members of the HUC/IRB or AUC review the progress reports throughout the year, and one of the following recommendations is made: 1) approval, 2) request additional information, or 3) request termination of the protocol. The members' recommendations are presented monthly to the HUC/IRB or AUC for final approval. The approved detail summary sheets of 535 protocols are included in this document.

The FY-92 APR process at WRAMC was administered by the Editorial Office, Research Administration Service, Department of Clinical Investigation, in coordination with the Research Review Service.
<table>
<thead>
<tr>
<th>TABLE OF CONTENTS</th>
<th>VOL#</th>
<th>PAGE#</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. UNIT SUMMARY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Objective</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>B. Technical Approach</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>C. Organization Scheme</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>D. DCI Staff</td>
<td>I</td>
<td>4</td>
</tr>
<tr>
<td>E. DCI Financial Support</td>
<td>I</td>
<td>9</td>
</tr>
<tr>
<td>F. Research Activity</td>
<td>I</td>
<td>9</td>
</tr>
<tr>
<td>II. PROTOCOL EXPENSES BY DEPARTMENT</td>
<td>I</td>
<td>19</td>
</tr>
<tr>
<td>III. PROTOCOL LIST BY DEPARTMENT</td>
<td>I</td>
<td>27</td>
</tr>
<tr>
<td>IV. LIST OF PUBLICATIONS, PRESENTATIONS, AND ABSTRACTS BY DEPARTMENT</td>
<td>I</td>
<td>78</td>
</tr>
<tr>
<td>V. AUTHOR INDEX</td>
<td>I</td>
<td>158</td>
</tr>
<tr>
<td>VI. INVESTIGATOR INDEX</td>
<td>I</td>
<td>187</td>
</tr>
<tr>
<td>VII. SUBJECT INDEX</td>
<td>I</td>
<td>196</td>
</tr>
<tr>
<td>VIII. DETAIL SUMMARY SHEETS</td>
<td>II</td>
<td>1-535</td>
</tr>
</tbody>
</table>

2
A. OBJECTIVE

To implement and manage the clinical investigation program at Walter Reed Army Medical Center (WRAMC) by promoting, supporting, coordinating, planning, conducting, and publishing ethical, scientific inquiry into clinical health problems of beneficiaries of the military health care system, to include studies in humans and animals.

B. TECHNICAL APPROACH

The clinical investigation program at WRAMC is conducted in accordance with the following:

- AR 40-7: Use of Investigational Drugs in Humans and the Use of Schedule I Controlled Drug Substances
- AR 40-38: Clinical Investigation Program
- AR 70-18: The Use of Animals in DOD Programs
- TB MED 525: Control of Hazards to Health from Ionizing Radiation Used by the Army Medical Department
- HSC 40-23: Management of Clinical Investigation Protocols and Reports
- WRAMC 70-1: Clinical Investigation Program, WRAMC Research Activities
- 45 CFR 46: Protection of Human Subjects
- 21 CFR A,D,& F: Food and Drug Administration

C. ORGANIZATION SCHEME

OFFICE OF THE CHIEF

- RESEARCH REVIEW SERVICE
  - Institutional oversight
  - Biometrics
  - Computer operations
- RESEARCH ADMINISTRATION SERVICE
  - Logistics
  - Editorial services
  - Grants management
- RESEARCH OPERATIONS SERVICE
  - Lab animal facility
  - General support lab
  - Specialty research labs
- KMU NURSING SERVICE
## D. DCI STAFF (Positions as of 30 September 1992)

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>GRADE</th>
<th>MOS</th>
<th>BRANCH</th>
<th>NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OFFICE OF THE CHIEF</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>06</td>
<td>61C</td>
<td>MC</td>
<td>Wray, HL</td>
<td>DCI</td>
</tr>
<tr>
<td>Secretary</td>
<td>07</td>
<td>0318</td>
<td>GS</td>
<td>Raghunand, Z</td>
<td>DCI</td>
</tr>
<tr>
<td>Medical Officer</td>
<td>15</td>
<td>0602</td>
<td>GM</td>
<td>Popovic, NA</td>
<td>Ortho Rsch</td>
</tr>
<tr>
<td><strong>RESEARCH REVIEW SERVICE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>0.5</td>
<td>60F</td>
<td>MC</td>
<td>Derderian, SS</td>
<td>DCI</td>
</tr>
<tr>
<td>Biostatistician</td>
<td>14</td>
<td>1530</td>
<td>GM</td>
<td>Chang, AS</td>
<td>DCI</td>
</tr>
<tr>
<td>Statistician</td>
<td>12</td>
<td>1530</td>
<td>GS</td>
<td>Howard, RS</td>
<td>DCI</td>
</tr>
<tr>
<td>Computer Programmer</td>
<td>11</td>
<td>0334</td>
<td>GS</td>
<td>Rose, JG</td>
<td>DCI</td>
</tr>
<tr>
<td>Research Coordinator</td>
<td>09</td>
<td>1083</td>
<td>GS</td>
<td>Coleman-Fraser, E</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>05</td>
<td>1087</td>
<td>GS</td>
<td>Green, IL</td>
<td>DCI</td>
</tr>
<tr>
<td>Computer Room Supv</td>
<td>E5</td>
<td>01H10</td>
<td>NC</td>
<td>Gomez, RJ</td>
<td>DCI</td>
</tr>
<tr>
<td><strong>RESEARCH ADMINISTRATION SERVICE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>12</td>
<td>0501</td>
<td>GS</td>
<td>Burton, ME</td>
<td>DCI</td>
</tr>
<tr>
<td>Tech Pub Editor</td>
<td>09</td>
<td>1083</td>
<td>GS</td>
<td>Walden, JF</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>07</td>
<td>1087</td>
<td>GS</td>
<td>Franklin, AD</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>07</td>
<td>1087</td>
<td>GS</td>
<td>Stacy, PG</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>06/07</td>
<td>1087</td>
<td>GS</td>
<td>Muchui, MJ</td>
<td>DCI</td>
</tr>
<tr>
<td>Supply Technician</td>
<td>06</td>
<td>2005</td>
<td>GS</td>
<td>Thomas, DR</td>
<td>DCI</td>
</tr>
<tr>
<td>Clerk Typist</td>
<td>04</td>
<td>0303</td>
<td>GS</td>
<td>Carter, C</td>
<td>DCI</td>
</tr>
<tr>
<td>DESCRIPTION</td>
<td>GRADE</td>
<td>MOS</td>
<td>BRANCH</td>
<td>NAME</td>
<td>ACTIVITY</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------</td>
<td>------</td>
<td>---------</td>
<td>-------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>(Research Administration Service cont.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Abt, MB</td>
<td>Urology</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Asplund, L</td>
<td>Ortho Resch</td>
</tr>
<tr>
<td><strong>Grant Personnel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Myers, DV</td>
<td>Urology</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Jamison, J</td>
<td>Hem/Onc</td>
</tr>
<tr>
<td>Secretary</td>
<td>05</td>
<td>0318</td>
<td>GS</td>
<td>Bryson, DD</td>
<td>Hem/Onc</td>
</tr>
<tr>
<td>Resch Audiologist</td>
<td>12</td>
<td>0665</td>
<td>GS</td>
<td>Clay, J</td>
<td>AA&amp;SC</td>
</tr>
<tr>
<td>Gen Health Sci</td>
<td>12</td>
<td>0601</td>
<td>GS</td>
<td>Summers, WV</td>
<td>AA&amp;SC</td>
</tr>
<tr>
<td>Dietitian</td>
<td>13</td>
<td>0630</td>
<td>GM</td>
<td>Mateski, DJ</td>
<td>Polyp Prev</td>
</tr>
<tr>
<td>Dietitian</td>
<td>11</td>
<td>0630</td>
<td>GS</td>
<td>Greaser, AM</td>
<td>Polyp Prev</td>
</tr>
<tr>
<td>Dietitian</td>
<td>11</td>
<td>0630</td>
<td>GS</td>
<td>Hancock, S</td>
<td>Polyp Prev</td>
</tr>
<tr>
<td>Dietitian</td>
<td>11</td>
<td>0630</td>
<td>GS</td>
<td>Miskovsky, VJ</td>
<td>Polyp Prev</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Slivka, C</td>
<td>Polyp Prev</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>09</td>
<td>0644</td>
<td>GS</td>
<td>Terrell, R</td>
<td>Polyp Prev</td>
</tr>
<tr>
<td>Secretary</td>
<td>06</td>
<td>0318</td>
<td>GS</td>
<td>Davis, C</td>
<td>Polyp Prev</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Pangaro, K</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Argauer, K</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Kushner, G</td>
<td>Pulmonary</td>
</tr>
</tbody>
</table>

**ARMY MEDICAL SPECIALIST CORPS CLINICAL INVESTIGATION AND RESEARCH SERVICE**

Chief       | 06    | 65B9A | SP     | Sweeney, JK       | DCI          |
<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>GRADE</th>
<th>MOS</th>
<th>BRANCH</th>
<th>NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RESEARCH OPERATIONS SERVICE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>05</td>
<td>68F</td>
<td>MS</td>
<td>Vacant</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab NCO</td>
<td>E7</td>
<td>92B40</td>
<td>NC</td>
<td>Sheldon, CM</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Kapur, JJ</td>
<td>DCI</td>
</tr>
<tr>
<td><strong>General Support Lab</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>03</td>
<td>68C00</td>
<td>MS</td>
<td>Payne, AM</td>
<td>DCI</td>
</tr>
<tr>
<td>Chemist</td>
<td>12</td>
<td>1320</td>
<td>GS</td>
<td>Abdel-Rahim, M</td>
<td>Biochem</td>
</tr>
<tr>
<td>Chemist</td>
<td>11</td>
<td>1320</td>
<td>GS</td>
<td>Bednarek, J</td>
<td>DCI</td>
</tr>
<tr>
<td>Bio Lab NCO</td>
<td>E6</td>
<td>01H30</td>
<td>NC</td>
<td>Williams, C</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab NCO</td>
<td>E5</td>
<td>92B20</td>
<td>NC</td>
<td>Dean, A</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab NCO</td>
<td>E5</td>
<td>92B20</td>
<td>NC</td>
<td>Vacant</td>
<td>Biochem</td>
</tr>
<tr>
<td>Med Lab Spec</td>
<td>E4</td>
<td>92B10</td>
<td>NC</td>
<td>Curtner, D</td>
<td>Cell Biology</td>
</tr>
<tr>
<td><strong>Animal Support Lab Research</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bio Lab Tech</td>
<td>10</td>
<td>0404</td>
<td>GS</td>
<td>Bailey, LR</td>
<td>Animal Resch</td>
</tr>
<tr>
<td>Bio Lab Tech</td>
<td>09</td>
<td>0404</td>
<td>GS</td>
<td>Jackson, D</td>
<td>Animal Resch</td>
</tr>
<tr>
<td><strong>Infectious Disease Research Laboratory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiologist</td>
<td>12</td>
<td>0403</td>
<td>GS</td>
<td>Dobek, AS</td>
<td>DCI</td>
</tr>
<tr>
<td><strong>Kyle Metabolic Research Laboratory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C, Nutrition Care</td>
<td>03</td>
<td>65C00</td>
<td>SP</td>
<td>Vacant</td>
<td>DCI</td>
</tr>
<tr>
<td>Supv Resch Chem</td>
<td>14</td>
<td>1320</td>
<td>GS</td>
<td>Carr, FE</td>
<td>DCI</td>
</tr>
<tr>
<td>DESCRIPTION</td>
<td>GRADE</td>
<td>MOS</td>
<td>BRANCH</td>
<td>NAME</td>
<td>ACTIVITY</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>-----------------</td>
<td>----------</td>
</tr>
<tr>
<td>(Kyle Metabolic Research Laboratory cont.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiologist</td>
<td>12</td>
<td>0413</td>
<td>GS</td>
<td>Lukes, YD</td>
<td>DCI</td>
</tr>
<tr>
<td>Chemist</td>
<td>12</td>
<td>1320</td>
<td>GS</td>
<td>Nicholson, DE</td>
<td>DCI</td>
</tr>
<tr>
<td>Chemist</td>
<td>11</td>
<td>1320</td>
<td>GS</td>
<td>Lahiri, S</td>
<td>DCI</td>
</tr>
<tr>
<td>Bio Lab Tech</td>
<td>09</td>
<td>0404</td>
<td>GS</td>
<td>Jenkins, EL</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Barnes, SG</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Technician</td>
<td>05</td>
<td>0645</td>
<td>GS</td>
<td>Martin, JL</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>07</td>
<td>1087</td>
<td>GS</td>
<td>Jacobson, A</td>
<td>DCI</td>
</tr>
<tr>
<td>Secretary</td>
<td>05</td>
<td>0318</td>
<td>GS</td>
<td>Phuong, U</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab NCO</td>
<td>E7</td>
<td>92840</td>
<td>NC</td>
<td>Ansley, R</td>
<td>DCI</td>
</tr>
<tr>
<td>Chemist</td>
<td>13</td>
<td>1320</td>
<td>GS</td>
<td>Tseng, YC</td>
<td>DCI</td>
</tr>
<tr>
<td>Resch Asst</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Solomon, BL</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Anderson, JS</td>
<td>DCI</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E5</td>
<td>01H20</td>
<td>NC</td>
<td>Baptiste, V</td>
<td>DCI</td>
</tr>
</tbody>
</table>

**Lab Support Unit**

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>GRADE</th>
<th>MOS</th>
<th>BRANCH</th>
<th>NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resch Chemist</td>
<td>13</td>
<td>0644</td>
<td>GS</td>
<td>Salata, KF</td>
<td>Allergy</td>
</tr>
<tr>
<td>Chemist</td>
<td>11</td>
<td>1320</td>
<td>GS</td>
<td>Maydonovich, CL</td>
<td>GI</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Armstrong, JM</td>
<td>Rheum</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Burgess, D</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>Cardiorespir Tech</td>
<td>E6</td>
<td>91N30</td>
<td>NC</td>
<td>Vacant</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Berger, TA</td>
<td>Allergy</td>
</tr>
<tr>
<td>Microbiologist</td>
<td>12</td>
<td>0403</td>
<td>GS</td>
<td>Billups, L</td>
<td>Flow Cytom</td>
</tr>
<tr>
<td>Resh Psychologist</td>
<td>12</td>
<td>0180</td>
<td>GS</td>
<td>Hamm, C</td>
<td>DCI</td>
</tr>
<tr>
<td>DESCRIPTION</td>
<td>GRADE</td>
<td>MOS</td>
<td>BRANCH</td>
<td>NAME</td>
<td>ACTIVITY</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------</td>
<td>-----</td>
<td>--------</td>
<td>------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Kyle Metabolic Unit Nursing Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supv ClIn Nurse</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Parchment, VA</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Bicknell, E</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Andersen, L</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>10</td>
<td>0610</td>
<td>GS</td>
<td>Burman, MS</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Coleman, A</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Chaudhari, NP</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Saxon, NJ</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>10</td>
<td>0610</td>
<td>GS</td>
<td>Stewart, MO</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Battle, OM</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Hicks, E</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>9/11</td>
<td>0610</td>
<td>GS</td>
<td>Vacant</td>
<td>DCI</td>
</tr>
<tr>
<td>Nurse Asst</td>
<td>05</td>
<td>0620</td>
<td>GS</td>
<td>Keeve, ML</td>
<td>DCI</td>
</tr>
</tbody>
</table>

The Department increased its number of assigned personnel during this year to a record of 78. The Sleep Disorders Respiratory Research Laboratory was given authorization to hire a Research Psychologist to function as the Sleep Lab supervisor. Carolyn Hamm, Ph.D., assumed the position during the second quarter and has worked hard to keep the lab running despite personnel shortages. The 7-year polyp prevention study (NIH grant), now in its second year, headed by LTC James Kikendall, MC, Gastroenterology Service, Department of Medicine, saw continued growth in staffing with the hiring of a clinical nurse and a secretary. This multi-center study is actively enrolling subjects who have undergone colonoscopic removal of adenomas. Subjects are randomized to no intervention or to a low fat, high fiber, high fruit and vegetable diet and extensive counseling. During the summer, the Research Operations Service saw the reassignment of its Chief, LTC Lloyd Lippert, MS, and the Chief, Nutrition Care, Kyle Metabolic Research Laboratory, MAJ Laurie Coffey, SP, separated from the Army. With the Base Realignment and Closure (BRAC) transition, the Department of Clinical Investigation gained five new authorizations to its TDA.
E. DCI FINANCIAL SUPPORT

<table>
<thead>
<tr>
<th></th>
<th>FY-88</th>
<th>FY-89</th>
<th>FY-90</th>
<th>FY-91</th>
<th>FY-92</th>
</tr>
</thead>
<tbody>
<tr>
<td>Civilian Personnel</td>
<td>$1,000,206</td>
<td>$1,000,402</td>
<td>$1,500,001</td>
<td>$1,922,896</td>
<td>$2,365,661</td>
</tr>
<tr>
<td>Consumable Supplies</td>
<td>$708,411</td>
<td>$707,272</td>
<td>$708,572</td>
<td>$650,531</td>
<td>$834,703</td>
</tr>
<tr>
<td>Civilian Contracts</td>
<td>$115,000</td>
<td>$88,898</td>
<td>$107,000</td>
<td>$204,385</td>
<td>$123,186</td>
</tr>
<tr>
<td>TDY</td>
<td>$28,401</td>
<td>$35,186</td>
<td>$36,102</td>
<td>$31,399</td>
<td>$54,433</td>
</tr>
<tr>
<td>Travel (non-federal sources)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>$22,211</td>
</tr>
<tr>
<td>Capital Expense</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equipment Program</td>
<td>$32,000</td>
<td>$57,860</td>
<td>$30,932</td>
<td>$77,164</td>
<td>$270,374</td>
</tr>
<tr>
<td>MEDCASE</td>
<td>$694,078</td>
<td>$557,178</td>
<td>$572,892</td>
<td>$1,000,076</td>
<td>$1,438,216</td>
</tr>
<tr>
<td>Other Grants</td>
<td>$254,102</td>
<td>$298,467</td>
<td>$528,140</td>
<td>$500,252</td>
<td>$913,851</td>
</tr>
<tr>
<td>Military</td>
<td>$432,504</td>
<td>$429,718</td>
<td>$392,137</td>
<td>$397,960</td>
<td>$402,488</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$3,264,702</strong></td>
<td><strong>$3,174,981</strong></td>
<td><strong>$3,875,776</strong></td>
<td><strong>$4,784,664</strong></td>
<td><strong>$6,425,123</strong></td>
</tr>
</tbody>
</table>

F. RESEARCH ACTIVITY

1. Accomplished in FY-92

With the mission to empower WRAMC researchers from planning to publication, the Department of Clinical Investigation (DCI) supported a record total of 715 active protocols this year (Table I). Twenty-five percent (180) of these studies were newly approved during the fiscal year, leaving 535 ongoing for at least one year that are summarized in this report. Medical Corps officers at WRAMC were Principal Investigators of 86% of the investigations. Medical Corps activities account for 96% of the investigations, and less than 1% were conducted at Army Community Hospitals in the Walter Reed Health Service Region (Table II). Human studies accounted for 83% of the investigations, with 27% involving research therapies including investigational drugs or devices and cooperative oncology group studies (Table III). Animal studies accounted for 7%, and laboratory studies accounted for 1%. Publication and presentation productivity by WRAMC staff included 94 published abstracts, 264 published articles, and 227 conference presentations (Table IV). There were 31 Clinical Investigation Recognition Seminars (now in its sixth year) presented by WRAMC researchers, providing local dissemination of WRAMC research presented at regional and national conferences.
### TABLE I. WRAMC Protocol Activity

<table>
<thead>
<tr>
<th>PROTOCOLS</th>
<th>FY-87</th>
<th>FY-88</th>
<th>FY-89</th>
<th>FY-90</th>
<th>FY-91</th>
<th>FY-92</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ONGOING at the beginning of FY</strong></td>
<td>408</td>
<td>456</td>
<td>474</td>
<td>520</td>
<td>552</td>
<td>535</td>
</tr>
<tr>
<td><strong>NEWLY APPROVED (+)</strong></td>
<td>170</td>
<td>145</td>
<td>197</td>
<td>172</td>
<td>153</td>
<td>180</td>
</tr>
<tr>
<td><strong>TOTAL ACTIVE During FY</strong></td>
<td>578</td>
<td>601</td>
<td>671</td>
<td>692</td>
<td>705</td>
<td>715</td>
</tr>
<tr>
<td><strong>COMPLETED (-)</strong></td>
<td>78</td>
<td>114</td>
<td>118</td>
<td>128</td>
<td>164</td>
<td>153</td>
</tr>
<tr>
<td><strong>TERMINATED (-)</strong></td>
<td>44</td>
<td>13</td>
<td>33</td>
<td>12</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td><strong>ONGOING at the end of FY</strong></td>
<td>456</td>
<td>474</td>
<td>520</td>
<td>552</td>
<td>535</td>
<td>551</td>
</tr>
</tbody>
</table>

### TABLE II. WRAMC FY-92 Active Investigations by AMEDD Officer Corps

<table>
<thead>
<tr>
<th>CORPS</th>
<th>GRAD TX PROG # (%)</th>
<th>OFFICERS IN TX # (%)</th>
<th>ACTIVE STUDIES # (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>55 (77)</td>
<td>434 (89)</td>
<td>684 (96)</td>
</tr>
<tr>
<td>Medical Service</td>
<td>9 (13)</td>
<td>27 (6)</td>
<td>10 (1)</td>
</tr>
<tr>
<td>Dental</td>
<td>4 (6)</td>
<td>12 (2)</td>
<td>3 (&lt;1)</td>
</tr>
<tr>
<td>Medical Specialist</td>
<td>2 (3)</td>
<td>11 (2)</td>
<td>4 (&lt;1)</td>
</tr>
<tr>
<td>Nursing</td>
<td>1 (1)</td>
<td>7 (1)</td>
<td>9 (1)</td>
</tr>
<tr>
<td>Veterinary</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (&lt;1)</td>
</tr>
<tr>
<td></td>
<td>71 (100)</td>
<td>491 (100)</td>
<td>712 (100)</td>
</tr>
</tbody>
</table>

Army Community Hospitals 3
### TABLE III. WRAMC FY-92 Active Investigations by Subject

<table>
<thead>
<tr>
<th>SUBJECT</th>
<th>ACTIVE STUDIES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>#</td>
</tr>
<tr>
<td>Human</td>
<td>660 (92)</td>
</tr>
<tr>
<td>Invest New Drug</td>
<td>45  (6)</td>
</tr>
<tr>
<td>Invest Device</td>
<td>9   (1)</td>
</tr>
<tr>
<td>Cooperative Oncology Group</td>
<td>144 (20)</td>
</tr>
<tr>
<td>Descriptive - Expedited</td>
<td>179 (25)</td>
</tr>
<tr>
<td>Greater Risk</td>
<td>233 (40)</td>
</tr>
<tr>
<td></td>
<td>660 (92)</td>
</tr>
<tr>
<td>Animal</td>
<td>50  (7)</td>
</tr>
<tr>
<td>Laboratory</td>
<td>5   (1)</td>
</tr>
</tbody>
</table>

Total: 715 (100)

### TABLE IV. WRAMC Publications and Presentations

<table>
<thead>
<tr>
<th>FY-87</th>
<th>FY-88</th>
<th>FY-89</th>
<th>FY-90</th>
<th>FY-91</th>
<th>FY-92</th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Articles</td>
<td>55</td>
<td>104</td>
<td>157'</td>
<td>276'</td>
<td>285'</td>
</tr>
<tr>
<td>Abstracts</td>
<td>86</td>
<td>106</td>
<td>73</td>
<td>6'</td>
<td>75</td>
</tr>
<tr>
<td>Presentations</td>
<td>55</td>
<td>93</td>
<td>61</td>
<td>106</td>
<td>110</td>
</tr>
</tbody>
</table>

* Published Articles related to approved clinical investigations:
  FY-89 = 22; FY-90 = 62; FY-91 = 71; FY-92 = 114

+ Abstracts related to approved clinical investigations: FY-92 = 91
With the end of the Gulf War, WRAMC returned to its peacetime missions. The professional staff renewed their efforts in the Clinical Investigation Program, as evidenced by the increase in the number of protocols approved (from 153 in FY-91 to 180 in FY-92). The number of approved protocols during FY-92 was second only to FY-89 when the HIV research program was initiated.

The DCI Strategic Planning process continued and involved all clinical departments and training programs. After consultation with the clinical investigation planners, 25 activities submitted written plans describing their 5-year research needs in terms of personnel, space, and equipment. The space planning progressed for the renovation of the animal facility and the construction of the Base Realignment and Closure (BRAC) Building that will house the administrative offices of DCI.

The first Army Medical Corps officer trained as a fellow in Clinical Investigation completed the 1-year program in September 1992. Highlights of this curriculum were presented at the 4th Annual AMEDD Clinical Investigation Postgraduate Short Course in April 1992. Under the auspices of the WRAMC Professional Education and Training Committee, the Department, with input from directors of the graduate medical education programs, developed a 15-hour research course targeted at new investigators. The first of five 3-hour sessions was given in September, and the remainder will be completed in October 1992.

The prestigious Bailey K. Ashford Clinical Research Award is bestowed annually on a member of the year's graduating class whose research accomplishments excelled during training. Ten graduating trainees, representing nine training programs, were nominated for the 1992 award. A selection committee named one semi-finalist and five finalists. The finalists presented their results at a symposium sponsored by the Department of Clinical Investigation. The 1992 finalists were: CPT Michael A. Carome, MC, Fellow, Nephrology Service, Department of Medicine, "Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) and TIMP-2 mRNAs: Detection and Quantitation in Isolated Whole Human Glomeruli by RT-PCR"; MAJ Timothy C. Landes, MC, Fellow, Gastroenterology Service, Department of Medicine, "Utility of Salivary Antibody to Helicobacter Pylori in Detecting Eradication Following Treatment: A Prospective Long-Term Study"; CPT Francis J Landry, Fellow, General Internal Medicine, Department of Medicine, "Outcome of Cardiopulmonary Resuscitation in the Intensive Care Setting"; LTC Charles F. Longer, MC, Fellow, Infectious Disease Service, Department of Medicine, "Hepatitis E Virus - A Newly Recognized Infection with Military Significance"; and MAJ Alan J. Magill, MC, Fellow, Infectious Disease Service, Department of Medicine, "Viscerotropic Leishmaniasis in Soldiers Returning from Desert Storm." Recipient of the 1992 Bailey K. Ashford Clinical Research Award, CPT Michael A. Carome, was announced at graduation in June.

The Research Review Service continued to be busy with an ever-increasing number of protocols requesting extramural support in the form of gifts and grants. This required the development of a system to track the progress of approval of these studies outside of WRAMC. The Service also
instituted new guidelines and a tracking system for the emergency use of investigational new drugs. The Biostatistical and Computer Support Sections had a 34% increase in the number of consults and continued to expand education programs directed at training researchers in the areas of statistics and the use of computer graphics. A high priority during the fiscal year was the completion and submission of the MEDCASE request for the DCI network upgrade.

The Research Administration Service provided support for the Department and all WRAMC investigators, managing intra- and extramural monies totalling over $6,400,000. Of this total, over $1,400,000 was received by the Department in MEDCASE funds. Extramural funding continued to expand and included support from the National Institutes of Health and the U.S. Army Medical Research and Development Command, as well as gifts and grants. The Editorial Office continued to improve its services, providing comprehensive support to investigators/authors in composing research protocols and manuscripts. The compilation of the Annual Progress Report has been fine-tuned to where annual reports are submitted within 30 days of request or the protocol is administratively reviewed and terminated. Additionally, the Editorial Office wrote a "Clinical Investigator's Guide," explaining the research review process and research resources at WRAMC and providing checklists, formats, and guidelines. To assist Principal Investigators further, a program was initiated whereby the routine forms and instructions required to compile a protocol are available to researchers on a user-friendly floppy disk.

During 1992, the Research Operations Service continued expansion of the services available in the core laboratories. With the installation of a cage washing system and the hiring of a new employee in the research animal facility, the facility now can support protocols requiring the use of rabbits. The core support laboratories implemented a chemical tracking system for the monitoring of hazardous materials used in the facilities. Rheumatology Service greatly expanded its use of research laboratory resources.

After adjusting to its new locations on Ward 75, the Kyle Metabolic Unit Nursing Service was able to support an average bed occupancy of 86% for its 16-bed ward. This was the highest occupancy rate in more than 10 years. The Kyle Metabolic Unit dietitian, MAJ Lauri M. Coffey, left the Army in June 1992, and the position remained unfilled for the rest of the fiscal year.

As in years past, Principal Investigators conducting research under the Clinical Investigation Program at WRAMC continued to receive national recognition during FY-92 for their outstanding research. The Journal of Speech and Hearing Research Editor's Award was bestowed on Brian E. Walden, Ph.D., Director of Research, Army Audiology and Speech Center, Department of Surgery, for his paper, "Visual Biasing of Normal and Impaired Auditory Speech Perception." The selection was made by the Editor and Associate Editors as the best from over 200 articles published during 1990. The award was made at the Annual Convention of the American Speech-Language-Hearing Association, Atlanta, GA, in November 1991.
Maj John Gilliland, MC, USAF, Reproductive Endocrinology, Department of Obstetrics and Gynecology, received the Founder's Award (first place) for his paper, "Atrial Natriuretic Peptide Receptors in Human Endometrial Stromal Cells." The paper was presented at the Armed Forces District Meeting of the American College of Obstetrics and Gynecology, Cincinnati, OH, in October 1991. With this recognition, his paper was entered into the "Annual Competition for Outstanding Papers Presented at District Meetings," The American College of Obstetricians and Gynecologists 40th Annual Clinical Meeting, in April 1992 and was awarded first prize.

The Annual Melvin Cheitlin Award for best fellow paper was presented to MAJ Andrew Carter, MC, Cardiology Service, Department of Medicine, for his paper entitled "Characterization of the Coronary Vascular Response to Injury Early After Balloon Angioplasty in a Porcine Model." Dr. Carter presented his paper at the Cardiology Subspecialty Session of the Army ACP Meeting in San Francisco, CA, in October 1991.

The William Beaumont Clinical Research Award was bestowed on MAJ Joseph R. Murphy, MC, Gastroenterology Service, Department of Medicine, at the 19th Annual William Beaumont Symposium, San Francisco, CA, in October 1991. The award recognizes Dr. Murphy's excellent research achievements during his GI fellowship. One paper has been published as a result of this research, "Prolonged Clearance is the Primary Abnormal Reflux Parameter in Patients with Progressive Systemic Sclerosis and Reflux Esophagitis," Digestive Disease Science 1992;37(6):833-41; and another, "Risk of Colonic Neoplasia in Acromegaly," has been submitted to the Gastroenterology.

For her work, "The Effect of Acute and Chronic Administration of Diltiazem on Pulmonary Gas Exchange and Oxygen Delivery in Severe COPD," CPT Lisa Moores, MC, Pulmonary and Critical Care Medicine Service, Department of Medicine, received the ACP Associates Award. Her presentation was made at the October 1991 Annual Army Scientific/American College of Physicians Meeting in San Francisco, CA.

2. Planned for FY-93

After a very busy year, with the largest number of active protocols and the highest level of funding, DCI hopes to continue this degree of activity in support of the record number (491) of graduate trainees at Walter Reed, to include 434 physicians. Areas of particular interest for the upcoming year will include the following.

a. The WRAMC Research Course will be completed and evaluated, and plans will be made for another course in the Fall of 1993.

b. DCI will continue Strategic Planning tasks and will complete its manpower survey, documenting and justifying identified research needs at WRAMC.

c. DCI will encourage extramural funding through all available sources and will endeavor to work closely with the Henry M. Jackson
Foundation for the Advancement of Military Medicine and the U.S. Army Medical Research and Development Command, as well as other research funding organizations. DCI will work to improve the time required for approval of extramural funding, which at present seems to be a major stumbling block to increasing this funding at WRAMC.

d. DCI hopes to increase the efficiency of research conducted at Walter Reed by a continuing emphasis on the expansion of the Editorial Office support and better utilization of the computer facilities.

3. Ongoing and Future Issues

The future role of Clinical Investigation depends critically on WRAMC's role in the Military Health Services System. Although some institutions may decrease their activities, it appears that WRAMC will maintain or increase its current patient care, training, and research activities. The major ongoing and future issue for DCI is funding of the WRAMC Clinical Investigation Program in this new environment.
TABLE V: Human Use Committee/Institutional Review Board Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas A. Klein, COL MC</td>
<td>Chairman, Chief, Dept of Obstetrics &amp; Gynecology, Representing Deputy Commander</td>
</tr>
<tr>
<td>Sarkis Derderian, LTC MC</td>
<td>Acting Co-Chairman, Assistant Chief, DCI</td>
</tr>
<tr>
<td>Darrel Bjornson, LTC MS</td>
<td>OIC, Hematology-Oncology Pharmacy, Representing Chief, Pharmacy Service</td>
</tr>
<tr>
<td>Sanford Dresin, COL CH</td>
<td>Chief, Dept of Ministry and Pastoral Care</td>
</tr>
<tr>
<td>Jack Farrell, Ph.D.**</td>
<td>Chief, Psychology Section, U.S. Soldiers’ &amp; Airmens’ Home</td>
</tr>
<tr>
<td>Eric Marks, M.D.*</td>
<td>Associate Professor, Dept of Medicine, USUHS</td>
</tr>
<tr>
<td>Laurel Meaney, DAC</td>
<td>Patients’ Rights Representative, WRAMC</td>
</tr>
<tr>
<td>Scott Murdoch, J.D.</td>
<td>Chief, Claims Office, Representing Center Judge Advocate</td>
</tr>
<tr>
<td>Richard Patterson, LTC SP</td>
<td>Chief, Education and Research, Nutrition Care Directorate, Representing Ch, Nutrition Care Dir</td>
</tr>
<tr>
<td>Jean Reeder, LTC AN</td>
<td>Chief, Nursing Research Service, Representing Chief, Dept of Nursing</td>
</tr>
<tr>
<td>Stephen Sihelnik, LTC MC</td>
<td>Staff, Urology Service, Representing Chief, DCI</td>
</tr>
<tr>
<td>Robert Smallridge, COL MC*</td>
<td>Chief, Dept of Clinical Physiology, Division of Medicine, WRAIR, Representing Director, WRAIR</td>
</tr>
</tbody>
</table>

*Non-affiliated
### TABLE VI: Clinical Investigation Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
</table>
| Sarkis Derderian, LTC MC | Acting Chairman  
|                       | Assistant Chief, DCI                                                      |
| Stephen Sihelnik, LTC MC | Acting Co-Chairman  
|                       | Staff, Urology Service, Dept of Surgery                                  |
| Jay Anderson, COL MC   | Chief, Nuclear Medicine  
|                       | Representing Radiation Control Comm                                       |
| Audrey Chang, Ph.D.    | Senior Biostatistician, DCI                                              |
| Jack Moore, COL MC     | Chief, Nephrology Service  
|                       | Representing Chief, Dept of Medicine                                     |
| Scott Murdoch, J.D.    | Chief, Claims Office  
|                       | Representing Center Judge Advocate                                        |
| Jean Reeder, LTC AN    | Chief, Nursing Research Service                                          |
| Jane Swecney, COL SP   | Chief, AMSC Research                                                     |
| Charles Yowler, LTC MC | Chief, Surgical Research  
|                       | Representing Chief, Dept of Surgery                                       |

### TABLE VII: Rotating Senior Investigators, Clinical Investigation Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Department</th>
</tr>
</thead>
<tbody>
<tr>
<td>Majorie Leek, Ph.D.</td>
<td>Army Audiology &amp; Speech Center</td>
</tr>
<tr>
<td>Bahman Jabbari, COL MC</td>
<td>Neurology Service</td>
</tr>
<tr>
<td>Terry Schultz, COL MC</td>
<td>Department of Psychiatry</td>
</tr>
<tr>
<td>Steven Shay, COL MC</td>
<td>Gastroenterology Service</td>
</tr>
<tr>
<td>Gary Carpenter, COL MC</td>
<td>Allergy-Immunology Service</td>
</tr>
<tr>
<td>Thomas Wiswell, LTC MC</td>
<td>Department of Pediatrics</td>
</tr>
</tbody>
</table>
### TABLE VIII: Animal Use Committee/Clinical Investigation Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judith Davis, MAJ VC</td>
<td>Attending Veterinarian, Chief, Animal Resource Department, Div of Veterinary Medicine, WRAIR</td>
</tr>
<tr>
<td>Lloyd Lippert, LTC MS</td>
<td>Ch, Research Operations Service, Dept of Clinical Investigation, WRAMC</td>
</tr>
<tr>
<td>Hernando Mena, LTC MC*</td>
<td>Asst Chairman, Dept of Neuropathology, Armed Forces Institute of Pathology</td>
</tr>
<tr>
<td>Ted Hadfield, MAJ BSC*</td>
<td>Armed Forces Institute of Pathology</td>
</tr>
</tbody>
</table>

*Non-affiliated

### TABLE IX: HIV Research/Clinical Investigation Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Oster, COL MC</td>
<td>Chief, Infectious Disease Service, Representing Program Director, HIV Research, Jackson Foundation</td>
</tr>
</tbody>
</table>
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS, 
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLERGY-IMMUNOLOGY SERVICE</td>
<td>1400-88</td>
<td>2,658</td>
<td>0</td>
<td>2,658</td>
</tr>
<tr>
<td></td>
<td>3221</td>
<td>21,527</td>
<td>0</td>
<td>21,527</td>
</tr>
<tr>
<td></td>
<td>3339</td>
<td>3,794</td>
<td>253</td>
<td>4,047</td>
</tr>
<tr>
<td></td>
<td>3340</td>
<td>7,478</td>
<td>0</td>
<td>7,478</td>
</tr>
<tr>
<td></td>
<td>3343</td>
<td>737</td>
<td>0</td>
<td>737</td>
</tr>
<tr>
<td></td>
<td>3344</td>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>3345</td>
<td>330</td>
<td>0</td>
<td>330</td>
</tr>
<tr>
<td></td>
<td>3346</td>
<td>1,541</td>
<td>97</td>
<td>1,638</td>
</tr>
<tr>
<td></td>
<td>3347</td>
<td>40</td>
<td>0</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>3349</td>
<td>2,763</td>
<td>0</td>
<td>2,763</td>
</tr>
<tr>
<td></td>
<td>3350</td>
<td>40</td>
<td>8</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>3351</td>
<td>271</td>
<td>60</td>
<td>331</td>
</tr>
<tr>
<td></td>
<td>53</td>
<td>1,439</td>
<td>918</td>
<td>2,357</td>
</tr>
<tr>
<td></td>
<td>3353</td>
<td>530</td>
<td>0</td>
<td>530</td>
</tr>
<tr>
<td></td>
<td>3354</td>
<td>3,344</td>
<td>1,059</td>
<td>4,403</td>
</tr>
<tr>
<td></td>
<td>3355</td>
<td>205</td>
<td>450</td>
<td>655</td>
</tr>
<tr>
<td></td>
<td>3357</td>
<td>3,533</td>
<td>9,111</td>
<td>13,144</td>
</tr>
<tr>
<td></td>
<td>3358</td>
<td>2,097</td>
<td>4,265</td>
<td>6,362</td>
</tr>
<tr>
<td></td>
<td>3359</td>
<td>0</td>
<td>834</td>
<td>834</td>
</tr>
<tr>
<td></td>
<td>3360</td>
<td>0</td>
<td>632</td>
<td>632</td>
</tr>
<tr>
<td></td>
<td>3363</td>
<td>0</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>3364</td>
<td>0</td>
<td>3,509</td>
<td>3,509</td>
</tr>
<tr>
<td></td>
<td>3365</td>
<td>0</td>
<td>11,276</td>
<td>11,276</td>
</tr>
<tr>
<td></td>
<td>3366</td>
<td>0</td>
<td>4,027</td>
<td>4,027</td>
</tr>
<tr>
<td></td>
<td>4811</td>
<td>0</td>
<td>6,611</td>
<td>6,611</td>
</tr>
<tr>
<td></td>
<td>4812</td>
<td>0</td>
<td>2,623</td>
<td>2,623</td>
</tr>
<tr>
<td></td>
<td>9272</td>
<td>35,445</td>
<td>171</td>
<td>35,616</td>
</tr>
<tr>
<td>TOTAL</td>
<td>87,777</td>
<td>46,768</td>
<td>134,545</td>
<td></td>
</tr>
</tbody>
</table>

DEPARTMENT OF CLINICAL INVESTIGATION

<table>
<thead>
<tr>
<th>DEPARTMENT OF CLINICAL INVESTIGATION</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2584</td>
<td>2,858</td>
<td>2,161</td>
<td>5,019</td>
<td></td>
</tr>
<tr>
<td>6276</td>
<td>0</td>
<td>1,294</td>
<td>1,294</td>
<td></td>
</tr>
<tr>
<td>926</td>
<td>1,446</td>
<td>0</td>
<td>1,446</td>
<td></td>
</tr>
<tr>
<td>9271</td>
<td>13,141</td>
<td>0</td>
<td>13,141</td>
<td></td>
</tr>
<tr>
<td>9275</td>
<td>16,791</td>
<td>0</td>
<td>16,791</td>
<td></td>
</tr>
<tr>
<td>9280</td>
<td>2,535</td>
<td>0</td>
<td>2,535</td>
<td></td>
</tr>
<tr>
<td>9281</td>
<td>2,253</td>
<td>1,026</td>
<td>3,279</td>
<td></td>
</tr>
<tr>
<td>9283</td>
<td>0</td>
<td>341</td>
<td>341</td>
<td></td>
</tr>
<tr>
<td>9284</td>
<td>0</td>
<td>1,900</td>
<td>1,900</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>39,024</td>
<td>6,722</td>
<td>45,746</td>
<td></td>
</tr>
</tbody>
</table>

HIV RESEARCH

<table>
<thead>
<tr>
<th>HIV RESEARCH</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8802</td>
<td>996</td>
<td>0</td>
<td>996</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>996</td>
<td>0</td>
<td>996</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS, BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF MEDICINE Cardiology Service</td>
<td>1264</td>
<td>0</td>
<td>517</td>
<td>517</td>
</tr>
<tr>
<td></td>
<td>1266</td>
<td>0</td>
<td>1,321</td>
<td>1,321</td>
</tr>
<tr>
<td></td>
<td>1268</td>
<td>0</td>
<td>2,236</td>
<td>2,236</td>
</tr>
<tr>
<td></td>
<td>1269</td>
<td>0</td>
<td>5,091</td>
<td>5,091</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>0</td>
<td>9,165</td>
<td>9,165</td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE Dermatology Service</td>
<td>1805</td>
<td>217,394</td>
<td>0</td>
<td>217,394</td>
</tr>
<tr>
<td></td>
<td>1815</td>
<td>0</td>
<td>1,100</td>
<td>1,100</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>217,394</td>
<td>1,100</td>
<td>218,494</td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE Endocrine-Metabolic Service</td>
<td>1300-88</td>
<td>2,755</td>
<td>0</td>
<td>2,755</td>
</tr>
<tr>
<td></td>
<td>1302-88</td>
<td>15,376</td>
<td>0</td>
<td>15,376</td>
</tr>
<tr>
<td></td>
<td>1311-88</td>
<td>0</td>
<td>658</td>
<td>658</td>
</tr>
<tr>
<td></td>
<td>1312-89</td>
<td>737</td>
<td>0</td>
<td>737</td>
</tr>
<tr>
<td></td>
<td>1313-89</td>
<td>11,346</td>
<td>0</td>
<td>11,346</td>
</tr>
<tr>
<td></td>
<td>1316-89</td>
<td>5,006</td>
<td>0</td>
<td>5,006</td>
</tr>
<tr>
<td></td>
<td>1320-90</td>
<td>3,304</td>
<td>3,940</td>
<td>7,244</td>
</tr>
<tr>
<td></td>
<td>1321-90</td>
<td>12,689</td>
<td>114</td>
<td>12,803</td>
</tr>
<tr>
<td></td>
<td>1322-90</td>
<td>427</td>
<td>1,050</td>
<td>1,477</td>
</tr>
<tr>
<td></td>
<td>1328-90</td>
<td>0</td>
<td>45,637</td>
<td>45,637</td>
</tr>
<tr>
<td></td>
<td>1329-90</td>
<td>0</td>
<td>236</td>
<td>236</td>
</tr>
<tr>
<td></td>
<td>1331-91</td>
<td>0</td>
<td>3,221</td>
<td>3,221</td>
</tr>
<tr>
<td></td>
<td>1333-91</td>
<td>0</td>
<td>17,635</td>
<td>17,635</td>
</tr>
<tr>
<td></td>
<td>1334-91</td>
<td>0</td>
<td>1,043</td>
<td>1,043</td>
</tr>
<tr>
<td></td>
<td>1335-91</td>
<td>0</td>
<td>28,343</td>
<td>28,343</td>
</tr>
<tr>
<td></td>
<td>1351-84</td>
<td>538</td>
<td>513</td>
<td>1,051</td>
</tr>
<tr>
<td></td>
<td>1356-84</td>
<td>4,352</td>
<td>0</td>
<td>4,352</td>
</tr>
<tr>
<td></td>
<td>1359-85</td>
<td>50,128</td>
<td>1,598</td>
<td>51,726</td>
</tr>
<tr>
<td></td>
<td>1361-85</td>
<td>80,475</td>
<td>0</td>
<td>80,475</td>
</tr>
<tr>
<td></td>
<td>1369-86</td>
<td>4,353</td>
<td>0</td>
<td>4,353</td>
</tr>
<tr>
<td></td>
<td>1371-86</td>
<td>10,705</td>
<td>698</td>
<td>11,403</td>
</tr>
<tr>
<td></td>
<td>1372-86</td>
<td>64,255</td>
<td>4,136</td>
<td>68,391</td>
</tr>
<tr>
<td></td>
<td>1376-86</td>
<td>18,811</td>
<td>0</td>
<td>18,811</td>
</tr>
<tr>
<td></td>
<td>1385-87</td>
<td>62,556</td>
<td>2,938</td>
<td>65,494</td>
</tr>
<tr>
<td></td>
<td>1386-87</td>
<td>3,979</td>
<td>0</td>
<td>3,979</td>
</tr>
<tr>
<td></td>
<td>1389-87</td>
<td>13,020</td>
<td>232</td>
<td>13,252</td>
</tr>
<tr>
<td></td>
<td>1390-87</td>
<td>81,905</td>
<td>58,691</td>
<td>140,596</td>
</tr>
<tr>
<td></td>
<td>1391-87</td>
<td>814</td>
<td>0</td>
<td>814</td>
</tr>
<tr>
<td></td>
<td>1393-87</td>
<td>142,503</td>
<td>1,998</td>
<td>144,501</td>
</tr>
<tr>
<td></td>
<td>1394-87</td>
<td>20,867</td>
<td>0</td>
<td>20,867</td>
</tr>
<tr>
<td></td>
<td>1395-87</td>
<td>144,669</td>
<td>37,691</td>
<td>182,360</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS, 
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td>Endocrine-Metabolic Service (continued)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1399-87</td>
<td>90,498</td>
<td>12,352</td>
<td>102,850</td>
</tr>
<tr>
<td></td>
<td>4299</td>
<td>13,443</td>
<td>575</td>
<td>14,018</td>
</tr>
<tr>
<td></td>
<td>4300</td>
<td>9,013</td>
<td>900</td>
<td>9,913</td>
</tr>
<tr>
<td></td>
<td>9266</td>
<td>23,963</td>
<td>0</td>
<td>23,963</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td><strong>892,487</strong></td>
<td><strong>224,199</strong></td>
<td><strong>1,116,686</strong></td>
</tr>
<tr>
<td></td>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td><strong>Gastroenterology Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1401</td>
<td>5,879</td>
<td>718</td>
<td>6,597</td>
</tr>
<tr>
<td></td>
<td>1404</td>
<td>100</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>1406</td>
<td>8,073</td>
<td>2,394</td>
<td>10,467</td>
</tr>
<tr>
<td></td>
<td>1409</td>
<td>1,307</td>
<td>0</td>
<td>1,307</td>
</tr>
<tr>
<td></td>
<td>1411</td>
<td>1,510</td>
<td>0</td>
<td>1,510</td>
</tr>
<tr>
<td></td>
<td>1413</td>
<td>34,319</td>
<td>0</td>
<td>34,319</td>
</tr>
<tr>
<td></td>
<td>1414</td>
<td>27,722</td>
<td>815</td>
<td>28,537</td>
</tr>
<tr>
<td></td>
<td>1416</td>
<td>1,484</td>
<td>424</td>
<td>1,908</td>
</tr>
<tr>
<td></td>
<td>1417</td>
<td>3,602</td>
<td>16,412</td>
<td>20,014</td>
</tr>
<tr>
<td></td>
<td>1419</td>
<td>0</td>
<td>350</td>
<td>350</td>
</tr>
<tr>
<td></td>
<td>1450</td>
<td>13,484</td>
<td>2,617</td>
<td>16,101</td>
</tr>
<tr>
<td></td>
<td>1462</td>
<td>3,141</td>
<td>351</td>
<td>3,492</td>
</tr>
<tr>
<td></td>
<td>1483</td>
<td>2,340</td>
<td>0</td>
<td>2,340</td>
</tr>
<tr>
<td></td>
<td>1487</td>
<td>1,158</td>
<td>0</td>
<td>1,158</td>
</tr>
<tr>
<td></td>
<td>1489</td>
<td>1,328</td>
<td>1,033</td>
<td>2,361</td>
</tr>
<tr>
<td></td>
<td>1495</td>
<td>4,160</td>
<td>0</td>
<td>4,160</td>
</tr>
<tr>
<td></td>
<td>1496</td>
<td>525</td>
<td>0</td>
<td>525</td>
</tr>
<tr>
<td></td>
<td>1497</td>
<td>1,250</td>
<td>0</td>
<td>1,250</td>
</tr>
<tr>
<td></td>
<td>2031</td>
<td>602</td>
<td>3,293</td>
<td>3,895</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td><strong>111,984</strong></td>
<td><strong>28,407</strong></td>
<td><strong>140,391</strong></td>
</tr>
<tr>
<td></td>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td><strong>Hematology-Oncology Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1639-86</td>
<td>445</td>
<td>3,678</td>
<td>4,123</td>
</tr>
<tr>
<td></td>
<td>1657-88</td>
<td>13,650</td>
<td>0</td>
<td>13,650</td>
</tr>
<tr>
<td></td>
<td>1673</td>
<td>5,469</td>
<td>0</td>
<td>5,469</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td><strong>19,564</strong></td>
<td><strong>3,678</strong></td>
<td><strong>23,242</strong></td>
</tr>
<tr>
<td></td>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td><strong>Infectious Disease Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>195'</td>
<td>7,236</td>
<td>0</td>
<td>7,236</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td><strong>7,236</strong></td>
<td><strong>0</strong></td>
<td><strong>7,236</strong></td>
</tr>
<tr>
<td></td>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td><strong>Nephrology Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1152</td>
<td>1,332</td>
<td>0</td>
<td>1,332</td>
</tr>
<tr>
<td></td>
<td>1156</td>
<td>1,131</td>
<td>0</td>
<td>1,131</td>
</tr>
<tr>
<td></td>
<td>1157</td>
<td>7,796</td>
<td>0</td>
<td>7,796</td>
</tr>
<tr>
<td></td>
<td>1158</td>
<td>1,463</td>
<td>0</td>
<td>1,463</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPLANATIONS FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY'S ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td>Nephrology Service (continued)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1160</td>
<td>17,731</td>
<td>0</td>
<td>17,731</td>
<td></td>
</tr>
<tr>
<td>1161</td>
<td>0</td>
<td>3,530</td>
<td>3,530</td>
<td></td>
</tr>
<tr>
<td>1162</td>
<td>0</td>
<td>8,598</td>
<td>8,598</td>
<td></td>
</tr>
<tr>
<td>1163</td>
<td>0</td>
<td>3,485</td>
<td>3,485</td>
<td></td>
</tr>
<tr>
<td>1164</td>
<td>0</td>
<td>16,810</td>
<td>16,810</td>
<td></td>
</tr>
<tr>
<td>1165</td>
<td>0</td>
<td>2,587</td>
<td>2,587</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>29,453</td>
<td>35,010</td>
<td>64,463</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td>Pulmonary Disease Service</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1707</td>
<td>11,267</td>
<td>520</td>
<td>11,787</td>
<td></td>
</tr>
<tr>
<td>1714</td>
<td>220</td>
<td>0</td>
<td>220</td>
<td></td>
</tr>
<tr>
<td>1717</td>
<td>1,090</td>
<td>0</td>
<td>1,090</td>
<td></td>
</tr>
<tr>
<td>1720</td>
<td>30,192</td>
<td>0</td>
<td>30,192</td>
<td></td>
</tr>
<tr>
<td>1724</td>
<td>1,979</td>
<td>3,079</td>
<td>5,058</td>
<td></td>
</tr>
<tr>
<td>1732</td>
<td>5,187</td>
<td>328</td>
<td>5,515</td>
<td></td>
</tr>
<tr>
<td>1742</td>
<td>0</td>
<td>750</td>
<td>750</td>
<td></td>
</tr>
<tr>
<td>1743</td>
<td>0</td>
<td>660</td>
<td>660</td>
<td></td>
</tr>
<tr>
<td>1747</td>
<td>0</td>
<td>3,003</td>
<td>3,003</td>
<td></td>
</tr>
<tr>
<td>1748</td>
<td>0</td>
<td>663</td>
<td>663</td>
<td></td>
</tr>
<tr>
<td>1971</td>
<td>4,308</td>
<td>0</td>
<td>4,308</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>54,243</td>
<td>9,003</td>
<td>63,246</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td>Rheumatology Service</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3220R</td>
<td>21,244</td>
<td>3,775</td>
<td>25,019</td>
<td></td>
</tr>
<tr>
<td>3703</td>
<td>723</td>
<td>0</td>
<td>723</td>
<td></td>
</tr>
<tr>
<td>3707</td>
<td>2,329</td>
<td>9,315</td>
<td>11,644</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>24,296</td>
<td>13,090</td>
<td>37,386</td>
<td></td>
</tr>
<tr>
<td>NEUROLOGY SERVICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7142</td>
<td>295</td>
<td>0</td>
<td>295</td>
<td></td>
</tr>
<tr>
<td>7147</td>
<td>0</td>
<td>1,744</td>
<td>1,744</td>
<td></td>
</tr>
<tr>
<td>9200</td>
<td>6,875</td>
<td>0</td>
<td>6,875</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>7,170</td>
<td>1,744</td>
<td>8,914</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF NURSING</td>
<td>Nursing Research Service</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7575</td>
<td>0</td>
<td>29</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>29</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</td>
<td>4243</td>
<td>50</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>4279</td>
<td>908</td>
<td>218</td>
<td>1,126</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>958</td>
<td>218</td>
<td>1,176</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</td>
<td>Gynecologic Oncology Group</td>
<td>4265</td>
<td>238</td>
<td>238</td>
</tr>
<tr>
<td>TOTAL</td>
<td>238</td>
<td>0</td>
<td>238</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS, BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR CURRENT TOTAL</th>
<th>FY's ($)</th>
<th>FY ($)</th>
<th>($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF PEDIATRICS</td>
<td>6059</td>
<td>3,031</td>
<td>0</td>
<td>3,031</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6064</td>
<td>9,154</td>
<td>9,531</td>
<td>18,685</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6215</td>
<td>8,545</td>
<td>0</td>
<td>8,545</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6245</td>
<td>1,878</td>
<td>0</td>
<td>1,878</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6256</td>
<td>67</td>
<td>1,241</td>
<td>1,308</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6257</td>
<td>8,681</td>
<td>10,898</td>
<td>19,579</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6258</td>
<td>0</td>
<td>1,667</td>
<td>1,667</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6274</td>
<td>0</td>
<td>165</td>
<td>165</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6277</td>
<td>0</td>
<td>232</td>
<td>232</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6291</td>
<td>0</td>
<td>7,615</td>
<td>7,615</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6295</td>
<td>0</td>
<td>16,392</td>
<td>16,392</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6298</td>
<td>0</td>
<td>400</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6299</td>
<td>0</td>
<td>3,482</td>
<td>3,482</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>82,979</td>
</tr>
<tr>
<td>DEPARTMENT OF PEDIATRICS</td>
<td>6213</td>
<td>11,961</td>
<td>315</td>
<td>12,276</td>
<td></td>
</tr>
<tr>
<td>Pediatric Hematology-Oncology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12,276</td>
</tr>
<tr>
<td>PHYSICAL MEDICINE AND REHABILITATION SERVICE</td>
<td>9612</td>
<td>0</td>
<td>2,058</td>
<td>2,058</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,058</td>
</tr>
<tr>
<td>DEPARTMENT OF PSYCHIATRY</td>
<td>1326-90</td>
<td>34</td>
<td>0</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7245</td>
<td>0</td>
<td>163</td>
<td>163</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7246</td>
<td>0</td>
<td>7,854</td>
<td>7,854</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8,051</td>
</tr>
<tr>
<td>DEPARTMENT OF RADIOLOGY</td>
<td>4538</td>
<td>0</td>
<td>500</td>
<td>500</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>500</td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td>2504</td>
<td>1,119</td>
<td>0</td>
<td>1,119</td>
<td></td>
</tr>
<tr>
<td>Army Audiology and Speech Center</td>
<td>2505</td>
<td>168</td>
<td>420</td>
<td>588</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2511</td>
<td>0</td>
<td>5,350</td>
<td>5,350</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2538</td>
<td>3,905</td>
<td>126</td>
<td>4,031</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2590</td>
<td>5,005</td>
<td>1,555</td>
<td>6,560</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2591</td>
<td>2,139</td>
<td>66.6</td>
<td>2,785</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2594</td>
<td>6,220</td>
<td>0</td>
<td>6,220</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2598</td>
<td>1,995</td>
<td>0</td>
<td>1,995</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28,648</td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td>3008</td>
<td>4,608</td>
<td>963</td>
<td>5,571</td>
<td></td>
</tr>
<tr>
<td>Critical Care Medicine Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,571</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,  
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER</th>
<th>PRIOR FY’s ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Surgery Service</td>
<td>2037</td>
<td>1,365</td>
<td>0</td>
<td>1,365</td>
</tr>
<tr>
<td></td>
<td>2058</td>
<td>0</td>
<td>795</td>
<td>795</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>1,365</td>
<td>795</td>
<td>2,160</td>
</tr>
<tr>
<td>Ophthalmology Service</td>
<td>2319</td>
<td>3,969</td>
<td>5,946</td>
<td>9,915</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>3,969</td>
<td>5,946</td>
<td>9,915</td>
</tr>
<tr>
<td>Organ Transplant Service</td>
<td>2630</td>
<td>362</td>
<td>0</td>
<td>362</td>
</tr>
<tr>
<td></td>
<td>2631</td>
<td>2,195</td>
<td>195</td>
<td>2,390</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>2,557</td>
<td>195</td>
<td>2,752</td>
</tr>
<tr>
<td>Orthopaedic Surgery Service</td>
<td>2401</td>
<td>0</td>
<td>962</td>
<td>962</td>
</tr>
<tr>
<td></td>
<td>2410</td>
<td>8,439</td>
<td>0</td>
<td>8,439</td>
</tr>
<tr>
<td></td>
<td>2414</td>
<td>195</td>
<td>0</td>
<td>195</td>
</tr>
<tr>
<td></td>
<td>2421</td>
<td>0</td>
<td>799</td>
<td>799</td>
</tr>
<tr>
<td></td>
<td>2424</td>
<td>0</td>
<td>962</td>
<td>962</td>
</tr>
<tr>
<td></td>
<td>2427</td>
<td>0</td>
<td>278</td>
<td>278</td>
</tr>
<tr>
<td></td>
<td>2429</td>
<td>0</td>
<td>819</td>
<td>819</td>
</tr>
<tr>
<td></td>
<td>2431</td>
<td>0</td>
<td>902</td>
<td>902</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>8,635</td>
<td>4,722</td>
<td>13,357</td>
</tr>
<tr>
<td>Otolaryngology-Head &amp; Neck Surgery Svc</td>
<td>2048</td>
<td>15,076</td>
<td>0</td>
<td>15,076</td>
</tr>
<tr>
<td></td>
<td>2501</td>
<td>5,874</td>
<td>0</td>
<td>5,874</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>20,950</td>
<td>0</td>
<td>20,950</td>
</tr>
<tr>
<td>Plastic Surgery Service</td>
<td>2909</td>
<td>1,042</td>
<td>0</td>
<td>1,042</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>1,042</td>
<td>0</td>
<td>1,042</td>
</tr>
<tr>
<td>Urology Service</td>
<td>2860</td>
<td>0</td>
<td>482</td>
<td>482</td>
</tr>
<tr>
<td></td>
<td>2862</td>
<td>5,109</td>
<td>8,780</td>
<td>13,889</td>
</tr>
<tr>
<td></td>
<td>2864</td>
<td>500</td>
<td>0</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>2867</td>
<td>0</td>
<td>1,517</td>
<td>1,517</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>5,609</td>
<td>10,779</td>
<td>16,388</td>
</tr>
<tr>
<td>VETERINARY SERVICE</td>
<td>9801</td>
<td>298</td>
<td>0</td>
<td>298</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>298</td>
<td>0</td>
<td>298</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
## ADDENDUM

EXPENSES FOR PROTOCOLS APPROVED DURING FY-92
FIRST ANNUAL PROGRESS REPORT TO BE SUBMITTED IN FY-93
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER</th>
<th>PRIOR FY'S ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALLERGY-IMMUNOLOGY SERVICE</strong></td>
<td>3367</td>
<td>0</td>
<td>2,573</td>
<td>2,573</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>2,573</td>
<td>2,573</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF CLINICAL INVESTIGATION</strong></td>
<td>9285</td>
<td>0</td>
<td>1,394</td>
<td>1,394</td>
</tr>
<tr>
<td></td>
<td>9286</td>
<td>0</td>
<td>1,738</td>
<td>1,738</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>3,132</td>
<td>3,132</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td>Endocrine-Metabolic Service</td>
<td>1336</td>
<td>0</td>
<td>6,758</td>
</tr>
<tr>
<td></td>
<td>1337</td>
<td>0</td>
<td>264</td>
<td>264</td>
</tr>
<tr>
<td></td>
<td>1339</td>
<td>0</td>
<td>837</td>
<td>837</td>
</tr>
<tr>
<td></td>
<td>1342</td>
<td>0</td>
<td>1,304</td>
<td>1,304</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>9,163</td>
<td>9,163</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td>Gastroenterology Service</td>
<td>1423</td>
<td>0</td>
<td>4,718</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>4,718</td>
<td>4,718</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td>Hematology-Oncology Service</td>
<td>1681</td>
<td>0</td>
<td>2,705</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>2,705</td>
<td>2,705</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td>Nephrology Service</td>
<td>1166</td>
<td>0</td>
<td>4,582</td>
</tr>
<tr>
<td></td>
<td>1167</td>
<td>0</td>
<td>4,324</td>
<td>4,324</td>
</tr>
<tr>
<td></td>
<td>1168</td>
<td>0</td>
<td>5,593</td>
<td>5,593</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>14,499</td>
<td>14,499</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td>Pulmonary Disease Service</td>
<td>1754</td>
<td>0</td>
<td>4,981</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>4,981</td>
<td>4,981</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td>Rheumatology Service</td>
<td>3709</td>
<td>0</td>
<td>25,923</td>
</tr>
<tr>
<td></td>
<td>3710</td>
<td>0</td>
<td>12,383</td>
<td>12,383</td>
</tr>
<tr>
<td></td>
<td>3711</td>
<td>0</td>
<td>26,334</td>
<td>26,334</td>
</tr>
<tr>
<td></td>
<td>3712</td>
<td>0</td>
<td>27,429</td>
<td>27,429</td>
</tr>
<tr>
<td></td>
<td>3714</td>
<td>0</td>
<td>1,271</td>
<td>1,271</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>93,340</td>
<td>93,340</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
## Addendum

Expenses for Protocols Approved During FY-92
First Annual Progress Report to be Submitted in FY-93
By Department and Service, Listed in Alphabetical Order

<table>
<thead>
<tr>
<th>Department/Service</th>
<th>Protocol Number</th>
<th>Prior FY's ($)</th>
<th>Current FY ($)</th>
<th>Total ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Department of Pediatrics</strong></td>
<td>6300</td>
<td>0</td>
<td>23,003</td>
<td>23,003</td>
</tr>
<tr>
<td></td>
<td>6307</td>
<td>0</td>
<td>2,371</td>
<td>2,371</td>
</tr>
<tr>
<td></td>
<td>6308</td>
<td>0</td>
<td>3,226</td>
<td>3,226</td>
</tr>
<tr>
<td></td>
<td>6313</td>
<td>0</td>
<td>6,024</td>
<td>6,024</td>
</tr>
<tr>
<td></td>
<td>6321</td>
<td>0</td>
<td>2,209</td>
<td>2,209</td>
</tr>
<tr>
<td></td>
<td>6327</td>
<td>0</td>
<td>5,115</td>
<td>5,115</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>0</td>
<td>41,948</td>
<td>41,948</td>
<td></td>
</tr>
<tr>
<td><strong>Department of Surgery</strong></td>
<td>251-</td>
<td>0</td>
<td>910</td>
<td>910</td>
</tr>
<tr>
<td></td>
<td>2516</td>
<td>0</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>2521</td>
<td>0</td>
<td>997</td>
<td>997</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>0</td>
<td>1,987</td>
<td>1,987</td>
<td></td>
</tr>
<tr>
<td><strong>Department of Surgery</strong></td>
<td>2435</td>
<td>0</td>
<td>5,959</td>
<td>5,959</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>0</td>
<td>5,959</td>
<td>5,959</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1400-88</td>
<td>Engler, Renata LTC(P) MC. A Pilot Study Evaluating Intestinal and Serum Immunoglobulin Levels in Patients with Acquired Hypogammaglobulinemia and Recurrent/Chronic Diarrhea of Undefined Etiology (2/88)</td>
<td>1</td>
</tr>
<tr>
<td>3221</td>
<td>Engler, Renata MAJ MC. The Role of IgG Subclasses in Hymenoptera Hypersensitivity and Immunotherapy (8/84)</td>
<td>2</td>
</tr>
<tr>
<td>3336</td>
<td>Engler, Renata LTC(P), MC. The Effect of Human Breast Milk Cell Supernatants on In Vitro Immunoglobulin Secretion (11/87)</td>
<td>3</td>
</tr>
<tr>
<td>3339</td>
<td>Squire, Edward LTC MC. Comparison of House Dust Mite Educational Programs on Selected Outcome Variables (7/88)</td>
<td>4</td>
</tr>
<tr>
<td>3340</td>
<td>Salata, Kalman PhD. Analysis of Carbohydrate Epitopes on Food Allergen Proteins: A Pilot Study (8/88)</td>
<td>5</td>
</tr>
<tr>
<td>3341</td>
<td>Squire, Edward LTC MC. Occurrence of Laryngeal Dysfunction Among Patients Initially Diagnosed as Having Bronchial Asthma (8/88)</td>
<td>6</td>
</tr>
<tr>
<td>3343</td>
<td>Salata, Kalman PhD. Standardized Vs. Nonstandardized Allergen Products Containing Dust Mite Antigens (10/88)</td>
<td>7</td>
</tr>
<tr>
<td>3344</td>
<td>Carpenter, Gary COL MC. The Effect of UVB (Ultraviolet-B) Light on Immediate, Late and Delayed Hypersensitivity (12/88)</td>
<td>8</td>
</tr>
<tr>
<td>3345</td>
<td>Salata, Kalman PhD. Cross Allergenicity of Pollen Allergens from American Linden and European Linden (6/89)</td>
<td>9</td>
</tr>
<tr>
<td>3346</td>
<td>Salata, Kalman PhD. Comparison of Three Methods of Assessing Induction of Mitogen and Allergen Specific Lymphocyte Proliferation (6/89)</td>
<td>10</td>
</tr>
<tr>
<td>3347</td>
<td>Salata, Kalman PhD. A Simple Prick Puncture End Point Titration Procedure to Evaluate the Safety of Switching from Nonstandardized to Standardized Allergen Extracts for Use in Immunotherapy (8/89)</td>
<td>11</td>
</tr>
<tr>
<td>3348</td>
<td>Engler, Renata LTC(P) MC. Immunotherapy Reactions (11/89)</td>
<td>12</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>3349</td>
<td>Salata, Kalman PhD. Mitogen-Inducible T Suppressor Cell Assay by Flow Cytometry (12/89)</td>
</tr>
<tr>
<td>3350</td>
<td>Salata, Kalman PhD. Flow Cytometric Analysis of Natural Killer Cell Activity and Antibody-Dependent Cell-Mediated Cytotoxicity (1/90)</td>
</tr>
<tr>
<td>3351</td>
<td>Salata, Kalman PhD. In Vitro House Dust Mite Allergy Assays: Comparison of a Monoclonal Antibody/Allergen Capture Method with a Fluorescent Allergosorbent Test (1/90)</td>
</tr>
<tr>
<td>3352</td>
<td>Squire, Edward LTC MC. Use of Steroid Sparing Agents Among Asthmatics Doing Poorly on Corticosteroids: A Pilot Study (1/90)</td>
</tr>
<tr>
<td>3353</td>
<td>Salata, Kalman PhD. Contrasuppressor Cells in Allergy Immunotherapy (3/90)</td>
</tr>
<tr>
<td>3354</td>
<td>Salata, Kalman PhD. Two Way Mixed Lymphocyte Culture: Analysis by Two Color Flow Cytometry (4/90)</td>
</tr>
<tr>
<td>3355</td>
<td>Salata, Kalman PhD. Effect of Methotrexate on Expression of Intercellular Adhesion Molecule I in Interleukin-1 Stimulated Cultured Human Cells (5/90)</td>
</tr>
<tr>
<td>3356</td>
<td>Davis, William CPT MC. High Dose Intravenous Immunoglobulin in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (8/90)</td>
</tr>
<tr>
<td>3357</td>
<td>McCormack, Emma MAJ MC. Serum and Secretory Immune Status of Patients with Chronic Sinusitis and Normals (9/90)</td>
</tr>
<tr>
<td>3358</td>
<td>Salata, Kalman PhD. Plasma Level of Mast Cell Tryptase in Patients Undergoing Immunodiagnostic or Immunotherapy Procedures who Experience Adverse Reactions (9/90)</td>
</tr>
<tr>
<td>3359</td>
<td>Salata, Kalman PhD. Leukotriene B4 Receptor Downregulation: Flow Cytometry Analysis (11/90)</td>
</tr>
<tr>
<td>3360</td>
<td>Salata, Kalman PhD. 3,3'-Dioctadecyloxacarbocyanine (DiO) Induced Immunosuppression: Inhibition of Mitogen, Antigen and Alloantigen Stimulated CD69 Expression (11/90)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>3361</td>
<td>Polly, Shirley MAJ MC. Pneumococcal Polysaccharide Vaccine: Adverse Reactions to Immunization (12/90)</td>
</tr>
<tr>
<td>3362</td>
<td>Salata, Kalman PhD. Immunologic Evaluation of Acute and Persistent Ectopic Gestation: A Collaborative Project with Portsmouth Naval Hospital (1/91)</td>
</tr>
<tr>
<td>3363</td>
<td>Salata, Kalman PhD. Stability of Cat and House Dust Mite Allergens in Allergy Immunotherapy Preparations (4/91)</td>
</tr>
<tr>
<td>3364</td>
<td>Salata, Kalman PhD. Effect of N-(Fluorenyl-9-methoxycarbonyl)-L-Leucine (FMOC-LEU) on Neutrophil Activation (5/91)</td>
</tr>
<tr>
<td>3365</td>
<td>Davis, William CPT MC. Leucocyte Subset Analysis in Patients Treated with Intravenous Immunoglobulin (IVIG) (7/91)</td>
</tr>
<tr>
<td>3366</td>
<td>Salata, Kalman PhD. Bird Antigen Detection in the Home and IgG and IgG Subclass Titers in Healthy Bird Owners Versus Those With Hypersensitivity Pneumonitis (8/91)</td>
</tr>
<tr>
<td>4811</td>
<td>Holmes, Kirby Capt BSC. Documentation of Irradiated Lymphocyte Inactivation Using the CD69 Surface Marker and Flow Cytometry (9/91)</td>
</tr>
<tr>
<td>4812</td>
<td>Bennett, Charles CPT MS. Quantitation of Red Cell Phenotypes in a Dual Population by Flow Cytometry (9/91)</td>
</tr>
<tr>
<td>9272</td>
<td>Lippert, Lloyd LTC MC. Relationship of Major Histocompatibility Complex Class II Genes to Inhibitor Antibody Formation in Hemophilia A (9/88)</td>
</tr>
<tr>
<td>2584</td>
<td>Derderian, Sarkis LTC MC. Evaluation of Patients with Obstructive Sleep Apnea Syndrome Following Uvulopalatopharyngoplasty (2/88)</td>
</tr>
<tr>
<td>4801</td>
<td>Lippert, Lloyd LTC MS. Fibrinogen Concentration in Two Methods of Cryoprecipitate Preparation (9/88)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4804</td>
<td>Lippert, Lloyd LTC MS. Antigen Typing Reticulocytes in Mixed Red Blood Cell Populations by Flow Cytometry (10/89)</td>
<td>36</td>
</tr>
<tr>
<td>6276</td>
<td>Lippert, Lloyd LTC MS. In Vivo Persistence of Reticulocyte and Antigen Phenotype in Post-Transfusion Patients Analyzed by Flow Cytometry (11/90)</td>
<td>37</td>
</tr>
<tr>
<td>9263</td>
<td>Derderian, Sarkis LTC MC. Neurohumoral Regulation of Ventilation in Patients with Elevated Adrenocorticotropic Hormone (ACTH) and Beta Endorphins (BE) (10/85)</td>
<td>38</td>
</tr>
<tr>
<td>9271</td>
<td>Derderian, Sarkis LTC MC. The Ventilatory Response to Carbon Dioxide in Compensated Hepatic Cirrhosis (9/87)</td>
<td>39</td>
</tr>
<tr>
<td>9275</td>
<td>Schaudies, Paul CPT MS. Quantitation and Characterization of EGF Levels in Rat Milk (10/88)</td>
<td>40</td>
</tr>
<tr>
<td>9280</td>
<td>Derderian, Sarkis LTC MC. Sleep and Respiratory Control in Kyphoscoliosis (2/90)</td>
<td>41</td>
</tr>
<tr>
<td>9281</td>
<td>Lippert, Lloyd LTC MS. Relationship of Aryl Hydrocarbon Hydroxylase Activity to V-Beta T Cell Receptor Phenotype in Inbred Mouse Strains: A Model for Cancer Risk (5/90)</td>
<td>42</td>
</tr>
<tr>
<td>9282</td>
<td>Coffey, Lauri MAJ SP. Nutrition Knowledge, Dietary Habits, Human Performance and HDL Ratios of Special Forces Soldiers (12/90)</td>
<td>43</td>
</tr>
<tr>
<td>9283</td>
<td>Culpepper, William DAC. Circadian Function in Patients with Sleep Apnea: A Pilot Study (3/91)</td>
<td>44</td>
</tr>
<tr>
<td>9284</td>
<td>Dobek, Arthur PhD. Comparison of the Hela Cell Monolayer Vs. the Toxi-titer System for Their Respective Ability to Detect Clostridium Difficile Toxin B in Stool Filtrate (4/91)</td>
<td>45</td>
</tr>
<tr>
<td>DEAIAL CLINIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9410</td>
<td>White, Ann CPT MC. Comparison of the Bacterial Flora in Pericoronitis in HIV-Infected Patients and Non-HIV-Infected Patients (12/90)</td>
<td>46</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>DENTAL CLINIC (continued)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9411</td>
<td>Patterson, Adrian LTC DC. Evaluation of Collagen Plugs to Prevent Localized Osteitis in the Sockets of Mandibular Third Molars Susceptible to Acute Pericoronitis (1/91)</td>
<td>47</td>
</tr>
<tr>
<td>9412</td>
<td>Bradford, Brant LTC DC. Comparison of Presurgical and Postsurgical Condylar Measurements as a Function of Orthognathic Surgical Fixation Technique (3/91)</td>
<td>48</td>
</tr>
<tr>
<td>FORT DIX, NEW JERSEY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9088</td>
<td>O'Connor, Francis CPT MC. Prevention of Low Back Pain in Military Basic Trainees (3/91)</td>
<td>49</td>
</tr>
<tr>
<td>HIV RESEARCH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1952</td>
<td>Oster, Charles COL MC. The Clinical Presentation of HIV Infected Patients at Walter Reed Army Medical Center (1/87)</td>
<td>50</td>
</tr>
<tr>
<td>1953</td>
<td>Drabick, Joseph MAJ MC. The Generation of Human Monoclonal Antibodies to the HIV (1/87)</td>
<td>51</td>
</tr>
<tr>
<td>1958</td>
<td>Hoover, David LTC MC. In Situ Hybridization for Detection of HIV in Langerhans Cells of HIV Infected Patients (7/87)</td>
<td>52</td>
</tr>
<tr>
<td>1970</td>
<td>Oster, Charles COL MC. Treatment IND Protocol for the Use of Videx in Patients with AIDS who are Intolerant to Zidovudine and Patients Exhibiting Significant Deterioration while Taking Zidovudine (2/90)</td>
<td>53</td>
</tr>
<tr>
<td>331.2</td>
<td>Birx, Deborah TC MC. Delayed Type Hypersensitivity Skin Testing: Correlation of Intradermal Injection Vs. Epicutaneous Antigen Placement and CD4 Number in Normals and HIV Seropositive Subjects (8/88)</td>
<td>54</td>
</tr>
<tr>
<td>806</td>
<td>Anderson, David MAJ MC. Pathological Manifestations of HIV Infections at Autopsy (12/89)</td>
<td>55</td>
</tr>
<tr>
<td>6220</td>
<td>Fischer, Gerald COL MC. Epidemiology of HIV In Pediatric and Perinatal Patients - A Natural History Study (7/88)</td>
<td>56</td>
</tr>
<tr>
<td>6222</td>
<td>Fischer, Gerald COL MC. Core Project: Evaluation of Diagnostic Assays for Human Immunodeficiency Virus (HIV) in Children with Evidence of HIV Exposure or HIV Illness (9/88)</td>
<td>57</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6264</td>
<td>Pettett, Gary COL MC. Perinatal HIV Infection: Epidemiology and Natural History (4/90)</td>
</tr>
<tr>
<td>6284</td>
<td>Pettett, Philip COL MC. Perinatal HIV Tissue Bank (3/91)</td>
</tr>
<tr>
<td>7243</td>
<td>Rundell, James MAJ MC. Psychiatric Natural History Study: Factors Related to Human Immunodeficiency Virus Transmission and Morbidity (4/90)</td>
</tr>
<tr>
<td>8802</td>
<td>Hawkes, Clifton LTC MC. VA Cooperative Study No. 298, Treatment of AIDS and AIDS Related Complex; Part I: Treatment of Patients with ARC (AZT Vs. Placebo) (4/88)</td>
</tr>
<tr>
<td>8803</td>
<td>Roberts, Chester, LTG MS. Core Protocol for HIV Developmental Diagnostics (Adults) (5/88)</td>
</tr>
<tr>
<td>8804</td>
<td>Chung, Raymond COL MC. The Natural History of HIV Infection and Disease in United States Military Beneficiaries (5/88)</td>
</tr>
<tr>
<td>8805</td>
<td>Konzelman, Joseph DDS. Natural History of Oral Manifestations of HIV Infection in a United States Military Population (10/88)</td>
</tr>
<tr>
<td>8806</td>
<td>Redfield, Robert LTC MC. Active Immunization of HIV Infected Patients with Recombinant GP160 HIV Protein: Phase I Study of Immunotherapy, Immunogenicity and Toxicity (11/88)</td>
</tr>
<tr>
<td>8808</td>
<td>Bjornson, Darrell LTC MS. A Pharmacokinetic Study to Develop a Database to Describe the Relationship Between Zidovudine (ZDV)/β-Lucuronyl (CZDV) Blood Levels and Drug Toxicity in HIV Infected Patients (1/89)</td>
</tr>
<tr>
<td>8810</td>
<td>Bombaugh, Maryann MAJ MC. Factors Affecting Heterosexual Transmission of Human Immunodeficiency Virus (5/88)</td>
</tr>
<tr>
<td>8811</td>
<td>Smith, Kathleen LTC MC. The Investigation of the Cutaneous Microflora Found in HIV Infected Patients as it Relates to the Onset, Severity and Progression of Disease (5/89)</td>
</tr>
<tr>
<td>8812</td>
<td>Smith, Kathleen LTC MC. The Investigation of the Cutaneous Manifestations of HIV Infection in Relation to the Onset, Severity and Progression of Disease, Dermatologic Natural History (5/89)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>8814</td>
<td>Bjornson, Darrel COL MS. Pharmacoepidemiologic Study to Develop a Database to Document Variations in the Outcome of Illness Which May be Due to Drug Effects and To Document Patterns of Drug use in HIV Infected Patients (8/89)</td>
</tr>
<tr>
<td>8815</td>
<td>Bjornson, Darrel COL MS. Pneumocystis Carinii Pneumonia in HIV Patients: A Cohort Study to Estimate the Protective Effect of Prophylactic Pentamidine Inhalation in Compliant Vs. Noncompliant Patients (8/89)</td>
</tr>
<tr>
<td>8816</td>
<td>McNeil, John MAJ MC. Assessment of Risk Factors for HIV Infection Among AD U.S. Army Personnel with Documented Recent HIV Antibody Seroconversion (8/89)</td>
</tr>
<tr>
<td>8817</td>
<td>Johnson, Steven MAJ MC. The Effect of HIV Infection on the Initial Manifestations and Response to Treatment of Syphilis (11/89)</td>
</tr>
<tr>
<td>8818</td>
<td>Mayers, Douglas CDR MC. Prospective Study of the Emergence of Zidovudine Resistance in Patients Infected with the Human Immunodeficiency Virus who are Treated with Zidovudine (6/90)</td>
</tr>
<tr>
<td>8819</td>
<td>Redfield, Robert LTC MC. Active Immunization of Early HIV Infected Patients with Recombinant GP160 HIV Protein: Phase II Study of Toxicity, Immunotherapy, In Vivo Immunoregulation and Clinical Efficacy (9/90)</td>
</tr>
<tr>
<td>8820</td>
<td>Redfield, Robert LTC MC. A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1-111B Vaccine in HIV+ Seropositive Adult Volunteers (9/90)</td>
</tr>
<tr>
<td>8821</td>
<td>Hendrix, Rose MAJ MC. Sleep Disturbances in HIV+ Patients: A Descriptive Study (1/91)</td>
</tr>
<tr>
<td>8822</td>
<td>Oster, Charles COL MC. An Open Study of Foscarnet Treatment of First Episode CMV-Retinitis in AIDS Patients (6/91)</td>
</tr>
<tr>
<td>8823</td>
<td>Oster, Charles COL MC. Safety and Efficacy of Amphotericin B Lipid Complex in Treatment of Cryptococcal Meningitis in Patients with Acquired Immune Deficiency Syndrome (6/91)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
# HIV RESEARCH (continued)

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>8824</td>
<td>Skillman, Donald MAJ MC. Phase I Study of Alferon N Injection in Persons with Asymptomatic Human Immunodeficiency Virus (HIV) Infection (9/91)</td>
</tr>
<tr>
<td>8400</td>
<td>McKee, Morris MAJ MC. Relationship Between Marksmanship and Contrast Sensitivity (8/89)</td>
</tr>
</tbody>
</table>

## DEPARTMENT OF MEDICINE

### Cancer & Leukemia Group B

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1501</td>
<td>Weiss, Raymond MD. CALGB 8935 Trimodality Therapy for Stage IIIA Non-small Cell Lung Cancer, Phase II (9/89)</td>
</tr>
<tr>
<td>1502</td>
<td>Weiss, Raymond MD. CALGB 8945 A Phase II Study of Toremifene in Metastatic Breast Cancer (12/89)</td>
</tr>
<tr>
<td>1503</td>
<td>Weiss, Raymond MD. CALGB 8965 Flow Cytometry and Reticulocyte Analysis in Myelodysplastic Syndromes (12/89)</td>
</tr>
<tr>
<td>1504</td>
<td>Weiss, Raymond MD. CALGB 8662 Monitoring Circulating Breast Cancer Associated Antigens with the 15-3 Radioimmunoassay in Metastatic Breast Cancer (1/90)</td>
</tr>
<tr>
<td>1505</td>
<td>Weiss, Raymond MD. CALGB 8963 Psychological Adaptation of Survivors of Acute Leukemia (2/90)</td>
</tr>
<tr>
<td>1506</td>
<td>Weiss, Raymond MD. CALGB 8922 Interleukin-2 in Acute Myelogenous Leukemia (2/90)</td>
</tr>
<tr>
<td>1509</td>
<td>Weiss, Raymond MD. CALGB 9011 A Study of Fludarabine Vs. Chlorambucil Vs. Both Drugs for Chronic Lymphatic Leukemia (11/90)</td>
</tr>
<tr>
<td>1510</td>
<td>Weiss, Raymond MD. CALGB 9051 A Study of Combination Chemotherapy Plus Irradiation for Early Stage Hodgkin's Disease (11/90)</td>
</tr>
<tr>
<td>1512</td>
<td>Weiss, Raymond MD. CALGB 8944 A Study of Intensive Combined Modality Therapy for Stage III Breast Cancer (11/90)</td>
</tr>
</tbody>
</table>

*Reference is to page number(s) in Volume II.*
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE* (VOL II)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1513</td>
<td>Weiss, Raymond MD. CALGB 8923 Randomized Studies of Induction Therapy Adjuncts and Intensification Therapy Regimens for Older Patients with Acute Myelocytic Leukemia (12/90)</td>
<td>91</td>
</tr>
<tr>
<td>1514</td>
<td>Weiss, Raymond MD. CALGB 9021 Induction Therapy for Relapsed or Refractory Acute Myelocytic Leukemia or Blast Crisis of Chronic Myelocytic Leukemia (12/90)</td>
<td>92</td>
</tr>
<tr>
<td>1515</td>
<td>Weiss, Raymond MD. CALGB 9022 Intensive Post Remission Therapy for Acute Myelocytic Leukemia (12/90)</td>
<td>93</td>
</tr>
<tr>
<td>1516-84</td>
<td>Weiss, Raymond MD. CALGB 8364: Immunological Diagnostic Studies in Adult ALL (10/83)</td>
<td>94</td>
</tr>
<tr>
<td>1517</td>
<td>Weiss, Raymond MD. CALGB 9013: Alpha Interferon and Cytarabine for Untreated Chronic Myelogenous Leukemia (2/91)</td>
<td>95</td>
</tr>
<tr>
<td>1518</td>
<td>Weiss, Raymond MD. CALGB 8761: Prognostic Implications of Chromosomal Abnormalities in Chronic Myelogenous Leukemia (2/91)</td>
<td>96</td>
</tr>
<tr>
<td>1519</td>
<td>Weiss, Raymond MD. CALGB 9142 Comparison of Chemotherapy Vs. Chemohormorotherapy in Premenopausal Women with Stage II Receptor Positive Breast Cancer (3/91)</td>
<td>97</td>
</tr>
<tr>
<td>1520</td>
<td>Weiss, Raymond MD. CALGB 9143 Comparison of Combination Chemotherapy with the CAF Regimen Vs. A 16-week 6-Drug Regimen for Stage II Receptor Negative Breast Cancer (3/91)</td>
<td>98</td>
</tr>
<tr>
<td>1521-91</td>
<td>Weiss, Raymond MD. CALGB 9194: Comparison of Adjuvant Chemotherapy with Concurrent or Delayed Tamoxifen vs. Tamoxifen Along in Postmenopausal Patients with Receptor Positive Stage II Breast Cancer (4/91)</td>
<td>99</td>
</tr>
<tr>
<td>1522-84</td>
<td>Weiss, Raymond MD. CALGB 8461: Cytogenetic Studies in Acute Leukemia: A Companion to CALGB 8011, 8323, 8321, and 8411 (9/84)</td>
<td>100</td>
</tr>
<tr>
<td>1536-R5</td>
<td>Weiss, Raymond MD. CALGB 8582: A Comparison of Pentostatin and Alpha Interferon in Splenectomized Patients with Active Hairy Cell Leukemia (5/85)</td>
<td>101</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1550-86</td>
<td>Weiss, Raymond MD. CALGB 8534: Combination Chemotherapy with Intensive ACE/PCE and Radiation Therapy to the Primary Tumor and Prophylactic Whole Brain Radiation Therapy with or without Warfarin in Limited Small Cell Carcinoma of the Lung (8/86)</td>
<td>102</td>
</tr>
<tr>
<td>1551-86</td>
<td>Weiss, Raymond MD. CALGB 8362: Pharmacokinetics of Ara-C in Patients with Acute Myelogenous Leukemia, A Companion to CALGB 8525 (9/86)</td>
<td>103</td>
</tr>
<tr>
<td>1564-87</td>
<td>Weiss, Raymond MD. CALGB 8692: Intergroup Study in Metastatic Sarcomas (6/87)</td>
<td>105</td>
</tr>
<tr>
<td>1573-87</td>
<td>Weiss, Raymond MD. CALGB 8762: Molecular Subtypes in Acute Lymphatic Leukemia with Philadelphia Chromosome (10/87)</td>
<td>106</td>
</tr>
<tr>
<td>1574-87</td>
<td>Weiss, Raymond MD. CALGB 8763: Immunoglobulin and T Cell Receptor Gene Rearrangement in Adult Acute Lymphatic Leukemia (10/87)</td>
<td>107</td>
</tr>
<tr>
<td>1577-80</td>
<td>Weiss, Raymond MD. CALGB 8361: Immunologic Diagnostic Studies in AML (blood drawing phase); previously CALGB 7921) CALGB 8321: A Comparative Study of 3 Remission Induction Regimens and 2 Maintenance Regimens for AML (treatment phase); previously CALGB 7921 (12/81)</td>
<td>108</td>
</tr>
<tr>
<td>1579-88</td>
<td>Weiss, Raymond MD. CALGB 8861: Monitoring Circulating Breast Cancer-Associated 15-3 Antigen in Stage II Breast Cancer (1/88)</td>
<td>109</td>
</tr>
<tr>
<td>1584-88</td>
<td>Weiss, Raymond MD. CALGB 8896: An Intergroup Study of Adjuvant Therapy of Primary Colon Cancer (9/88)</td>
<td>111</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator</th>
<th>Title and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1590-89</td>
<td>Weiss, Raymond MD.</td>
<td>CALGB 8852: A Study of CHOPE in Diffuse Lymphomas (1/89)</td>
</tr>
<tr>
<td>1595-89</td>
<td>Weiss, Raymond MD.</td>
<td>CALGB 8961 RAS Mutations in Myelodysplasia (4/89)</td>
</tr>
<tr>
<td>1596-89</td>
<td>Weiss, Raymond MD.</td>
<td>CALGB 8897 Evaluation of Adjuvant Therapy for Node Negative Primary Breast Cancer, Phase III (8/89)</td>
</tr>
<tr>
<td>1598-89</td>
<td>Weiss, Raymond MD.</td>
<td>CALGB 8952 Combination Chemotherapy for Advanced Hodgkin's Disease, Phase III (8/89)</td>
</tr>
<tr>
<td>1243</td>
<td>Laird, John MAJ MC.</td>
<td>Percutaneous Balloon Valvuloplasty for Patients with Mitral Stenosis or Aortic Stenosis: A Pilot Study (10/86)</td>
</tr>
<tr>
<td>1245</td>
<td>Wortham, Dale COL MC.</td>
<td>A Double Blind Study of the Safety and Efficacy of Multiple Intravenous Infusions of Disodium EDTA in Patients with Obstructive Peripheral Arterial Disease and Intermittent Claudication (7/87)</td>
</tr>
<tr>
<td>1249</td>
<td>Rogan, Kevin MAJ MC.</td>
<td>Multicenter Study of Silent Ischemia (12/87)</td>
</tr>
<tr>
<td>1256</td>
<td>Cambier, Patrick CPT MC.</td>
<td>High Resolution Ambulatory Holter Monitoring in Preoperative Cardiac Evaluation of Vascular Surgery Patients (3/89)</td>
</tr>
<tr>
<td>1258</td>
<td>Hull, Robert CPT MC.</td>
<td>Combined Effects of Angiotensin-Converting Enzyme Inhibitors and Digoxin in the Chronic Treatment of Idiopathic Dilated Cardiomyopathy (7/89)</td>
</tr>
<tr>
<td>1260</td>
<td>Weston, Lawrence MAJ MC.</td>
<td>Antiarrhythmic Therapy in Congestive Heart Failure, VA Cooperative Study #320 (10/89)</td>
</tr>
<tr>
<td>1262</td>
<td>Gaither, Neal MAJ MC.</td>
<td>Utility of Transesophageal Echocardiography in Evaluation of Young Patients with Unexplained Cerebral Ischemia and Infarction (1/90)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1264</td>
<td>Carter, Andrew MAJ MC. The Role of Tumor Necrosis Factor After Balloon Angioplasty in a Pig Model (10/90)</td>
<td>123</td>
</tr>
<tr>
<td>1265</td>
<td>Prewitt, Kerry CPT MC. Cardiac Safety of Sexual Intercourse Following Myocardial Infarction as Assessed by High Resolution Hoiter Monitor (10/90)</td>
<td>124</td>
</tr>
<tr>
<td>1266</td>
<td>Weston, Lawrence MAJ MC. Transcoronary Mapping of Ventricular Tachycardia: Catheter Feasibility Study (12/90)</td>
<td>125</td>
</tr>
<tr>
<td>1267</td>
<td>Gorman, Patrick MAJ MC. Cholesterol and Recurrent Events (5/91)</td>
<td>126</td>
</tr>
<tr>
<td>1268</td>
<td>Stajduhar, Karl MAJ MC. Intracoronary Pacing: Acute and Longterm Safety, Efficacy During Ischemia, and Efficacy in Epicardial Pace-Mapping (7/91)</td>
<td>127</td>
</tr>
<tr>
<td>1269</td>
<td>Carter, Andrew MAJ MC. The Porcine Restenosis Model: Characterization of the Vascular Proliferative Response to Injury (7/91)</td>
<td>128</td>
</tr>
<tr>
<td>1270</td>
<td>Wiley, Thomas MAJ MC. Electrophysiologic Identification of Concealed Accessory Pathway Conduction as a Potential Predisposing Factor in &quot;Lone&quot; Atrial Fibrillation (7/91)</td>
<td>129</td>
</tr>
<tr>
<td>1271</td>
<td>Hudak, Craig CPT MC. A Retrospective Study of Infective Endocarditis (8/91)</td>
<td>130</td>
</tr>
</tbody>
</table>

* DEPARTMENT OF MEDICINE

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1805</td>
<td>Benson, Paul MAJ MC. Use of Isotretinoin in Prevention of Basal Cell Carcinoma (5/83)</td>
<td>131</td>
</tr>
<tr>
<td>1811</td>
<td>James, William LTC MC. Evaluation of Antibiotic Induced Changes in the Microbial Flora of the External Ear (2/89)</td>
<td>132</td>
</tr>
<tr>
<td>1814</td>
<td>O'Donnell, Brian MAJ MC. Split Thickness Tangential Excision of Tattoos with Correlation to Tattoo Pigment Depth (11/90)</td>
<td>133</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>DEPARTMENT AND SERVICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROTOCOL NUMBER</td>
<td>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</td>
<td>DEPARTMENT OF MEDICINE</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF MEDICINE**

Dermatology Service (continued)

1815 Rowe, Jane MAJ MC. Investigation of a Viral Etiology in Pityriasis Rosea (1/91)

**DEPARTMENT OF MEDICINE**

Endocrine-Metabolic Service

1300-88 Burman, Kenneth COL MC. Postoperative Evaluation of Patients with Differentiated Thyroid Cancer: A Study Comparing 131I, 201Tl and Magnetic Resonance Imaging (MRI) (1/88)

1302-88 Burman, Kenneth COL MC. Cholestyramine Treatment of Thyrotoxicosis (3/88)

1303-88 Burman, Kenneth COL MC. The Clinical Application of In Situ Hybridization to Detect Viral Genomes and Oncogenes in Diseases of the Thyroid and Selected Viral Infections (4/88)

1306-88 Coffey, Lauri MAJ SP. Predicting Energy Requirements in Women with Gestational Diabetes Mellitus (GDM) (5/88)


1312-89 Glass, Allan COL MC. Treatment of Oligospermia with Antiestrogens (4/89)

1313-89 Burman, Kenneth COL MC. The Influence of Prolonged Polar Residence Upon Cellular Receptors: The Environmental Genome Interaction (5/89)

1314-89 Coffey, Lauri MAJ SP. The Efficacy of Iodine Restricted Diets in the Treatment of Thyroid Cancer (5/89)

1316-89 Burman, Kenneth COL MC. Identification of Unique Nucleotides in the Thyroid Gland of Patients with Various Thyroid Disorders (7/89)

1317-89 Duncan, William LTC MC. Self Efficacy Beliefs and Diabetes Management Survey (9/89)

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1320-90</td>
<td>Humphrey, Michael MAJ MC. Evaluation of Pathological and Normal Thyroid Tissue for the Presence of Retroviral Genomic Nucleotides (1/90)</td>
</tr>
<tr>
<td>1321-90</td>
<td>Tseng, Yueh-Chu PhD. Processing of Atrial Natriuretic Peptide (ANP) and Its Receptor on Cultured Human Thyroid Cells: Effect of Thyroid Stimulating Hormone (2/90)</td>
</tr>
<tr>
<td>1322-90</td>
<td>Humphrey, Michael CPT MC. Treatment of Impotence in Diabetic Men (5/90)</td>
</tr>
<tr>
<td>1324-90</td>
<td>Schaaf, Marcus MD. Use of Corticotropin Release Hormone in the Evaluation of Hypercortisolemia and Hypocortisolemia (5/90)</td>
</tr>
<tr>
<td>1328-90</td>
<td>Carr, Frances PhD. Mechanisms of Thyrotropin Releasing Hormone Regulation of Thyrotropin Gene Expression (10/90)</td>
</tr>
<tr>
<td>1329-90</td>
<td>Humphrey, Michael MAJ MC. Search for p53 Genetic Abnormalities in Tissue obtained from Normal and Pathological Thyroid Glands (12/90)</td>
</tr>
<tr>
<td>1330-90</td>
<td>Clement, Stephen MAJ MC. A 16 Week Double Blind Placebo Controlled Dose Response Study Using Glipizide GITS Tablets for the Treatment of Noninsulin Dependent Diabetes Mellitus (12/90)</td>
</tr>
<tr>
<td>1331-91</td>
<td>Humphrey, Michael MAJ MC. Response of Multirodular Goiters with Substantial Extension to Therapeutic Doses of Iodine-131 (2/91)</td>
</tr>
<tr>
<td>1332-91</td>
<td>Solomon, Barbara DNSc. Thermogenic Agent Promotion of Weight Loss in Obese Soldiers (3/91)</td>
</tr>
<tr>
<td>1333-91</td>
<td>Jackson, Sharon MAJ USAF. Endothelin and Cultured Human Thyroid Cells (4/91)</td>
</tr>
<tr>
<td>1334-91</td>
<td>Clement, Stephen MAJ MC. A Search for Glycosylated Insulin in Patients with Non-Insulin-Dependent Diabetes Mellitus (5/91)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
DEPARTMENT OF MEDICINE
   Endocrine-Metabolic Service (continued)

1335-91 Francis, Thomas CPT MC. The Preparation of a Selective
   Pericentromeric Chromosome 10 YAC (Yeast Artificial
   Chromosome) DNA Library to Further Define MEN2 Gene Location
   (6/91) 156

1351-84 Wartofsky, Leonard COL MC. Cyclosporin Treatment of Graves'
   Ophthalmopathy (1/84) 157

1356-84 Glass, Allan LTC MC. Ketoconazole-Induced Suppression of
   Serum Testosterone Levels in Men (7/84) 158

1359-85 Burman, Kenneth COL MC. Newer Investigations into the Immune
   Mechanisms of Thyroid Disease (1985) (2/85) 159

1361-85 Duncan, William LTC MC. 1,25-Dihydroxyvitamin D Action at
   the Nuclear Level (5/85) 160

1369-86 Burman, Kenneth COL MC. Magnesium Status and Thyroid Disease
   (10/85) 161

1371-86 Glass, Allan COL MC. Transplantation Antigens on Spermatozoa
   (11/85) 162

1372-86 Glass, Allan COL MC. Effect of Altered Energy Balance on
   Sexual Maturation in Rats (11/85) 163

1376-86 Glass, Allan COL MC. Ketoconazole Effects on Vitamin D in
   Hypercalcemic Patients (4/86) 164

1385-87 Burman, Kenneth COL MC. Molecular Biology of Thyroid Disease
   (10/86) 165

1386-87 Burman, Kenneth COL MC. In Vitro Determination of Messenger
   RNA Isolated from Porcine Thyroid Glands (12/86) 166

1389-87 Duncan, William LTC MC. 1,25-Dihydroxyvitamin D3 Induction
   of Ornithine Decarboxylase Activity in Regenerating Rat Liver
   (5/87) 167

1390-87 Burman, Kenneth COL MC. Dynamic Assessment of Zinc Status in
   Thyroid Disease (5/87) 168

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1391-87</td>
<td>Duncan, William LTC MC. Bone Mineral Density (BMD) in Patients with Chronic Renal Failure (6/87)</td>
<td>169</td>
</tr>
<tr>
<td>1393-87</td>
<td>Carr, Frances PhD. Regulation of Rat TSH Betz Subunit Gene Expression (8/87)</td>
<td>170</td>
</tr>
<tr>
<td>1394-87</td>
<td>Burman, Kenneth COL MC. Molecular Biology of Nutrient Alterations in Rats (8/87)</td>
<td>171</td>
</tr>
<tr>
<td>1395-87</td>
<td>Burman, Kenneth COL MC. Oncogenes and Thyroid Receptors (9/87)</td>
<td>172</td>
</tr>
<tr>
<td>1399-87</td>
<td>Tseng, Yueh-Chu PhD. Growth Factors and the Thyroid Gland (12/87)</td>
<td>173</td>
</tr>
<tr>
<td>1812</td>
<td>Burman, Kenneth COL MC. Oncogenes in Basal Cell Nevus Syndrome, Cowden’s Disease and Tore’s Disease (9/89)</td>
<td>174</td>
</tr>
<tr>
<td>4299</td>
<td>Fein, Henry LTC MC. T-Cell Dysfunction as a Prognosticator for the Development of Autoimmune Thyroid Disease in Microsomal Antibody Positive Postpartum Women (8/90)</td>
<td>175</td>
</tr>
<tr>
<td>4300</td>
<td>Tseng, Yueh-Chu Ph.D. Atrial Natriuretic Peptide and the Endometrium (9/90)</td>
<td>176</td>
</tr>
<tr>
<td>9266</td>
<td>Burman, Kenneth COL MC. The Treatment of Graves’ Disease with Anti-Idiotype Therapy Using Intravenous Immunoglobulin (5/86)</td>
<td>177</td>
</tr>
<tr>
<td>9273</td>
<td>Burman, Kenneth COL MC. Identification and Characterization of Thyroid Autoantigens (9/88)</td>
<td>178</td>
</tr>
<tr>
<td>1401</td>
<td>Murphy, Joseph MAJ MC. The Effect of Normalization of Intraesophageal pH on Mucosal Proliferation in Barrett’s Esophagus (9/88)</td>
<td>179</td>
</tr>
<tr>
<td>1404</td>
<td>Moses, Frank LTC MC. Treatment of the Microscopic Colitis/Colagenous Colitis Syndrome with Sulfasalazine: A Double-Blind Crossover Controlled Trial (12/88)</td>
<td>180</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1406</td>
<td>Crespo, Israel MAJ MC. Campylobacter Pylori: Serologic Studies as a Measure of Efficacy of Treatment (3/89)</td>
</tr>
<tr>
<td>1407</td>
<td>Wong, Roy COL MC. Effectiveness of Pneumatic Dilations in the Treatment of Achalasia (4/89)</td>
</tr>
<tr>
<td>1408</td>
<td>Landes, Tim MAJ MC. Nocturnal Gastroesophageal Reflux--Factors Associated with Reflux Events: A Retrospective Review of 24 Hour Esophageal pH Monitoring Data (5/89)</td>
</tr>
<tr>
<td>1409</td>
<td>Stamm, Carl MAJ MC. Comparison of Intravenous H2 Antagonists and Their Influence on Gastric Emptying in Humans (8/89)</td>
</tr>
<tr>
<td>1410</td>
<td>Moses, Frank LTC MC. Open Label Trial of Low Dose Oral Pulse Methotrexate Therapy for Primary Sclerosing Cholangitis (10/90)</td>
</tr>
<tr>
<td>1411</td>
<td>DeMarkles, Michael CPT MC. The Effect of Lithium Carbonate on Gastric Emptying and Gastrointestinal Hormones in Humans: A Double Blind Randomized Study (1/90)</td>
</tr>
<tr>
<td>1412</td>
<td>Murphy, Joseph MAJ MC. Clinical and Serologic Evaluation of Blood Donors at Walter Reed Army Medical Center (2/90)</td>
</tr>
<tr>
<td>1413</td>
<td>Kikendall, J. Walter COL MC. Large Bowel Adenomatous Polyp Dietary Intervention Study-Clinical Centers (2/90)</td>
</tr>
<tr>
<td>1414</td>
<td>Kikendall, James LTC MC. Case Control Study of Colonic Adenomas (3/90)</td>
</tr>
<tr>
<td>1415</td>
<td>Sjogren, Robert COL MC. The Compassionate Use of Cisapride in the Treatment of Patients with Refractory Nonulcer Dyspepsia, Diabetic Gastroparesis with Intolerance to Metoclopramide and Chronic Intestinal Pseudoobstruction (4/90)</td>
</tr>
<tr>
<td>1416</td>
<td>Murphy, Joseph MAJ MC. Association of Acromegaly and Intermediate Markers of Neoplasia (5/90)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1417</td>
<td>Wong, Roy COL MC. Incidence of Gastric Mucosal Injury in Patients Ingesting Liquid Versus Solid Ibuprofen (6/90)</td>
<td>192</td>
</tr>
<tr>
<td>1418</td>
<td>Moses, Frank LTC MC. Prospective Evaluation of 99mTc Sulfur Colloid Liver Spleen Scan and 99mTc Mebrofenin Hepatobiliary Radionuclide Scan for Diagnosis of Diffuse Hepatocellular Disease (6/91)</td>
<td>193</td>
</tr>
<tr>
<td>1419</td>
<td>Mecredy, Timothy MAJ MC. Mechanisms of Gastroesophageal Reflux in Women with Heartburn in the Third Trimester of Pregnancy (9/91)</td>
<td>194</td>
</tr>
<tr>
<td>1450</td>
<td>Kikendall, James LTC MC. Adenomatous Colonic Polyps: A Vitamers and MFO Induction (7/82)</td>
<td>195</td>
</tr>
<tr>
<td>1462</td>
<td>Shay, Steven COL MC. The Evaluation of Postprandial Supine Reflux Events by Simultaneous Esophageal Manometry, Esophageal pH Monitoring, and Gastroesophageal Scintiscanning in Patients with Hiatus Hernia and Esophagitis (8/83)</td>
<td>196</td>
</tr>
<tr>
<td>1483</td>
<td>Peller, Thomas MAJ MC. Evaluation of Gastroesophageal Reflux as a Cause of Hoarseness (4/86)</td>
<td>197</td>
</tr>
<tr>
<td>1487</td>
<td>Wong, Roy COL MC. Prospective Evaluation of the Effect of Medical Therapy on Plasma and Tissue Zinc Levels in Esophagitis (7/86)</td>
<td>198</td>
</tr>
<tr>
<td>1489</td>
<td>Murphy, Joseph MAJ MC. The Evaluation of Postprandial Supine Reflux Events by Simultaneous Esophageal Manometry, Esophageal pH Monitoring, and Gastroesophageal Scintiscanning in Patients with Progressive Systemic Sclerosis with Severe Endoscopic Esophagitis (12/86)</td>
<td>199</td>
</tr>
<tr>
<td>1495</td>
<td>Kikendall, James COL MC. Effect of Beta-Carotene on Mucosal Proliferation in Patients with Colonic Carcinoma (10/87)</td>
<td>200</td>
</tr>
<tr>
<td>1496</td>
<td>Wong, Roy COL MC. The Effects of Non-Steroidal Anti-Inflammatory Drugs on the Secretion of Human Salivary Epidermal Growth Factor (10/87)</td>
<td>201</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1497</td>
<td>Murphy, Joseph MAJ MC. The Effect of Indomethacin on Rectosigmoid Mucosal Blood Flow and Rectosigmoid Mucosal Prostaglandin Levels in Humans (10/87)</td>
</tr>
<tr>
<td>1498</td>
<td>Shay, Steven COL MC. Pathophysiology and Treatment for Non-Ulcer Dyspepsia (Using Cisapride) (12/87)</td>
</tr>
<tr>
<td>2031</td>
<td>Moses, Frank LTC MC. Gastrointestinal Blood Loss During Marathon Running and the Effect of Cimetidine on its Prevention (9/88)</td>
</tr>
<tr>
<td>1026</td>
<td>Kroenke, Kurt LTC MC. Dizziness: A Prospective Study of Patient Characteristics and Outcome (1/90)</td>
</tr>
<tr>
<td>1027</td>
<td>Kroenke, Kurt LTC MC. Symptoms in the Community: Prevalence, Etiology and Psychiatric Co-Morbidity (11/90)</td>
</tr>
<tr>
<td>1028</td>
<td>Roy, Michael CPT MC. Termination of the Physician-Patient Relationship in a Primary Care Clinic (8/91)</td>
</tr>
<tr>
<td>1507</td>
<td>Weiss, Raymond MD. WRAMC 9010: A NCI-WRAMC Collaborative Phase I Study of Tetraplatin (8/90)</td>
</tr>
<tr>
<td>1511</td>
<td>Weiss, Raymond MD. CALGB 9081 An Intergroup Study of Rectal Cancer Adjuvant Therapy (11/90)</td>
</tr>
<tr>
<td>1516-90</td>
<td>Ward, Frank LTC MC. Recombinant DNA GM-CSF in Compassionate Circumstances (12/90)</td>
</tr>
<tr>
<td>1522-91</td>
<td>Weiss, Raymond MD. CALGB 9064: Analysis of Neuroendocrine Markers on Tissue Blocks in Patients with Stage IIIA Non-Small Cell Lung Cancer (4/91)</td>
</tr>
<tr>
<td>1639-86</td>
<td>Hartman, Kip MAJ(P) MC. Characterization of Human Antineutrophil Antibodies (3/86)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator</th>
<th>Title</th>
<th>Department and Service</th>
</tr>
</thead>
<tbody>
<tr>
<td>1650-87</td>
<td>Lombardo, Fredric MAJ MS</td>
<td>Exploratory Phase Finding Study to Assess the Efficacy and Safety of Intravenous AHR 11190B (Zacopride Hydrochloride) in the Prevention of Cisplatin-Induced Emesis (11/87)</td>
<td>Hematology-Oncology Service (continued)</td>
</tr>
<tr>
<td>1657-88</td>
<td>Ward, Frank MAJ MC</td>
<td>Long Term 5-FU Infusion for Recurrent Head and Neck Cancer, A Phase II Pilot Study (5/88)</td>
<td></td>
</tr>
<tr>
<td>1658-88</td>
<td>Alving, Barbara LTC MC</td>
<td>Verification of the Heterogeneity of Lupus Anticoagulant Using Purified IgG and IgM from Patients with Lupus Anticoagulant (7/88)</td>
<td></td>
</tr>
<tr>
<td>1659-88</td>
<td>Kark, John COL MC</td>
<td>Antisickling Effect of Erythrocyte 2,3-DPG Depletion (8/88)</td>
<td></td>
</tr>
<tr>
<td>1660-88</td>
<td>Hargis, Jeffrey CPT MC</td>
<td>Assessing the Usefulness of a Quantitative Measure of Mucosal Neutrophils in Profoundly Neutropenic Patients (10/88)</td>
<td></td>
</tr>
<tr>
<td>1668-89</td>
<td>Burrell, Linda MAJ MC</td>
<td>WRAMC 8904 High Dose Chemotherapy and Autologous Bone Marrow Transplantation for Poor Prognosis Lymphomas, Phase II (8/89)</td>
<td>Hematology-Oncology Service (continued)</td>
</tr>
<tr>
<td>1669-89</td>
<td>Burrell, Linda MAJ MC</td>
<td>WRAMC 8905: Chemotherapy with Autologous Bone Marrow Support for Selected Advanced Solid Tumors, Phase II (9/89)</td>
<td></td>
</tr>
<tr>
<td>1672</td>
<td>Ward, Frank MAJ MC</td>
<td>5-Fluorouracil and Low Dose Leucovorin After Ultrasound Guided Laser Ablation of Colorectal Carcinoma Metastatic to the Liver (5/90)</td>
<td></td>
</tr>
<tr>
<td>1673</td>
<td>Bednarek, Jana PhD</td>
<td>Molecular Basis of the Maturation of Bone Marrow Granulocytes: Isolation, Purification and Characterization of Granulocyte Maturation Regulators from Normal Human Serum (5/90)</td>
<td></td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>protocol number</th>
<th>principal investigator, title, and approval date</th>
<th>page*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1671</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1672</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1674</td>
<td>Reid, Thomas MAJ MC. Ifosfamide for Metastatic or 223</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unresectable Primary Transitional Cell Carcinoma of the</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urothelial Tract: A Phase II Pilot Study (5/90)</td>
<td>223</td>
</tr>
<tr>
<td>1675</td>
<td>Weiss, Raymond MD. WRAMC 9004 A Study of Interferon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alpha-2A in Combination with 5FU Plus Leucovorin in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metastatic or Recurrent Colorectal Cancer (6/90)</td>
<td>224</td>
</tr>
<tr>
<td>1676</td>
<td>Alving, Barbara COL MC. Detection of Lupus Anticoagulants in Patients with Anticardiolipin Antibodies (9/90)</td>
<td>225</td>
</tr>
<tr>
<td>1677</td>
<td>Burrell, Linda MAJ MC. Fludarabine Phosphate (FAMP:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NSC-312887) in Compassionate Circumstances (4/91)</td>
<td>226</td>
</tr>
<tr>
<td>1678</td>
<td>Wright, Daniel COL MC. Tiazofurin Treatment of Adults with Chronic Myelogenous Leukemia in Blast Crisis (8/91)</td>
<td>227</td>
</tr>
<tr>
<td>9022-83</td>
<td>La Russa, Vincent PhD. Studies of the Proliferation and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Differentiation of Pluripotent Stem Cells and Committed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hematopoietic Precursors from Normal Bone Marrow Maintained in Continuous Long-term Cultures (10/82)</td>
<td>228</td>
</tr>
<tr>
<td>1956</td>
<td>Cross, Alan COL MC. Neutrophil Function in Patients with Diabetes Mellitus (5/87)</td>
<td>229</td>
</tr>
<tr>
<td>1965</td>
<td>Oster, Charles COL MC. Treatment of Cutaneous Leishmaniasis with Pentostam (2/89)</td>
<td>230</td>
</tr>
<tr>
<td>1967</td>
<td>Cross, Alan COL MC. Pharmacokinetics of Polyvalent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyperimmune Globulin Directed Against Pseudomonas and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Klebsiella (6/89)</td>
<td>231</td>
</tr>
<tr>
<td>1972</td>
<td>Chung, Raymond COL MC. Cytokine Release by Amphotericin B (10/90)</td>
<td>232</td>
</tr>
<tr>
<td>1973</td>
<td>Magill, Alan MAJ MC. Prospective, Controlled Randomized Study Comparing the Efficacy and Safety of Intravenous Ciprofloxacin with Standard Antibiotic Therapy in the Treatment of Selected Tissue Infections (10/90)</td>
<td>233</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
DEPARTMENT OF MEDICINE
Infectious Disease Service (continued)

1974 Artenstein, Andrew CPT MC. Phase I Trial of a Polyvalent
Escherichia Coli-Toxin A Conjugate Vaccine (11/90)

1975 Artenstein, Andrew CPT MC. A Double Blind Randomized
Prospective Controlled Study of the Safety, Immunogenicity
and Efficacy of Gram-Negative Bacterial Vaccines in Wounded
Soldiers (2/91)

DEPARTMENT OF MEDICINE
Nephrology Service

1152 Gouge, Steven MAJ MC. In Vitro Analysis of Removal of
Radiocontrast Agents (RCA) by Artificial Membranes (6/87)

1155 Moore, Jack LTC MC. The Effect of Thyroid Hormone
Administration in Acute Renal Failure (9/87)

1156 Welch, Paul MAJ MC. Retrospective Analysis of the Use of
Renal Ultrasound at Walter Reed Army Medical Center (10/87)

1157 Moore, Jack LTC MC. Effects of Thyroid Hormone and
Thyrotropin (TSH) on Cultured Kidney Cells: Modulation of
ANP Receptors and Epithelial Function (11/88)

1158 Welch, Paul MAJ MC. Tumor Necrosis Factor and Interleukin-1
Levels in Patients with Systemic Lupus Erythematosus (3/89)

1160 Yuan, Christine CPT MC. Hemodynamic and Renal Response in
\( \text{r} \) Rate to Hemorrhagic Hypotension in the Presence of ANF
Antibody and in the Presence of Thiorphan, A Selective
Metalloendoprotease Inhibitor (8/89)

1161 Yuan, Christine CPT MC. Mechanisms of Action of Thiorphan
and Atrial Natriuretic Peptide on Renal Function During
Hemorrhagic Shock (11/90)

1162 Carome, Michael CPT MC. The Regulation of Insulin-like
Growth Factor I and Insulin-like Growth Factor Binding
Protein Gene Expression in the Mouse Glomerulus (1/91)

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page*</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nephrology Service (continued)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>i163</td>
<td>Yuan, Christine CPT MC. Effects of Cyclosporin A on the Production of Vasoactive Hormones by Endothelial Cells in Culture (3/91)</td>
<td>244</td>
</tr>
<tr>
<td>i164</td>
<td>Moore, Jack LTC MC. Synthesis and Degradation of Collagen and Modulation of its Biology in Sclerosing Forms of Human Glomerulonephritis: Analysis of Gene Expression (4/91)</td>
<td>245</td>
</tr>
<tr>
<td>i165</td>
<td>Bohen, Erin CPT MC. The Effects of Cisplatin on the Production of Endothelin and Other Vasoactive Hormones by Endothelial Cells in Culture (8/91)</td>
<td>246</td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pulmonary Disease Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1707</td>
<td>Rajagopal, Krishnan LTC MC. Relationship Between Respiratory Control Mechanisms and Nocturnal Desaturation in Diffuse Pulmonary Fibrosis (2/81)</td>
<td>247</td>
</tr>
<tr>
<td>1714</td>
<td>Dillard, Thomas LTC MC. Mechanisms Limiting Exercise Ventilation in Chronic Obstructive Lung Disease (9/83)</td>
<td>248</td>
</tr>
<tr>
<td>1717</td>
<td>Dillard, Thomas LTC MC. Prediction of Maximum Exercise Response from Resting Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease (5/85)</td>
<td>249</td>
</tr>
<tr>
<td>1720</td>
<td>Derderian, Sarkis LTC MC. Pilot Study On the Use of Conjunctival Oxygen Tension Monitoring in the Sleep Apnea Syndrome (4/87)</td>
<td>250</td>
</tr>
<tr>
<td>1724</td>
<td>Dillard, Thomas MAJ MC. Mechanisms of Hypoxia During Simulated Air Travel in Patients with Chronic Obstructive Pulmonary Disease (1/88)</td>
<td>251</td>
</tr>
<tr>
<td>1725</td>
<td>Rajagopal, Krishnan LTC MC. Evaluation of Respiratory Parameters in the Response to Inhaled Bronchodilators (2/88)</td>
<td>252</td>
</tr>
<tr>
<td>1726</td>
<td>Rajagopal, Krishnan LTC MC. Physiologic Assessment of Exercise Limitation in Upper Airway Obstruction (2/88)</td>
<td>253</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1732</td>
<td>Derderian, Sarkis LTC MC. Pleural Pressure Measurements in Normal Healthy Volunteers During the Administration of Nasal Continuous Positive Airway Pressure (NCPAP) (9/88)</td>
<td>254</td>
</tr>
<tr>
<td>1736</td>
<td>Poropatich, Ronald MAJ MC. Treatment of Pulmonary Sarcoidosis with High Dose Inhaled Triamcinolone Acetonide (1/90)</td>
<td>255</td>
</tr>
<tr>
<td>1737</td>
<td>Dillard, Thomas MAJ MC. Predicting Exercise Responses in COPD Patients (2/90)</td>
<td>256</td>
</tr>
<tr>
<td>1738</td>
<td>Eliasson, Arn MAJ MC. Incidence of Arrhythmias During Pentamidine Therapy (7/90)</td>
<td>257</td>
</tr>
<tr>
<td>1739</td>
<td>Eliasson, Arn MAJ MC. VA Cooperative Study No. 316: Efficacy of Passive Immunization in the Prevention of Infection due to Klebsiella Pneumoniae and Pseudomonas Aeruginosa (7/90)</td>
<td>258</td>
</tr>
<tr>
<td>1740</td>
<td>Moores, Lisa CPT MC. The Effect of Diltiazem on Pulmonary Gas Exchange in Patients with Chronic Obstructive Lung Disease at Rest, with Exercise, with Exposure to a Hypoxic Environment and during Sleep (7/90)</td>
<td>259</td>
</tr>
<tr>
<td>1742</td>
<td>Roach, James CPT MC. The Effect of Pyridostigmine on Bronchial Hyperreactivity (10/90)</td>
<td>260</td>
</tr>
<tr>
<td>1743</td>
<td>Hnatiuk, Oleh CPT MC. Maximum inspiratory Flow Rate as a Determinant of Maximum Voluntary Ventilation in Normal Patients and Patients with Obstructive Lung Disease (10/90)</td>
<td>261</td>
</tr>
<tr>
<td>1745</td>
<td>Torrington, Kenneth LTC MC. Beta Agonist Bronchodilator Inhalation in Mechanically Ventilated COPD Patients: A Comparison of Nebulizer and Metered Dose Inhaler with IspirEase (1/91)</td>
<td>262</td>
</tr>
<tr>
<td>1746</td>
<td>Hnatiuk, Oleh MAJ MC. Clinical Utility of Post-Thoracentesis Radiography (4/91)</td>
<td>263</td>
</tr>
<tr>
<td>1747</td>
<td>Torrington, Kenneth LTC MC. Increased Use of Repeat Fiberoptic Bronchoscopy: Utility in Patients with Suspected Bronchogenic Carcinoma (8/91)</td>
<td>264</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1746</td>
<td>Torrington, Kenneth LTC MC. Utility of Fiberoptic Bronchoscopy in Stage I Bronchogenic Carcinoma (8/91)</td>
</tr>
<tr>
<td>1747</td>
<td>Dillard, Thomas LTC MC. Air Transport of Patients with Pulmonary Defects (9/91)</td>
</tr>
<tr>
<td>1971</td>
<td>Poropatich, Ron MAJ MC. Early Diagnosis of Tuberculosis Using the Polymerase Chain Reaction (7/90)</td>
</tr>
<tr>
<td>3220R</td>
<td>Tesar, Joseph MD. An Experimental Model of Seronegative Lupus - A Study of Biological Role of Anti-Ro/SSA and La/SSB Antibodies (5/84)</td>
</tr>
<tr>
<td>3703</td>
<td>Strickland, Roger MAJ MC. Autoimmune Phenomena in Patients with Inflammatory Osteoarthritis and Primary Nodal Osteoarthritis (5/88)</td>
</tr>
<tr>
<td>3704</td>
<td>Strickland, Roger MAJ MC. Iontophoresis Therapy for Rheumatoid Arthritis (4/89)</td>
</tr>
<tr>
<td>3705</td>
<td>Strickland, Roger MAJ MC. Iontophoresis Therapy for Osteoarthritis (4/89)</td>
</tr>
<tr>
<td>3706</td>
<td>Strickland, Roger MAJ MC. Iontophoresis Therapy for Bursitis and Tendinitis (4/89)</td>
</tr>
<tr>
<td>3707</td>
<td>Ha. man, Kip MAJ MC. A Study of Autoantibodies to Neutrophil Integrin Proteins in Patients with Rheumatoid Arthritis (8/90)</td>
</tr>
<tr>
<td>7136</td>
<td>Salazar, Andres COL MC. An Investigation of Frontal Lobe Mediated Knowledge Representation (2/88)</td>
</tr>
<tr>
<td>7138</td>
<td>Jabbari, Bahman COL MC. Investigation of the Usefulness of Motor Evoked Potentials in Neurological Disorders (5/88)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>7141</td>
<td>Salazar, Andres COL MC. Recombinant Beta Interferons as Treatment for Multiple Sclerosis: A Multicenter Protocol (2/89)</td>
<td>276</td>
</tr>
<tr>
<td>7142</td>
<td>Salazar, Andres COL MC. Intramuscular Poly-ICLC and CCNU in the Management of Malignant Gliomas: An Open Trial (3/89)</td>
<td>277</td>
</tr>
<tr>
<td>7143</td>
<td>Jabbari, Bahman COL MC. Investigation of the Effectiveness of Nimodipine in Movement Disorders (11/89)</td>
<td>278</td>
</tr>
<tr>
<td>7144</td>
<td>Salazar, Andres COL MC. A Controlled Efficacy Study of a Brief Multidisciplinary Brain Injury Rehabilitation Program in Moderately Head Injured Service Members (7/90)</td>
<td>279</td>
</tr>
<tr>
<td>7145</td>
<td>Harper, Michael LTC MC. Dyesthetic Pain: A Blinded and Controlled Study of Treatment with Capsaicin 0.075% (12/90)</td>
<td>280</td>
</tr>
<tr>
<td>7146</td>
<td>Jabbari, Bahman COL MC. Investigation of Cardiac and Cerebrovascular Effects of the Diving Reflex (12/90)</td>
<td>281</td>
</tr>
<tr>
<td>7147</td>
<td>Jabbari, Bahman COL MC. Investigation of the Localizing Value of Clinical Signs Observed During Epileptic Seizures (4/91)</td>
<td>282</td>
</tr>
<tr>
<td>9200</td>
<td>Salazar, Andres COL MC. Anatomical and Functional Sequelae of Head Injuries Incurred in Vietnam (6/80)</td>
<td>283</td>
</tr>
<tr>
<td>7520</td>
<td>Sarnecky, Mary LTC MC. The Relationship of the Sense of Coherence and Hardiness to the Nutritional Status of Anorectic Head and Neck Cancer Patients Currently Undergoing Radiation Therapy (5/90)</td>
<td>284</td>
</tr>
<tr>
<td>7521</td>
<td>B'key, Valerie COL AN. Pregnancy Attitudes, Ambivalence and Symptom Distress (12/90)</td>
<td>285</td>
</tr>
<tr>
<td>7522</td>
<td>Sarnecky, Mary LTC AN. A History of Walter Reed Army Medical Center: 1909-1990 (2/91)</td>
<td>286</td>
</tr>
<tr>
<td>7526</td>
<td>P'yrov, Jean RN MS. The Effect of a Self Learning Module for Cancer Pain Management on Nurses' Knowledge, Interventions, and Pain Relief for Cancer Patients (7/91)</td>
<td>287</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>DEPARTMENT OF NURSING</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PROTOCOL NUMBER</td>
</tr>
<tr>
<td>DEPARTMENT OF NURSING</td>
<td>Nursing Research Service</td>
</tr>
<tr>
<td></td>
<td>7523 Reeder, Jean LTC AN. Families Coping with Combat Injury (3/91)</td>
</tr>
<tr>
<td></td>
<td>7524 Gurney, Cynthia LTC AN. Determinants of Intent to Leave Among Nurses with Doctoral Degrees by Occupational Setting (4/91)</td>
</tr>
<tr>
<td></td>
<td>7525 Gurney, Cynthia LTC AN. Determinants of Effective Coping and Adaptation Among Army Medical Department Soldiers During Operation Desert Storm (4/91)</td>
</tr>
<tr>
<td>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4243 Klein, Thomas COL MC. The Effect of Vaginal Lubricants on Sperm Motility in the Postcoital Test (2/87)</td>
</tr>
<tr>
<td></td>
<td>4262 Barnhill, Danny LTC MC. A Multicenter Randomized Trial of Adjuvant Cisplatin/Bleomycin Plus Whole Pelvis Irradiation Vs. Cisplatin/Bleomycin Alone in High Risk Stage IB and IIA Carcinoma of the Cervix (5/88)</td>
</tr>
<tr>
<td></td>
<td>4279 Klein, Thomas COL MC. Epidermal Growth Factor and Endometrial Growth (7/89)</td>
</tr>
<tr>
<td></td>
<td>4301 Allen, Rodney CPT MC. Pelvic Ureter Identification During Laparoscopy: A Prospective Study (4/91)</td>
</tr>
<tr>
<td>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</td>
<td></td>
</tr>
<tr>
<td>Gynecologic Oncology Group</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4113 Barnhill, Danny LTC MC. Cooperative Gynecologic Oncology Group (1/74)</td>
</tr>
<tr>
<td></td>
<td>4163 Barnhill, Danny LTC MC. GOG 26C: A Phase II Trial of Cis-platinum in the Treatment of Advanced Gyn Cancer (3/79)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4187</td>
<td>Barnhill, Danny LTC MC. GOG 26N: A Phase II Trial of Dihydroxyanthracenedione (DHAD) in Patients with Advanced Pelvic Malignancies (4/81)</td>
</tr>
<tr>
<td>4203</td>
<td>Barnhill, Danny LTC MC. GOG 26Q: A Phase II Trial of Aminothiadiazole in Patients with Advanced Pelvic Malignancies (1/83)</td>
</tr>
<tr>
<td>4212</td>
<td>Barnhill, Danny LTC MC. GOG 72: Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phase II Trial of l-Asparaginase and Secondary Treatment with Cisplatin in Patients with Progressive Disease (5/84)</td>
</tr>
<tr>
<td>4224</td>
<td>Barnhill, Danny LTC MC. GOG 26S: A Phase II Trial of Teniposide (VM-26) in Patients with Advanced Pelvic Malignancies (7/85)</td>
</tr>
<tr>
<td>4225</td>
<td>Barnhill, Danny LTC MC. GOG 71: Treatment of Patients with Suboptimal (Bulky) Stage IB Carcinoma of the Cervix: A Randomized Comparison of Radiation Therapy Vs. Radiation Therapy plus Adjuvant Extrafascial Hysterectomy, Phase III (7/85)</td>
</tr>
<tr>
<td>4231</td>
<td>Barnhill, Danny LTC MC. GOG 87A: Master Protocol for Phase II Drug Studies in the Treatment of Recurrent or Advanced Uterine Sarcomas (5/86)</td>
</tr>
<tr>
<td>4232</td>
<td>Barnhill, Danny LTC MC. GOG 87B: A Phase II Trial of Ifosfamide and the Uroprotector, Mesna, in the Treatment of Recurrent or Advanced Uterine Sarcomas (5/86)</td>
</tr>
<tr>
<td>4234</td>
<td>Barnhill, Danny LTC MC. GOG 26U: A Phase II Trial of Ifosfamide and the Uroprotector, Mesna, in Patients with Advanced Pelvic Malignancies (8/86)</td>
</tr>
<tr>
<td>4244</td>
<td>Barnhill, Danny LTC MC. GOG 90: Evaluation of Cisplatin, Etoposide and Bleomycin (BEP) Induction Followed by Vincristine, Daunorubicin and Cyclophosphamide (VAC) Consolidation in Advanced Ovarian Germ Cell Tumors, Phase II (3/87)</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Investigator</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>4246</td>
<td>Barnhill, Danny</td>
<td>A Phase II Study of the Treatment of Papillary Serous Carcinoma of the Endometrium Stage I and II and Maximally Debulked Advanced Endometrial Carcinoma with Total Abdominal Radiation Therapy (4/87)</td>
<td>308</td>
</tr>
<tr>
<td>4247</td>
<td>Barnhill, Danny</td>
<td>Randomized Clinical Trial for the Treatment of Women with Selected Stage IC and II (A,B,C) and Selected Stage IAi and IBi and IAii and IBii Ovarian Cancer, Phase III (5/87)</td>
<td>309</td>
</tr>
<tr>
<td>4251</td>
<td>Barnhill, Danny</td>
<td>A Phase II Trial of Echinomycin in Patients with Advanced Pelvic Malignancies (6/87)</td>
<td>310</td>
</tr>
<tr>
<td>4253</td>
<td>Barnhill, Danny</td>
<td>A Phase II Trial of Tamoxifen Citrate in Patients with Advanced or Recurrent Endometrial Carcinoma Responsive to Progestins (7/87)</td>
<td>311</td>
</tr>
<tr>
<td>4254</td>
<td>Barnhill, Danny</td>
<td>Evaluation of Intraperitoneal Chronic Phosphate Suspension Therapy Following Negative Second-Look Laparotomy for Epithelial Ovarian Carcinoma, Stage III, Phase III (7/87)</td>
<td>312</td>
</tr>
<tr>
<td>4255</td>
<td>Barnhill, Danny</td>
<td>Evaluation of Adjuvant Vinblastine, Bleomycin and Cisplatin Therapy in Totally Reducing Choriocarcinoma, Endodermal Sinus Tumor or Embryonal Carcinoma of the Ovary, Pure and Mixed with Other Elements, Phase II (9/87)</td>
<td>313</td>
</tr>
<tr>
<td>4257</td>
<td>Barnhill, Danny</td>
<td>A Phase III Randomized Study of Adjunctive Radiation Therapy in Intermediate Risk Endometrial Adenocarcinoma (10/87)</td>
<td>314</td>
</tr>
<tr>
<td>4262</td>
<td>Barnhill, Danny</td>
<td>A Phase II Trial of Gallium Nitrate in Patients with Advanced Pelvic Malignancies (6/88)</td>
<td>315</td>
</tr>
<tr>
<td>4265</td>
<td>Barnhill, Danny</td>
<td>Intraperitoneal Administration of Cisplatin and 5-FU in Residual Ovarian Carcinoma, Phase II (6/88)</td>
<td>316</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page*</th>
</tr>
</thead>
<tbody>
<tr>
<td>4266</td>
<td>Barnhill, Danny LTC MC. GOG 76A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Cervix. (7/88)</td>
<td>317</td>
</tr>
<tr>
<td>4268</td>
<td>Barnhill, Danny LTC MC. GOG 26DD: A Phase II Trial of Amonafide in Patients with Advanced Pelvic Malignancies (11/88)</td>
<td>318</td>
</tr>
<tr>
<td>4272</td>
<td>Barnhill, Danny LTC MC. GOG 87C: A Phase II Trial of Hydroxyurea, Dacarbazine, and Etoposide in Patients with Advanced or Recurrent Uterine Sarcomas (12/88)</td>
<td>319</td>
</tr>
<tr>
<td>4274</td>
<td>Barnhill, Danny LTC MC. GOG 104: Intraperitoneal Cisplatinum/Intravenous Cyclophosphamide Vs. Intravenous Cisplatinum/Intravenous Cyclophosphamide in Patients with Nonmeasurable Disease Stage III Ovarian Cancer, Phase III (1/89)</td>
<td>320</td>
</tr>
<tr>
<td>4275</td>
<td>Barnhill, Danny LTC MC. GOG 107 A Randomized Study of Doxorubicin Vs. Doxorubicin Plus Cisplatin in Patients with Primary Stage III and IV Recurrent Endometrial Adenocarcinoma, Phase III (3/89)</td>
<td>321</td>
</tr>
<tr>
<td>4277</td>
<td>Barnhill, Danny LTC MC. GOG 108: Ifosfamide and the Uroprotector, Mesna, with or without Cisplatin in Patients with Advanced or Recurrent Mixed Mesodermal Tumors of the Uterus, Phase III (5/89)</td>
<td>322</td>
</tr>
<tr>
<td>4278</td>
<td>Barnhill, Danny LTC MC. GOG 26EE A Phase II Trial of Didemnin B in Patients with Advanced Pelvic Malignancies (7/89)</td>
<td>323</td>
</tr>
<tr>
<td>4281</td>
<td>Barnhill, Danny LTC MC. GOG 8801 A Phase I Evaluation of Multiple Daily Fraction Radiation and Hydroxyurea in Patients with Stage IIB, III and IVA Carcinoma of the Cervix with Negative Para-aortic Nodes (1/90)</td>
<td>324</td>
</tr>
<tr>
<td>4282</td>
<td>Barnhill, Danny LTC MC. GOG 8901 A Phase I Evaluation of Multiple Daily Fraction Radiation and 5FU Plus Cisplatin in Stage IIB, III and IVA Carcinoma of the Cervix with Negative Para-aortic Nodes (1/90)</td>
<td>325</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE
BY DEPARTMENT AND SERVICE

DEPARTMENT OF OBSTETRICS AND GYNECOLOGY
Gynecologic Oncology Group (continued)

4292 Barnhill, Danny LTC MC. GOG 26HH A Phase II Trial of 5-Fluorouracil and Leucovorin in Advanced Metastatic or Recurrent Pelvic Malignancies (5/90) 326

4294 Barnhill, Danny LTC MC. GOG 8803 Flow Cytometrically Determined Tumor DNA Content in Advanced Epithelial Ovarian Cancer (6/90) 327

4295 Barnhill, Danny LTC MC. GOG 8809 Flow Cytometrically Determined Tumor DNA Content in Ovarian Tumors of Low Malignant Potential (6/90) 328

4296 Barnhill, Danny LTC MC. GOG 8810 Flow Cytometrically Determined DNA Content in Endometrial Carcinoma (6/90) 329

4298 Barnhill, Danny LTC MC. GOG 111 A Phase III Randomized Study of Cyclophosphamide and Cisplatin Vs. Taxol and Cisplatin in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma (6/90) 330

DEPARTMENT OF OBSTETRICS AND GYNECOLOGY
Gynecological Oncology Group

4291 Barnhill, Danny LTC MC. GOG 26GG A Phase II Trial of Fazarabine in Patients with Advanced or Recurrent Pelvic Malignancies (5/90) 331

DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES

4809 Knoll, Susan CAPT BC. The Effects of Storage on Irradiated Red Blood Cells: An In Vitro and In Vivo Study (3/91) 332

4810 Adair, Carol MAJ MC. Immunohistochemistry of Type II Pneumocytes in Hyperplasia and Neoplasia (5/91) 333

DEPARTMENT OF PEDIATRICS

6038 Maybee, David COL MC. Collection and Cryopreservation of Spleen Cells for the Production of Monoclonal Antibodies (4/83) 334

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6059</td>
<td>Poth, Merrily MD. Malondialdehyde Production by Neonatal Erythrocytes (9/86)</td>
</tr>
<tr>
<td>6063</td>
<td>Francis, Gary LTC MC. The Effect of Mestinon on Growth in Non-growth Hormone Deficient Short Children (2/88)</td>
</tr>
<tr>
<td>6064</td>
<td>Francis, Gary LTC MC. The Effect of Somatomedin C on Androgen Receptor and 5-a-reductase Activities in a Hormonally Responsive Tissue, the Penile Foreskin (8/89)</td>
</tr>
<tr>
<td>6215</td>
<td>Jesse, Steven CPT MC. The Enteral Absorption of Human IgG by the Neonatal Guinea Pig and Its Retention of Opsonic Activity Type III Group B Streptococcus (5/88)</td>
</tr>
<tr>
<td>6219</td>
<td>Maybee, David COL MC. Chronic Stress, Change in Social Support, and Uncertainty (7/88)</td>
</tr>
<tr>
<td>6223</td>
<td>Zawadsky, Peter COL MC. Ceftriaxone for Outpatient Management of Suspected Occult Bacteremia: A Multicenter Cooperative Study (10/88)</td>
</tr>
<tr>
<td>6231</td>
<td>Restuccia, Robert LTC MC. Advanced Airway Management Skill Station Using Cats (2/89)</td>
</tr>
<tr>
<td>6240</td>
<td>Zawadsky, Peter COL MC. A Prospective Study of Short Vs. Long Course Antibiotic Therapy for Central Venous Catheter Infections in Pediatric Patients (4/89)</td>
</tr>
<tr>
<td>6245</td>
<td>Beachy, Joanna MAJ MC. The Effect of Asphyxia on the Susceptibility of the Suckling P. B. Streptococcal Infection (6/89)</td>
</tr>
<tr>
<td>6256</td>
<td>Francis, Gary LTC MC. The In Vitro Effect of Tumor Necrosis Factor on the Function of the Pituitary Gonadotrophs of the Rat (1/90)</td>
</tr>
<tr>
<td>6257</td>
<td>Francis, Gary LTC MC. The In Vitro Effect of Tumor Necrosis Factor on the Function of the Gonadal Axis of the Rat (1/90)</td>
</tr>
<tr>
<td>6258</td>
<td>Francis, Gary LTC MC. Polymorphism of Prolactin in Neonatal Cord Blood (1/90)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6266</td>
<td>Edwards, E. Glenn MAJ MC. High Dose Chemotherapy with Autologous Bone Marrow Rescue in Children with Recurrent or Progressive Solid Tumors or Primary CNS Malignancies, Phase II (4/90)</td>
</tr>
<tr>
<td>6267</td>
<td>Maybee, David COL MC. The Value of Sequential C-Reactive Protein Levels in Sickle Cell Anemia Patients Presenting with Symptoms of Crisis or Infection (4/90)</td>
</tr>
<tr>
<td>6274</td>
<td>Bent, Rebecca MAJ MC. Assessment of Meconium Suction Techniques in the Piglet Trachea (10/90)</td>
</tr>
<tr>
<td>6275</td>
<td>Weisman, Leonard COL MC. Modified Immune Serum Globulin in Neonates (1990) (10/90)</td>
</tr>
<tr>
<td>6277</td>
<td>Wiswell, Thomas LTC MC. The Meconium Aspiration Syndrome: Unanswered Questions (12/90)</td>
</tr>
<tr>
<td>6283</td>
<td>Zawadsky, Peter COL MC. Retrospective Followup of Infant Fever Outcome (2/91)</td>
</tr>
<tr>
<td>6286</td>
<td>Zawadsky, Peter COL MC. Retrospective Analysis of Patients with Stomatococcus Mucilaginosus Bacteremia (4/91)</td>
</tr>
<tr>
<td>6290</td>
<td>Hachey, Wayne CPT MC. Utilization of Foot Length as an Estimation of Gestational Age in the Neonate (6/91)</td>
</tr>
<tr>
<td>6291</td>
<td>Nickels, David MAJ MC. Effect of Growth Hormone on the Development of Diabetic Nephropathy in the Rat (7/91)</td>
</tr>
<tr>
<td>6295</td>
<td>Curtis, Jetri LCDR MC. Comparison of Intravenous and Endotracheal Tolazoline Effects on Hypoxia-Induced Pulmonary Hypertension in Newborn Lambs (8/91)</td>
</tr>
<tr>
<td>6299</td>
<td>Pierce, John COL MC. In-Vitro Comparison of Three Rapid Latex Agglutination Tests for the Detection of H. Influenzae Type b Antigenuria from Four H. Influenzae Conjugate Vaccines (9/91)</td>
</tr>
<tr>
<td>6299</td>
<td>Phillips-Dawkins, Terri CPT MC. The Neonatal Rat Pup as a Model for Staphylococcus Epidermidis Sepsis in the Newborn: The Effects of a Lipid Emulsion on Survival and Neutrophil Function (9/91)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
### DEPARTMENT OF PEDIATRICS

#### Pediatric Hematology-Oncology Service

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator</th>
<th>Title and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6121</td>
<td>Maybee, David COL MC.</td>
<td>POG 7799 Rare Tumor Registry (1/80)</td>
</tr>
<tr>
<td>6144</td>
<td>Maybee, David COL MC.</td>
<td>POG 8158 NWTS Long Term Follow-up Study (2/82)</td>
</tr>
<tr>
<td>6148</td>
<td>Maybee, David COL MC.</td>
<td>POG 8104 Comprehensive Care of the Child with Neuroblastoma: A Stage and Age Oriented Study, Phase III (5/82)</td>
</tr>
<tr>
<td>6162</td>
<td>Maybee, David COL MC.</td>
<td>POG 8451 Intergroup Rhabdomyosarcoma III (12/84)</td>
</tr>
<tr>
<td>6175</td>
<td>Maybee, David COL MC.</td>
<td>POG 8532 Treatment of Intracranial Ependymomas, A Pediatric Oncology Group Phase III Study (1/86)</td>
</tr>
<tr>
<td>6177</td>
<td>Maybee, David COL MC.</td>
<td>POG 8602 Evaluation of Treatment Regimens in Acute Lymphoid Leukemia of Childhood (ALinCl4), A POG Phase III Study (5/86)</td>
</tr>
<tr>
<td>6181</td>
<td>Maybee, David COL MC.</td>
<td>POG 8625/8626 Combined Therapy and Restaging in the Treatment of Stages I, IIA, IIIA1 Hodgkin's Disease in Pediatric Patients, A Phase II Study (6/86)</td>
</tr>
<tr>
<td>6184</td>
<td>Maybee, David COL MC.</td>
<td>POG 8653 Study of Childhood Soft Tissue Sarcomas Other than Rhabdomyosarcoma and Its Variants, A POG Phase III Study (6/86)</td>
</tr>
<tr>
<td>6188</td>
<td>Maybee, David COL MC.</td>
<td>POG 8650 National Wilm's Tumor Study 4; A POG Phase III Study (10/86)</td>
</tr>
</tbody>
</table>

### DEPARTMENT OF PEDIATRICS

#### Pediatric Hematology-Oncology Group

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator</th>
<th>Title and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6191</td>
<td>Maybee, David COL MC.</td>
<td>POG 8616 Intensive Chemotherapies for Stage III Diffuse Undifferentiated Lymphoma (DU NHL Burkitt and Non-Burkitt), A Randomized Phase III Study (1/87)</td>
</tr>
<tr>
<td>6192</td>
<td>Maybee, David COL MC.</td>
<td>POG 8651 Osteosarcoma Study 2: A Randomized Trial of Pre-Surgical Chemotherapy Vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma, A POG Phase III Study (1/87)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6193</td>
<td>Maybee, David COL MC. POG 8615 A Phase III Study of Large Cell Lymphomas in Children and Adolescents, A Comparison of Two Treatment Regimens, ACOP+ Vs. APO (2/87)</td>
</tr>
<tr>
<td>6194</td>
<td>Maybee, David COL MC. POG 8617/8618 Therapy for B-Cell Acute Lymphoblastic Leukemia and Advanced Diffuse Undifferentiated Lymphomas, A Phase II Study (2/87)</td>
</tr>
<tr>
<td>6195</td>
<td>Maybee, David COL MC. POG 8633/8634 The Treatment of Children Less Than Three Years of Age with Malignant Brain Tumors Using Postoperative Chemotherapy and Delayed Irradiation, A POG Phase II Study (4/87)</td>
</tr>
<tr>
<td>6196</td>
<td>Maybee, David COL MC. POG 8741/8742 Treatment of Stage D Neuroblastoma in Children Greater than 365 Days at Diagnosis, A POG Phase II/III Study (4/87)</td>
</tr>
<tr>
<td>6199</td>
<td>Maybee, David COL MC. POG 8704: T-Cell #3 Protocol, A POG Phase III Study (6/87)</td>
</tr>
<tr>
<td>6202</td>
<td>Maybee, David COL MC. POG 8739: Evaluation of Alpha Interferon in the Treatment of Recurrent Brain Tumors in Children, A POG Phase II Study (7/87)</td>
</tr>
<tr>
<td>6204</td>
<td>Maybee, David COL MC. POG 8751: Low Dose Methotrexate in the Treatment of Rhabdomyosarcoma, A POG Phase II Study (7/87)</td>
</tr>
<tr>
<td>6205</td>
<td>Maybee, David COL MC. POG 8759: The Effectiveness of Phase II Agents in Untreated Metastatic Osteosarcoma or Unresectable Primary Osteosarcoma Vs. Previously Treated Recurrent Osteosarcoma, POG Phase II/III Study (8/87)</td>
</tr>
<tr>
<td>6206</td>
<td>Maybee, David COL MC. POG 8763: Evaluation of Response and Toxicity of Ifosfamide and VP-16-213 in Children with Resistant Malignant Tumors, A POG Phase II Study (8/87)</td>
</tr>
<tr>
<td>6207</td>
<td>Maybee, David COL MC. POG 8719: Trial of Shortened Therapy without Maintenance for the Treatment of Localized Non-Hodgkin's Lymphoma, A POG Phase III Study (9/87)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEPARTMENT OF PEDIATRICS</strong>&lt;br&gt;Pediatric Hematology-Oncology Service (continued)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6210</td>
<td>Maybee, David COL MC. POG 8761: A Phase II Study of Homoharringtonine for the Treatment of Children with Refractory Nonlymphoblastic Leukemia (9/87)</td>
<td>380</td>
</tr>
<tr>
<td>6211</td>
<td>Maybee, David COL MC. POG 8731: A Phase II Study of Low-Dose &quot;Continuous&quot; Oral Methotrexate in the Treatment of Children with Progressive or Recurrent Brain Tumors (10/87)</td>
<td>381</td>
</tr>
<tr>
<td>6212</td>
<td>Maybee, David COL MC. POG 8764: Chemotherapy Regimen for Early and Initial Induction Failures in Childhood Acute Lymphoblastic Leukemia, A POG Phase II Study (10/87)</td>
<td>382</td>
</tr>
<tr>
<td>6213</td>
<td>Maybee, David COL MC. POG 8823/24: Recombinant Alpha Interferon in Childhood Chronic Myelogenous Leukemia, Phase II (12/87)</td>
<td>383</td>
</tr>
<tr>
<td>6216</td>
<td>Maybee, David COL MC. POG 8710: Protocol for Second Induction and Maintenance in Childhood Acute Lymphoblastic Leukemia (SIMAL #5), A POG Phase III Study (5/88)</td>
<td>384</td>
</tr>
<tr>
<td>6217</td>
<td>Maybee, David COL MC. POG 8725: Randomized Study of Intensive Chemotherapy (MOPP/ABVD Plus/Minus Low Dose Total Nodal Radiation Therapy in the Treatment of Stages IIB, IIIA2, IIIB, IV Hodgkin's Disease in Pediatric Patients, Phase III (5/88)</td>
<td>385</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF PEDIATRICS</strong>&lt;br&gt;Pediatric Hematology-Oncology Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6221</td>
<td>Maybee, David COL MC. POG 8821: Intensive Multiagent Therapy Vs. Autologous Bone Marrow Transplant Early in First CR for Children with Acute Myelocytic Leukemia - A Phase III Study (9/88)</td>
<td>386</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF PEDIATRICS</strong>&lt;br&gt;Pediatric Hematology-Oncology Service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6224</td>
<td>Maybee, David COL MC. POG 8827: Treatment of Children with Hodgkin's Disease in Relapse, A POG Phase II Study (11/88)</td>
<td>387</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6227</td>
<td>Maybee, David COL MC. POG 8862: Treatment of First Marrow and/or Extramedullary Relapse of Childhood Acute T-Lymphoblastic Leukemia and T-Non-Hodgkin's Lymphoma with Combination Chemotherapy Including 2' -Deoxycoformycin (1/89)</td>
<td>388</td>
</tr>
<tr>
<td>6228</td>
<td>Maybee, David COL MC. POG 8866: Polyethylene Glycol-Conjugated L-Asparaginase Vs. Native L-Asparaginase in Combination with Standard Agents as Second Line Induction Therapy for Children with Acute Lymphocytic Leukemia in Bone Marrow Relapse, Phase II Randomized Trial (1/89)</td>
<td>389</td>
</tr>
<tr>
<td>6229</td>
<td>Maybee, David COL MC. POG 8850: Evaluation of Vincristine, Adriamycin, Cyclophosphamide and Dactinomycin with or without the Addition of Ifosfamide and Etoposide in the Rx of Patients with Newly Diagnosed Ewing's Sarcoma of Primitive Neuroectodermal Tumor or Bone, Phase III (1/89)</td>
<td>390</td>
</tr>
<tr>
<td>6230</td>
<td>Maybee, David COL MC. POG 8832: Pre-irradiation Combination Chemotherapy with Cisplatin and Ara-C for Children with Incompletely Resected Supratentorial Malignant Tumors: A Phase II Study (1/89)</td>
<td>391</td>
</tr>
<tr>
<td>6233</td>
<td>Maybee, David COL MC. POG 8820 VP-16, AMS, and 5-Azacitidine in Refractory ANLL, Phase II-III Study (2/89)</td>
<td>392</td>
</tr>
<tr>
<td>6236</td>
<td>Maybee, David COL MC. POG 8829 A Protocol for a Case Control Study of Hodgkin's Disease in Childhood (4/89)</td>
<td>393</td>
</tr>
<tr>
<td>6238</td>
<td>Maybee, David COL MC. POG 8889 Intergroup Rhabdomyosarcoma Study-IV: Pilot Study for Clinical Group IV Disease (4/89)</td>
<td>394</td>
</tr>
<tr>
<td>6242</td>
<td>Maybee, David COL MC. POG 8828 Late Effects of Treatment of Hodgkin's Disease: A POG Nontherapeutic Study (5/89)</td>
<td>395</td>
</tr>
<tr>
<td>6244</td>
<td>Maybee, David COL MC. POG 8863 High Dose Cytosine Arabinoside in the Treatment of Advanced Childhood Tumors Resistant to Conventional Therapy, Phase II (5/89)</td>
<td>396</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE (VOL II)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6244</td>
<td>Maybee, David COL MC. POG 8865 Recombinant Alpha Interferon in Relapsed T-Cell Disease: A Phase II Study (5/89)</td>
<td>397</td>
</tr>
<tr>
<td>6249</td>
<td>Maybee, David COL MC. POG 8788: Intergroup Rhabdomyosarcoma Study IV: A Pilot Study for Clinical Group III Disease (6/89)</td>
<td>398</td>
</tr>
<tr>
<td>6250</td>
<td>Maybee, David COL MC. POG 8935 A Study of Biological Behavior of Optic Pathway Tumors (7/89)</td>
<td>399</td>
</tr>
<tr>
<td>6251</td>
<td>Maybee, David COL MC. POG 8936 Carboplatin in Progressive Optic Pathway Tumors: Phase II (7/89)</td>
<td>400</td>
</tr>
<tr>
<td>6252</td>
<td>Maybee, David COL MC. POG 8945 An Intergroup Protocol for the Treatment of Hepatoblastoma and Hepatocellular Carcinoma, Phase III (10/89)</td>
<td>401</td>
</tr>
<tr>
<td>6253</td>
<td>Maybee, David COL MC. POG 8930 Comprehensive Genetic Analysis of Brain Tumors (12/89)</td>
<td>402</td>
</tr>
<tr>
<td>6260</td>
<td>Maybee, David COL MC. POG 9046 A Molecular Genetic Analysis of Wilms' Tumors and Nephrogenic Rests (2/90)</td>
<td>403</td>
</tr>
<tr>
<td>6261</td>
<td>Maybee, David COL MC. POG 9047 Neuroblastoma Biology Protocol (2/90)</td>
<td>404</td>
</tr>
<tr>
<td>6263</td>
<td>Maybee, David COL MC. POG 9049 A Study of High Risk Malignant Germ Cell Tumors in Children: A Phase III Treatment Study (3/90)</td>
<td>405</td>
</tr>
<tr>
<td>6265</td>
<td>Maybee, David COL MC. POG 9082 Development of Intervention Strategies to Reduce the Time between Symptom Onset and Diagnosis of Childhood Cancer (4/90)</td>
<td>406</td>
</tr>
<tr>
<td>6269</td>
<td>Maybee, David COL MC. POG 9060 Intensive QOD Ifosfamide for the Treatment of Children with Recurrent or Progressive CNS Tumors, Phase II (5/90)</td>
<td>407</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6270</td>
<td>Maybee, David COL MC. POG 9048 The Treatment of Children with Localized Germ Cell Tumors, Phase II (6/90)</td>
<td>408</td>
</tr>
<tr>
<td>62/1</td>
<td>Maybee, David COL MC. POG 9061 The Treatment of Isolated Central Nervous System Leukemia (6/90)</td>
<td>409</td>
</tr>
<tr>
<td>6272</td>
<td>Maybee, David COL MC. POG 9031 The Treatment of Children with High Stage Medulloblastoma: Cisplatin/VP-16 Pre Vs. Post Irradiation, Phase III (7/90)</td>
<td>410</td>
</tr>
<tr>
<td>6278</td>
<td>Maybee, David COL MC. POG 9000 Acute Lymphocytic Leukemia in Childhood #15 Classification Protocol: A Non-therapeutic Study (12/90)</td>
<td>411</td>
</tr>
<tr>
<td>6279</td>
<td>Maybee, David COL MC. POG 9005 Dose Intensification of Methotrexate and 6-Mercaptopurine for ALL in Childhood, Phase III (12/90)</td>
<td>412</td>
</tr>
<tr>
<td>6280</td>
<td>Maybee, David COL MC. POG 9006 Acute Lymphocytic Leukemia in Children Study #15: Up Front Alternating 6-MP and Methotrexate Vs. Up Front Alternating Chemotherapy (12/90)</td>
<td>413</td>
</tr>
<tr>
<td>6281</td>
<td>Maybee, David COL MC. POG 9140 Treatment for Recurrent or Refractory Neuroblastoma (1/91)</td>
<td>414</td>
</tr>
<tr>
<td>6285</td>
<td>Maybee, David COL MC. POG 9107 The Treatment of Acute Lymphocytic Leukemia in Infants: Phase III (3/91)</td>
<td>415</td>
</tr>
<tr>
<td>6287</td>
<td>Maybee, David COL MC. NPC-1 A Phase I Study of Pre-Irradiation Chemotherapy for Pediatric and Adolescent Patients with Nasopharyngeal Carcinoma (4/91)</td>
<td></td>
</tr>
<tr>
<td>6288</td>
<td>Maybee, David COL MC. POG 9110: SIMAL #6: Rotational Drug Therapy After First Marrow Relapse of Non-T Non-B ALL: Pediatric Oncology Group Pilot Study for a Phase III Trial (6/91)</td>
<td>417</td>
</tr>
<tr>
<td>6289</td>
<td>Maybee, David COL MC. POG 9139: A Dose-Escalating Study of Cisplatin Used Concomitantly with Hyperfractionated Irradiation in the Treatment of Children with Newly Diagnosed Brain Stem Glioma Cancer: A Phase I Study (6/91)</td>
<td>418</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6292</td>
<td>Maybee, David</td>
<td>Pre-Radiation Chemotherapy for Children with Supratentorial Malignant Gliomas and Poorly Differentiated Embryonal Tumors of Childhood</td>
<td>419</td>
</tr>
<tr>
<td>6293</td>
<td>Maybee, David</td>
<td>Phase I/II Dose Escalating Trial of Hyperfractionated Irradiation in the Treatment of Supratentorial Malignant Tumors of Childhood</td>
<td>420</td>
</tr>
<tr>
<td>6294</td>
<td>Maybee, David</td>
<td>Etoposide and Ifosfamide Plus G-CSF in Children with Recurrent Sarcomas: Including Soft Tissue Sarcoma, Ewing’s Sarcoma, Rhabdomyosarcoma, and Osteosarcoma: A Pediatric Oncology Group Pilot Study</td>
<td>421</td>
</tr>
<tr>
<td>6296</td>
<td>Maybee, David</td>
<td>Intergroup Rhabdomyosarcoma Study IV: STAGE I Disease: A POG Phase III Study</td>
<td>422</td>
</tr>
<tr>
<td>6297</td>
<td>Maybee, David</td>
<td>Intergroup Rhabdomyosarcoma Study IV: STAGE IV, Clinical Group IV, and All Patients with Metastatic Disease: A POG Phase III Study</td>
<td>423</td>
</tr>
<tr>
<td>3600</td>
<td>Nelson, Bruce</td>
<td>Determination of Noncompliance in Prescription Pickup</td>
<td>424</td>
</tr>
<tr>
<td>3601</td>
<td>Bjornson, Darrell</td>
<td>Evaluation of the Effect of Clinical Pharmacists on Inpatient Health Care Outcomes</td>
<td>425</td>
</tr>
<tr>
<td>3602</td>
<td>Davies, William</td>
<td>Demographic Evaluation of Prescription Utilization and Expenditures in a Military Health Facility</td>
<td>426</td>
</tr>
<tr>
<td>5672</td>
<td>Bryant, Philip</td>
<td>Radial Nerve F Wave Study</td>
<td>427</td>
</tr>
<tr>
<td>9612</td>
<td>Sweeney, Jane</td>
<td>Epidemiology of Injuries Requiring Physical Therapy During Operation Desert Shield</td>
<td>428</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>9613</td>
<td>Sinnott, Melissa MAJ SP. The Effects of a Clinical Reasoning Development Program on Documentation and Staff Morale: A Multi-site Study for Program Evaluation (11/90)</td>
<td>429</td>
</tr>
<tr>
<td>9614</td>
<td>Dillingham, Timothy CPT MC. A Descriptive Analysis of Patient Referrals to Army Physical Medicine Services During Armed Conflict (2/91)</td>
<td>430</td>
</tr>
<tr>
<td>9615</td>
<td>Marin, Raul CPT MC. An Analysis of the Extensor Digitorium Brevis Deep Tendon Reflex in Normals and in Patients with L5 Radicular Compression Syndromes (3/91)</td>
<td>431</td>
</tr>
<tr>
<td>9616</td>
<td>Braverman, Steven CPT MC. Intern Perceptions of Physical Medicine and Rehabilitation (6/91)</td>
<td>432</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF PSYCHIATRY**

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1326-90</td>
<td>Joslin, Scott CPT MC. Predictors of Thyroid Dysfunction in Patients Treated with Lithium (9/90)</td>
<td>433</td>
</tr>
<tr>
<td>7239</td>
<td>Blair, Sidney CAPT MC. Visual Information Processing in Psychiatric Patients (7/88)</td>
<td>434</td>
</tr>
<tr>
<td>7240</td>
<td>Warden, Debra MD. Cerebral Dysfunction in Schizophrenic Subtypes (12/89)</td>
<td>435</td>
</tr>
<tr>
<td>7241</td>
<td>Wain, Harold PhD. The Relationship Between Hypnotic Capacity and Dissociative Experience (2/90)</td>
<td>436</td>
</tr>
<tr>
<td>7244</td>
<td>Weir Linda LTC MC. Visual-Auditory Masking (4/91)</td>
<td>437</td>
</tr>
<tr>
<td>7245</td>
<td>Hall, Donald CPT MC. Investigation of Ultradian Rhythms of Mood in Depression (5/91)</td>
<td>438</td>
</tr>
<tr>
<td>7246</td>
<td>Oleshansky, Marvin LTC MC. A Randomized Concentration-Controlled Trial of Fluoxetine in the Treatment of Major Depressive Disorder (8/91)</td>
<td>439</td>
</tr>
<tr>
<td>9106</td>
<td>Jones, Franklin MD. Differences in Proportions of Diagnosis Between Ethnic Groups: The Case of Puerto Rican Psychiatric Patients in the Military (12/84)</td>
<td>440</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>4525</td>
<td>Anderson, Jay COL MC. Intravenous Administration of I-131-6-B Iodomethylnorcholesterol for Adrenal Evaluation and Imaging (11/80)</td>
<td>441</td>
</tr>
<tr>
<td>4527</td>
<td>Anderson, Jay COL MC. Technetium (Tc99m) Antimony Trisulfide Colloid - A Lymphoscintigraphic Agent (11/81)</td>
<td>442</td>
</tr>
<tr>
<td>4531</td>
<td>Anderson, Jay COL MC. Diagnostic Imaging of Adrenal Medulla (Pheochromocytoma, Paragangliomas, and Neuroblastomas) with I-131 MIBG (Metaiodobenzylguanidine Sulfate) (9/84)</td>
<td>443</td>
</tr>
<tr>
<td>4535</td>
<td>Kohanski, Phillip CPT MC. Pharyngeal and Esophageal Manifestations of Rheumatoid Arthritis (8/88)</td>
<td>444</td>
</tr>
<tr>
<td>4538</td>
<td>Dachman, Abraham MD. Ultrasound Guided Laser Ablation of Tumors (9/89)</td>
<td>445</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF SURGERY**

**Anesthesia-Operative Service**

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023A</td>
<td>Karan, Steven MAJ MC. In Vitro Determination of the Response of Skeletal Muscle to Halothane, Caffeine and Halothane Plus Caffeine (12/85)</td>
<td>446</td>
</tr>
<tr>
<td>2032A</td>
<td>Lupkas, Raymond CPT MC. Pain Control After Thoracotomy and Its Effect on Pulmonary Function (9/88)</td>
<td>447</td>
</tr>
<tr>
<td>2038A</td>
<td>Stama~os, John CPT MC. Prevention of Spinal Headaches after Incidental Dural Puncture during Epidural Catheter Placement (4/89)</td>
<td>448</td>
</tr>
<tr>
<td>2045A</td>
<td>Hahn, Marc CPT MC. Multicenter Study of the Davol Intraspinal Port (10/89)</td>
<td>449</td>
</tr>
<tr>
<td>2050A</td>
<td>Hahn, Marc MAJ MC. Indirective Use of Patient Controlled Anxiolysis (2/90)</td>
<td>450</td>
</tr>
<tr>
<td>2051A</td>
<td>Kline, Mark CPT MC. Perioperative Myocardial Ischemia or Infarction During and Following Noncardiac Surgery in Patients who have Undergone Previous Coronary Artery Bypass Graft or Percutaneous Transluminal Coronary Artery Surgery (4/90)</td>
<td>451</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2052A</td>
<td>Stamatos, John CPT MC. Preanesthetic Management in Children: A Combination of Intramuscular Midazolam and Ketamine as Compared to Each Medication Separately (5/90)</td>
<td>452</td>
</tr>
<tr>
<td>2054A</td>
<td>Condon, Brian COL MC. The Effect of the Sprotte Atraumatic 24 Gauge Spinal Needle on the Incidence of Postdural Puncture Headache (1/91)</td>
<td>453</td>
</tr>
<tr>
<td>2055A</td>
<td>Crowl, Frank MAJ MC. The Comparison of Propofol/Sufentanil and Midazolam/Sufentanil as Conscious Sedatives for Extracorporeal Shock Wave Lithotripsy (4/91)</td>
<td>454</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2504</td>
<td>Cord, Mary MA. The Effect of Speech Babble on the Speech Recognition Ability of Soldiers with H-3 Physical Profiles (6/90)</td>
<td>455</td>
</tr>
<tr>
<td>2505</td>
<td>Summers, W. Van PhD. The Use of Temporal and Spectral Cues in the Identification of Vowels by Hearing Impaired Listeners (7/90)</td>
<td>456</td>
</tr>
<tr>
<td>2507</td>
<td>McClean, Michael PhD. Acoustic and Perceptual Analysis of Voice Quality Following Laryngotraceoplasty (10/90)</td>
<td>457</td>
</tr>
<tr>
<td>2508</td>
<td>Grant, Kenneth PhD. Auditory Supplements to Speechreading (11/90)</td>
<td>458</td>
</tr>
<tr>
<td>2510</td>
<td>McClean, Michael PhD. Predictability from Physiologic Measures of Speech Motor Systems (1/91)</td>
<td>459</td>
</tr>
<tr>
<td>2511</td>
<td>Grant, Kenneth PhD. The Transmission of Prosodic Information Via Selected Spectral Regions of Speech (4/91)</td>
<td>460</td>
</tr>
<tr>
<td>2513</td>
<td>McClean, Michael PhD. Neuromotor Aspects of Speech Disfluency (7/91)</td>
<td>461</td>
</tr>
<tr>
<td>2514</td>
<td>Grant, Kenneth Ph.D. Evaluating the Articulation Index for Auditory-Visual Consonant Recognition (8/91)</td>
<td>462</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2588</td>
<td>Leek, Marjorie PhD. Hearing Loss and the Perception of Complex Sounds (8/88)</td>
</tr>
<tr>
<td>2590</td>
<td>Leek, Marjorie PhD. Modeling Impaired Frequency Resolution in Normal Ears (1/89)</td>
</tr>
<tr>
<td>2591</td>
<td>Leek, Marjorie PhD. Nonlinear Cochlear Processing in Normal Hearing and Hearing Impaired Listeners (2/89)</td>
</tr>
<tr>
<td>2594</td>
<td>MacNeil, Donna MA. Measurement of Ear Canal Sound Pressure Levels in Infant and Young Children (5/89)</td>
</tr>
<tr>
<td>2598</td>
<td>Leek, Marjorie PhD. Frequency Resolution on Hearing Impaired and Noise Masked Normal Hearing Listeners (2/90)</td>
</tr>
<tr>
<td>3006</td>
<td>Hnatiuk, Oleh MAJ MC. Validation of the Accuracy and Reliability of the Present System Used in the SICU for Culturing Intravascular Catheter Segments (2/90)</td>
</tr>
<tr>
<td>3007</td>
<td>Yowler, Charles LTC MC. Total Parenteral Nutrition Via Pulmonary Artery Catheter (2/90)</td>
</tr>
<tr>
<td>3008</td>
<td>Stoltzfus, Daniel MAJ MC. The Use of Capnography During the Transport of Intubated Patients (2/90)</td>
</tr>
<tr>
<td>3009</td>
<td>Stoltzfus, Daniel MAJ MC. Effect of Empirical Dose Amphotericin B on the Development of Disseminated Candidiasis in a Surgical Intensive Care Unit (3/90)</td>
</tr>
<tr>
<td>3010</td>
<td>Bowes, Joan CPT MC. Comparison of Norepinephrine with Phentolamine to Dopamine Alone and to Norepinephrine with Low Dose Dopamine as an Adjunct Agent for Inotropic/Pressor Support in Normovolemic Patients in Septic Shock (1/91)</td>
</tr>
<tr>
<td>3011</td>
<td>Poropatich, Ronald MAJ MC. Comparison of Work of Breathing During Mechanical Ventilation Using Assist Control and Intermittent Mandatory Ventilation (2/91)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2035</td>
<td>Azarow, Kenneth CPT MC. Investigation of the Etiology of Postoperative Hypocalcemia after Thyroidectomy in the Thyrotoxic Patient (1/89)</td>
<td>474</td>
</tr>
<tr>
<td>2037</td>
<td>Lane, Brian CPT MC. The Effect of Cyclooxygenase Inhibition on Mortality and Tumor Necrosis Factor in a Lethal Model of Septic Shock in the Rat (4/89)</td>
<td>475</td>
</tr>
<tr>
<td>2057</td>
<td>Jaques, David LTC MC. Endotoxin and Cytokine Regulation of Contractile Function of Human Vasculature (2/91)</td>
<td>476</td>
</tr>
<tr>
<td>2058</td>
<td>Azarow, Kenneth CPT MC. Vascular Rupture 35 Years of Treating This Anomaly (6/91)</td>
<td>477</td>
</tr>
<tr>
<td>2059</td>
<td>Azarow, Kenneth CPT MC. Perianal Paget's Disease: Lateral Advancement Flaps as an Alternative to Skin Grafts (9/91)</td>
<td>478</td>
</tr>
<tr>
<td>2317</td>
<td>Kramer, Kenyon COL MC. Intraocular Irrigating Solutions: Effect on Corneal Endothelium (4/83)</td>
<td>479</td>
</tr>
<tr>
<td>2318</td>
<td>Wertz, Fleming COL MC. The Effects Upon Ocular Structures of Optical Polycarbonate and of Various Eye Protective Substances Applied to and Incorporated Within It (1/90)</td>
<td>480</td>
</tr>
<tr>
<td>2319</td>
<td>Wertz, Fleming COL MC. The Efficacy of Cyanoacrylates in the Primary Closure of Conjunctival Scleral Lacerations (1/90)</td>
<td>481</td>
</tr>
<tr>
<td>2320</td>
<td>Cox, Kevin CPT MC. Mood and Behavior Changes with Topical Ophthalmic Beta-Adrenergic Blockade (2/90)</td>
<td>482</td>
</tr>
<tr>
<td>2630</td>
<td>Shaver, Timothy MAJ MC. The Concomittant Use of Azathioprine and Pretransplant Transfusions (11/83)</td>
<td>483</td>
</tr>
<tr>
<td>2631</td>
<td>Fernandez, Carlos LTC MC. Development of an Extracorporeal Liver Support System (1/86)</td>
<td>484</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(VOL II)</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF SURGERY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Organ Transplant Service (continued)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2632</td>
<td>Shaver, Timothy MAJ MC. Treatment with Liver Transplantation and Human Monoclonal Anti-Hepatitis B Virus IgG of a Hepatitis B Virus Carrier who has End Stage Chronic Active Hepatitis (7/88)</td>
<td>485</td>
</tr>
<tr>
<td>2633</td>
<td>Bueno, Carlos MD. Use of Antilymphocyte Preparations in Solid Organ Transplantation (12/89)</td>
<td>486</td>
</tr>
<tr>
<td>2634</td>
<td>Shaver, Timothy MAJ MC. Determination of Epstein-Barr Virus Replication in Lateral Tongue Epithelium of Immunosuppressed Patients (4/90)</td>
<td>487</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF SURGERY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Orthopaedic Surgery Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2401</td>
<td>Hopkinson, William LTC MC. Evaluation of Porous Coated Total Knee and Hip Prostheses in Achieving a Stable Prosthesis Bone Interface (8/83)</td>
<td>488</td>
</tr>
<tr>
<td>2410</td>
<td>Hopkinson, William LTC MC. The Use of Arthroscopic Abrasion Chondroplasty in the Treatment of Osteoarthritis of the Knee (8/87)</td>
<td>489</td>
</tr>
<tr>
<td>2414</td>
<td>Berrey, Hudson LTC MC. Use of Platelet Derived Growth Factor in Sarcoma Detection (11/88)</td>
<td>490</td>
</tr>
<tr>
<td>2417</td>
<td>McHale, Kathleen MAJ MC. A Prospective Study of Back Pain in Pregnancy (8/89)</td>
<td>491</td>
</tr>
<tr>
<td>2418</td>
<td>van Dam, Bruce LTC MC. Clinical Investigation of the PWB Spine System (10/89)</td>
<td>492</td>
</tr>
<tr>
<td>2419</td>
<td>Smith, Allan COL MC. The Treatment of Carpal Tunnel Syndrome with Pyridoxine (12/89)</td>
<td>493</td>
</tr>
<tr>
<td>2420</td>
<td>Berrey, Hudson LTC MC. MRI Characteristics following Surgical Excision of Soft Tissue Sarcomas and Radiation Therapy in Determining Normal Postsurgical and Radiation Changes from Recurrent Disease (3/90)</td>
<td>494</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2421</td>
<td>Kim, Christopher CPT MC. The Effect of Methotrexate on Bone Ingrowth in a Rabbit Model (3/90)</td>
</tr>
<tr>
<td>2424</td>
<td>Tenuta, Joachim CPT MC. Early Percutaneous Intramedullary Fixation of Long Bone Deformity in Severe Osteogenesis Imperfecta (11/90)</td>
</tr>
<tr>
<td>2425</td>
<td>McHale, Kathleen LTC MC. Treatment of Residual Clubfoot, the Bean Shaped Foot, by Opening Wedge Medial Cuneiform Osteotomy and Closing Wedge Cuboid Osteotomy: Clinical Review and Cadaver Correlation (1/91)</td>
</tr>
<tr>
<td>2426</td>
<td>Busey, James CPT MS. Chart Review of Infected Diabetic Feet (1/91)</td>
</tr>
<tr>
<td>2427</td>
<td>Tenuta, Joachim CPT MC. The Effects of Intraoperative Blood Loss on Serum Antibody Level in Patients Undergoing Total Joint Arthroplasty (3/91)</td>
</tr>
<tr>
<td>2428</td>
<td>Hayda, Roman CPT MC. Postoperative Fever Associated with Patient Controlled Analgesia in Orthopaedic Patients (6/91)</td>
</tr>
<tr>
<td>2429</td>
<td>Stevens, William CPT MC. Evaluation of Somatic Sensory, Auditory, and Motor Evoked Potentials in Idiopathic Scoliosis with Brainstem MRI Correlation (7/91)</td>
</tr>
<tr>
<td>2430</td>
<td>Brown, Maurice CPT MC. Closed Osteotomy Using Lithotripsy--Cadaver Trials (8/91)</td>
</tr>
<tr>
<td>2431</td>
<td>Beauchesne, Richard MAJ MC. Roentgenographic Evaluation of the AML Porous Coated Acetabular Components: A Six-Year Minimum Follow-Up Study (9/91)</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF SURGERY**

Otolaryngology-Head & Neck Surgery Svc

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2048</td>
<td>Schoenfeld, Phil CPT MC. Effect of IL-1 on Glucocorticoid Inhibition of Wound Healing (2/90)</td>
</tr>
<tr>
<td>2501</td>
<td>Livermore, George CPT MC. Tensile Strength of Wounds Closed Under Increasing Tension in the Pig Model (?)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2503</td>
<td>Brammer, Robert COL MC. Salicylate Ototoxicity in Humans, A Clinical Study (5/90)</td>
<td>506</td>
</tr>
<tr>
<td>2509</td>
<td>Tzikas, Thomas MAJ MC. Wound Healing: The Effect of Platelet Derived Growth Factor on the Tensile Strength of Wounds Closed Under Tension in Rats (12/90)</td>
<td>507</td>
</tr>
<tr>
<td>2512</td>
<td>Hayes, David MAJ MC. Analysis of Wounds by a Soft Tissue Hardness Transducer (STHT) System: A Pilot Study (5/91)</td>
<td>508</td>
</tr>
<tr>
<td>2585</td>
<td>Callahan, Scott CPT MC. Incidence of Maxillary Sinusitis in Nasally Intubated Patients (3/88)</td>
<td>509</td>
</tr>
<tr>
<td>2597</td>
<td>Pickett, Bradley CPT MC. Wound Healing: Development of Tensile Strength Vs. Time for Wounds Closed Under Tension in Rats (11/89)</td>
<td>510</td>
</tr>
<tr>
<td>2114</td>
<td>Villavicencio, Leonel MD. Phase I Study of the Sclerosant Agent Aethoxyskerol in Patients with Varicose Veins of the Lower Extremities (10/90)</td>
<td>511</td>
</tr>
<tr>
<td>2906</td>
<td>Robie, Daniel CPT MC. Intracellular Studies with Epidermal Growth Factor (3/88)</td>
<td>512</td>
</tr>
<tr>
<td>2909</td>
<td>Smith, George COL MC. Analysis of Antibiotic Diffusion Rates and Bacteriocidal Efficacy of Diffused Antibiotics Across a Silicone Breast Implant (5/90)</td>
<td>513</td>
</tr>
<tr>
<td>2911</td>
<td>Mayer, Michael LTC MC. The Use of Bone Repair Materials for Maxillary Alveolar Clefts (10/90)</td>
<td>514</td>
</tr>
<tr>
<td>2911</td>
<td>Mayer, Michael LTC MC. Orbital Floor Reconstruction with Bone Repair Materials (10/90)</td>
<td>515</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plastic Surgery Service (continued)</td>
<td></td>
</tr>
<tr>
<td>2912</td>
<td>Mayer, Michael LTC MC. Rigid Skeletal Fixation of</td>
<td>516</td>
</tr>
<tr>
<td></td>
<td>the Immature Craniofacial Skeleton (10/90)</td>
<td></td>
</tr>
<tr>
<td>2913</td>
<td>Antoine, Gregory LTC MC. Platelet Derived Growth</td>
<td>517</td>
</tr>
<tr>
<td></td>
<td>factor Formula in the Treatment of Chronic Wounds</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1/91)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thoracic Surgery Service</td>
<td></td>
</tr>
<tr>
<td>2710</td>
<td>Edwards, Fred LTC MC. Fresh Tissue Procurement</td>
<td>518</td>
</tr>
<tr>
<td></td>
<td>for NIH Tissue Culture (4/87)</td>
<td></td>
</tr>
<tr>
<td>2712</td>
<td>Edwards, Fred COL MC. Surgical Implications of</td>
<td>519</td>
</tr>
<tr>
<td></td>
<td>Three-dimensional Modeling of the Heart (9/91)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urology Service</td>
<td></td>
</tr>
<tr>
<td>2837</td>
<td>McLeod, David COL MC. NPCP 2200 A Comparison of</td>
<td>520</td>
</tr>
<tr>
<td></td>
<td>Leuprolide with Leuprolide and Flutamide in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Previously Untreated Patients with Clinical Stage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D2 Cancer of the Prostate (2/85)</td>
<td></td>
</tr>
<tr>
<td>2843</td>
<td>McLeod, David COL MC. ECOG EST 1887 A Phase III</td>
<td>521</td>
</tr>
<tr>
<td></td>
<td>Trial of Cystectomy Alone Vs. Neoadjuvant M-VAC +</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cystectomy in Patients with Locally Advanced</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bladder Cancer (10/88)</td>
<td></td>
</tr>
<tr>
<td>2847</td>
<td>McLeod, David COL MC. ECOG EST 5886 A Phase III</td>
<td>522</td>
</tr>
<tr>
<td></td>
<td>Trial of Cisplatin Alone or in Combination with</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Doxorubicin, Vinblastine and Methotrexate in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advanced Bladder Cancer (10/88)</td>
<td></td>
</tr>
<tr>
<td>2850</td>
<td>McLeod, David COL MC. ECOG EST 3887 Phase III</td>
<td>523</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy of Disseminated Advanced Stage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Testicular Cancer with Cisplatin Plus Etoposide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>with Either Plomycin or Ifosfamide (12/88)</td>
<td></td>
</tr>
<tr>
<td>2854</td>
<td>McLeod, David COL MC. ECOG EST 3886 Randomized</td>
<td>524</td>
</tr>
<tr>
<td></td>
<td>Phase III Evaluation of Hormonal Therapy Vs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Observation in Patients with Stage D1 Adenocarcin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>oma of the Prostate Following Pelvic Lymphadeno</td>
<td></td>
</tr>
<tr>
<td></td>
<td>nectomy and Radical Prostatectomy (2/89)</td>
<td></td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2858</td>
<td>McLeod, David COL MC. Treatment of Benign Prostatic Enlargement Using Balloon Dilatation (7/89)</td>
<td>525</td>
</tr>
<tr>
<td>2859</td>
<td>McLeod, David COL MC. SWOG 8894 A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Prostate Cancer (9/89)</td>
<td>526</td>
</tr>
<tr>
<td>2860</td>
<td>Moul, Judd MAJ MC. Expression of C-ErbB-2 Oncoprotein in Prostatic Carcinoma (10/89)</td>
<td>527</td>
</tr>
<tr>
<td>2862</td>
<td>Moul, Judd MAJ MC. Flow Cytometric Proliferative Activity in Stage I Nonseminomatous Testicular Cancer (4/90)</td>
<td>528</td>
</tr>
<tr>
<td>2863</td>
<td>McLeod, David COL MC. A Dose Response Study of the Effect of Flutamide on Benign Prostatic Hypertrophy (6/90)</td>
<td>529</td>
</tr>
<tr>
<td>2864</td>
<td>Moul, Judd MAJ MC. ECOG EST 9887 A Phase III Trial of Treatment of Pathologic Stage C Carcinoma of the Prostate with Adjuvant Radiotherapy (7/90)</td>
<td>530</td>
</tr>
<tr>
<td>2865</td>
<td>Sihelnik, Stephen LTC MC. A Randomized Trial of Transurethral Resection of the Prostate Vs. Open Prostatectomy or Nonoperative Treatment (7/90)</td>
<td>531</td>
</tr>
<tr>
<td>2866</td>
<td>McLeod, David COL MC. ECOG 1890 A Phase II Study of Taxol in Metastatic Prostate Cancer (11/90)</td>
<td>532</td>
</tr>
<tr>
<td>2867</td>
<td>Nicely, Eric M. Utilization of Cystoscopically Placed Cobalt Catheters for Directed Irrigation of Lower Pole Calyceal Stones During Extracorporeal Shock Wave Lithotripsy (ESWL) (9/91)</td>
<td>533</td>
</tr>
<tr>
<td>2868</td>
<td>McLeod, David COL MC. Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockade in Clinical B2 (T2bNxMo) Prostate Cancer (9/91)</td>
<td>534</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE* (VOL II)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VETERINARY SERVICE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9801</td>
<td>Mouer, Thomas DAC. Production of Positive and Negative Control Slides and Mouse Brain Suspension for Fluorescent Rabies Antibody Test (12/86)</td>
<td>535</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

ALLERGY-IMMUNOLOGY SERVICE

Bennett C, Billups L, Lippert L, Salata K: Quantitative antigen typing red cells in mixed red blood cell populations by flow cytometry. Mid-Atlantic Association of Blood Banks Meeting, Fredericksburg, VA, April, 1992. [4812]


* Number in [] is the protocol number.
** P = publication, A = abstract, Pr = presentation
ALLERGY-IMMUNOLOGY SERVICE (continued)


Huh M, Davis W, Engler R, Salata K, Berger T, Smith L, Bartoszek D: Improved response to 2 day high-dose intravenous immunoglobulin (IVIG) in chronic neuropathy. 43rd Annual Fitzsimons Symposium, Fitzsimons Army Medical Center, Aurora, CO, February, 1992. [3350]

Huh M, Davis W, Engler R, Salata K, Berger T, Smith L, Bartoszek D: Improved response to 2 day high-dose intravenous immunoglobulin (IVIG) in chronic neuropathy. Annual Meeting of the American Academy of Allergy and Immunology, Orlando, FL, March, 1992. [3350]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

ALLERGY-IMMUNOLOGY SERVICE (continued)


Squire E, Lombardo F: Methotrexate may successfully control severe asthma when Troleandomycin and hydroxychloroquine fail, but not vice versa. J Allergy Clin Immunol 1992;89(1 Pt. 2):286:566A. [3352]

Squire E, Lombardo F: Methotrexate may successfully control severe asthma when Troleandomycin and hydroxychloroquine fail, but not vice versa. 20th Annual Meeting of the Association of Military Allergists, Fitzsimons Army Medical Center, Aurora, CO, February, 1992. [3352]

Squire E, Lombardo F: Methotrexate may successfully control severe asthma when Troleandomycin and hydroxychloroquine fail, but not vice versa. American Academy of Allergy and Immunology 48th Annual Meeting, Orlando, FL, March, 1992. [3352]

DEPARTMENT OF CLINICAL INVESTIGATION


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


Derderian S, Rajagopal K, Burgess L: Sleep disordered breathing following uvulopalatopharyngoplasty (UPPP): for better or for worse?. Am Rev Respir Dis 1991;143:A588. [2584]


DENTAL CLINIC


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*  TYPE**

FORT DIX, NEW JERSEY


HIV RESEARCH


Anderson D: Pathology of HIV disease itself. Uniformed Services University of the Health Sciences Conference on HIV in the Military, Bethesda, MD, October, 1991. [4806]


Birx D, Loomis L, Van Cott T: Restricted V3 reactivity associated with clinical HIV stage. Annual Meeting of the Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, 1991. [8803]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)

Birx D: Immunogenicity and safety of rgp120 (lai) in early stage HIV positive patients. 5th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Chantilly, VA, September, 1992. [8820]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION* TYPE**

HIV RESEARCH (continued)


Holland T, Smith K, Skelton H: Cutaneous histopathologic findings in chemotherapeutic iontophoresis. Twenty-Ninth Annual Meeting of the American Society of Dermatology, Dallas, TX, December, 1991. [8812]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

HIV RESEARCH (continued)


* Number in [] is the protocol number.
** P - publication, Ab - abstract, Pr - presentation


Mayers D: Is HIV antiviral drug resistance clinically or epidemiologically important?. Sixth Conference on Military Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, October, 1991. [881d]

Mayers D: The clinical significance of AZT resistance. Infectious Disease Department, University of California, San Diego, CA, March, 1992. [8818]

Mayers D: The clinical significance of AZT resistance. Infectious Diseases Department, Naval Hospital, San Diego, CA, March, 1992. [8818]

Mayers D: The clinical significance of AZT resistance. Infectious Diseases Department, National Naval Medical Center, Bethesda, MD, March, 1992. [8818]


Mayers D: The clinical and epidemiological significance of antiretroviral drug resistance. Infectious Disease Department, Walter Reed Army Medical Center, Washington, DC, May, 1992. [8813]

Mayers D: The clinical and epidemiological significance of antiretroviral drug resistance. AIDS Program, Centers for Disease Control, Atlanta, GA, June, 1992. [8818]

* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation.
CITATION*

HIV RESEARCH (continued)


* Number in [] is the protocol number.
** P = publication, Ab = abstract Pr = presentation
HIV RESEARCH (continued)


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)


Roberts C: Laboratory diagnosis of retroviral infections. Dermatologic Clinics 1991;9(3):453-64. [8803]

Roberts C: How reliable are tests for HIV?. Sixth Annual Conference on Military Medicine, Washington, DC, October, 1991. [8803]

Roberts C: Diagnosis of human retroviral infections in the military population. Fifth Biennial AMEDD HIV/AIDS Symposium, Denver, CO June, 1992. [8803]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


Rundell J: Is central nervous system involvement in early-stage HIV infection significant?. Symposium at the Sixth Annual Conference on Military Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, October, 1991. [7243]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

HIV RESEARCH (continued)

Smith K, Skelton H, James W, Frissman D, Barrett T, Angritt P, Lupton P:
Papular eruption of HIV disease: a review of the clinical, histologic, and
immunohistochemical findings in forty-eight cases. Am J Dermatopathol

Smith K, Skelton H, Lupton G: Intraepidermal neuroendocrine (Merkel
cell) carcinoma with Bowenoid dysplasia and tubular
differentiation. Twenty-Ninth Annual Meeting of the American
Society of Dermatology, Dallas, TX, December, 1991. [8812]

Smith K, Skelton H, Lupton G: Intraepidermal neuroendocrine (Merkel
cell) carcinoma with Bowenoid dysplasia and tubular

Smith K, Skelton H, Yeager J, Angritt P, Wagner K, James W, Giblin W,
Lupton G: Cutaneous histopathologic, immunohistochemical, and
clinical manifestations in patients with hemophagocytic syndrome.

Smith K, Skelton H, Yeager J, Angritt P, James W, Wagner K:
Ultrastructural pr the presence of molluscum contagiosum in the
skin adjacent to clinical lesions in HIV-1 infected patients.
Arch Dermatol 1992;128(2). [8812]

Smith K, Skelton H, Yeager J, Angritt P: Sarcomatoid variant of a
B-cell lymphoma in an HIV-infected patient. Twenty-Ninth Annual
Meeting of the American Society of Dermatology, Dallas, TX,
December, 1991. [8812]

Smith K, Skelton H, Yeager J, Angritt P: The spectrum of graft-vs-host
disease in cutaneous lesions of HIV-1 infected patients.
Twenty-Ninth Annual Meeting of the American Society of
Dermatology, Dallas, TX, December, 1991. [8812]

Smith K, Skelton H, Yeager J, Angritt P: Sarcomatoid variant of a
B-cell lymphoma in an HIV-infected patient. J Cut Pathol
1991;18(5):391. [8812]

Smith K, Skelton H, Yeager J, Angritt P: The spectrum of graft-vs-host
disease in cutaneous lesions of HIV-1 infected patients. J Cut

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)


Temoshok L: How can research findings on transmission-relevant behaviors in HIV infected individuals be translated into interventions? Symposium at the Sixth Annual Conference on Military Medicine, Uniformed Services University, Bethesda, MD, October, 1991. [7243]

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

HIV RESEARCH (continued)


Temoshok L: A biopsychological perspective on HIV/AIDS. Seminar at the Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD, November, 1991. [7243]


Yeager J, Smith K, Skelton H: A unique anaerobic gram negative rod infection of the hair follicle in a HIV positive patient. Twenty-Ninth Annual Meeting of the American Society of Dermatology, Dallas, TX, December, 1991. [8812]


DEPARTMENT OF MEDICINE
Cardiology Service


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
Citation*

**Department of Medicine**

**Cardiology Service (continued)**


**Department of Medicine**

**Dermatology Service**


**Department of Medicine**

**Endocrine-Metabolic Service**


---

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service (continued)


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


Carr F, Wong N: Negative transcriptional regulation by T3 is mediated by a half-site motif of a T3RE. American Thyroid Association Meeting, Rochester, MN. September, 1992. [1393-87]

Carr F, Wong N: Negative transcriptional regulation by T3 is mediated by a half-site motif of a T3RE. Endocrinology 1992;(suppl 122). [1393-87]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


Wartofsky L: Management of Graves' ophthalmopathy. 74th Annual Meeting of the Endocrine Society, San Antonio, TX, June, 1992. [1351-84]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

DEPARTMENT OF MEDICINE
Gastroenterology Service


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF MEDICINE
Gastroenterology Service (continued)


Shay S, Abreu S, Tsuchida A: Scintigraphy in gastroesophageal reflux disease: a comparison to endoscopy, LESp, and 24-h pH score, as well as to simultaneous pH monitoring. Am J Gastroenterol 1992;87(9):1094-101. [1462]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF MEDICINE
General Medicine Service


Roy M: When the doctor leaves the patient: transfer of care in the clinic. Society of General Internal Medicine Mid-Atlantic Region Annual Conference, Uniformed Services University of the Health Sciences, Bethesda, MD, February, 1992. [1028]

Roy M: When the doctor leaves the patient: transfer of care in the clinic. Annual Graduate Student Colloquium, Uniformed Services University of the Health Sciences, Bethesda, MD, April, 1992. [1028]

DEPARTMENT OF MEDICINE
Hematology-Oncology Service


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


Carome M, Peter E, Moore J, Stetler-Stevenson W, Striker G, Striker L: Tissue inhibitor of metalloproteinase-1 (TIMP 1) and TIMP-2 MRNAs: detection and quantitation in isolated whole human glomeruli by RT-PCR. International Meeting on Molecular Approaches to Nephrology: Prospects in Diagnosis and Management, Bari, Italy, March, 1992. [1164]


Carome M, Striker L, Elliot S, Peter E, Stetler-Stevenson W, Striker G: TIMP1 and alpha-I type IV collagen mRNAs in mouse mesangial cells at low and high density. 24th Annual Meeting of the American Society of Nephrology, Baltimore, MD, November, 1991. [1162]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
## Publications/Presentations by Department/Service and Author

### Department of Medicine

Pulmonary Disease Service (continued)

<table>
<thead>
<tr>
<th>Citation*</th>
<th>Type**</th>
</tr>
</thead>
</table>

* Number in [] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF MEDICINE
Pulmonary Disease Service (continued)


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
<table>
<thead>
<tr>
<th>DEPARTMENT OF MEDICINE</th>
<th>TYPE**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Disease Service (continued)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CITATION*</th>
<th>TYPE**</th>
</tr>
</thead>
</table>

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF MEDICINE
Pulmonary Disease Service (continued)


DEPARTMENT OF MEDICINE
Rheumatology Service


NEUROLOGY SERVICE


Jabbari B, Bartoszek D: Magnetic evoked potential in "painful leg moving toe" syndrome. International Movement Disorder Society Meeting, Munich, Germany, June, 1992. [7143]

Jabbari B, Yoder C: Alternating epileptic dystonia: which dystonic limb has localizing value?. Epilepsia 1991;32(suppl):56. [7147]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*  TYPE**

DEPARTMENT OF NURSING


DEPARTMENT OF NURSING

Nursing Research Service

Gurney C: Determinants of intent to leave among nurses with doctoral degrees by occupational setting. 14th Annual Meeting of the Midwest Nursing Research Society, Oklahoma City, OK, 1991. [7524]

Gurney C: Determinants of intent to leave among nurses with doctoral degrees by occupational setting. Annual Meeting of the Midwest Sociological Society, Des Moines, IA, 1991. [7524]

Gurney C: Interaction effects in determinants of intent to leave. 4th Biennial Conference on Nursing Administration Research, Iowa City, IA, October, 1991. [7524]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*  TYPE**

DEPARTMENT OF NURSING
Nursing Research Service (continued)

Reeder J: Families coping with combat injury. Annual Medical-Surgical Update, Department of Nursing, Walter Reed Army Medical Center, Washington, DC, April, 1992. [7523]


DEPARTMENT OF OBSTETRICS AND GYNECOLOGY


DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES


Knoll S: Plasma potassium levels in stored irradiated units of CPDA1 anticoagulated red blood cells. Armed Services Blood Bank Fellowship Graduation Program, Walter Reed Army Medical Center, Washington, DC, January, 1991. [4809]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION* 

DEPARTMENT OF PEDIATRICS


Dykstra K, Payne M, Abdel-Rahim M, Francis G: Insulin-like growth factor-I but not growth hormone has in vitro proliferation effects on neonatal foreskin fibroblasts. Endocrine Society, San Antonio, TX, June, 1992. [6064]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


Bjornson D: Clinical pharmacy justification study - WRAMC. Ralph D. Arnold Pharmaceutical Services Management Course, San Antonio, TX, 1991. [3601]


* Number in [] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*  TYPE**

PHARMACY SERVICE (continued)


PHYSICAL MEDICINE AND REHABILITATION SERVICE


DEPARTMENT OF PSYCHIATRY


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF PSYCHIATRY (continued)

Weir L: Visual auditory interactions. WRAMC Department of Psychiatry

DEPARTMENT OF RADIOLOGY

Dachman A, Van De Merwe W, Czege J, Ward F, Garra B, Beam T, Shay S:
Interstitial tumor ablation of hepatic metastases from colorectal
carcinoma using Nd:YAG laser; initial clinical experience. 40th
Annual Meeting of the Association of University Radiologists,
Chicago, April, 1992. [4538]

Dachman A, Van De Merwe W, Czege J, Ward F, Garra B, Beam T, Shay S:
Interstitial tumor ablation of hepatic metastases from colorectal
carcinoma using Nd:YAG laser; initial clinical experience. 12th
Annual Meeting of the American Society for Laser Medicine and
Surgery, Lake Buena Vista, FL, May, 1992. [4538]

DEPARTMENT OF SURGERY

Anesthesia-Operative Service

Hahn M, Bettencourt J, Stamatos J: The use of the Davol catheter for
the treatment of cancer pain. American Society of
Anesthesiologists Meeting, Las Vegas, NV, October, 1991. [2045A]

Kline H, Guzzi L, Reynolds P, Stoltzfus D, Hagemeister B: Patterns of
ischemia - Holter monitoring following non-cardiac surgery in
patients with previous PTCA or CABG. Anesthesiology 1992;77:A90.
[2051A]

Reynolds P, Hahn M: Early diagnosis of a spinal epidural abscess. Reg

Stamatos J, Crowl F, Kline M: Premedication of pediatric patients: a
combination of midazolam and ketamine versus each drug separately.
New York Postgraduate Assembly of Anesthesiologists, New York, NY,
December, 1991. [2052A]

DEPARTMENT OF SURGERY

Army Audiology and Speech Center

Cord M: The effect of noise on the speech recognition ability of
soldiers with H-3 physical profiles. Military Audiology Short
Course, Nashville, TN, March, 1992. [2504]

* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*  

DEPARTMENT OF SURGERY  
Army Audiology and Speech Center (continued)


Leek M: Effects of frequency resolution on speech understanding by hearing-impaired persons. Invited presenter, Department of Speech and Hearing Science, University of Maryland, College Park, MD, April, 1992. [2588]

* Number in [] is the protocol number.  
** P = publication, Ab = abstract, Pr = presentation
### DEPARTMENT OF SURGERY

#### Army Audiology and Speech Center (continued)

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type **</th>
</tr>
</thead>
</table>

#### DEPARTMENT OF SURGERY

##### General Surgery Service

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type **</th>
</tr>
</thead>
</table>

#### DEPARTMENT OF SURGERY

##### Ophthalmology Service

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type **</th>
</tr>
</thead>
</table>

#### DEPARTMENT OF SURGERY

##### Organ Transplant Service

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type **</th>
</tr>
</thead>
</table>

---

* Number in [ ] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
<table>
<thead>
<tr>
<th>DEPARTMENT OF SURGERY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urology Service</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CITATION*</th>
<th>TYPE**</th>
</tr>
</thead>
</table>

* Number in [] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF SURGERY
Urology Service (continued)


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR FROM PROTOCOLS CLOSED PRIOR TO FY-92

CITATION* 

DEPARTMENT OF CLINICAL INVESTIGATION


DEPARTMENT OF MEDICINE

Dermatology Service


DEPARTMENT OF MEDICINE

Endocrine-Metabolic Service

Baker J, Miller F, Steinberg A, Burman K. Thyroid stimulating and thyrotropin binding inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. Thyroid 1991;1:229-34. [1355-87]


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation

121
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-92

CITATION*

DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service (continued)


Nagy E, Burch H, Lukes Y, Burman K. Lymphocyte responsiveness to immunogenic peptides of the human TSH receptor. 74th Annual Meeting of the Endocrine Society, San Antonio, TX, June, 1992. [1355-87]


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation
CITATION* | TYPE**
--- | ---

DEPARTMENT OF MEDICINE  
Gastroenterology Service  

DEPARTMENT OF MEDICINE  
General Medicine Service  

DEPARTMENT OF MEDICINE  
Hematology-Oncology Service  


DEPARTMENT OF MEDICINE  
Hematology-Oncology Service (continued)  


* Number in [ ] is the closed protocol number  
** P = publication, Ab = abstract, Pr = presentation  
123
ADDITIONUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-92

CITATION*  TYPE**

DEPARTMENT OF MEDICINE
Infectious Disease Service


DEPARTMENT OF MEDICINE
Pulmonary Disease Service


Argyros, G. Water loss without heat flux in exercise induced Pr asthma. District of Columbia Thoracic Society Annual Meeting (Fellow Award recipient), Washington, DC, April, 1992. [1742]


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation
<table>
<thead>
<tr>
<th>DEPARTMENT OF MEDICINE</th>
<th>TYPE**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Disease Service (continued)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NEUROLOGY SERVICE</th>
<th>TYPE**</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>DEPARTMENT OF OBSTETRICS-GYNECOLOGY</th>
<th>TYPE**</th>
</tr>
</thead>
</table>

* Number in [] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation
CITATION* TYPE**

DEPARTMENT OF PEDIATRICS


PHYSICAL MEDICINE AND REHABILITATION SERVICE


DEPARTMENT OF PSYCHIATRY


DEPARTMENT OF SURGERY

Army Audiology and Speech Center


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation
CITATION*                                                                 TYPE**

DEPARTMENT OF SURGERY
General Surgery Service


DEPARTMENT OF SURGERY
Organ Transplant Service


DEPARTMENT OF SURGERY
Orthopaedic Surgery Service


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

ALLERGY-IMMUNOLOGY SERVICE


DENTAL CLINIC


HIV RESEARCH


DEPARTMENT OF MEDICINE
Cardiology Service


* P = publication, Ab = abstract

128
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Cardiology Service (continued)


DEPARTMENT OF MEDICINE
Dermatology Service


* P = publication, Ab = abstract

129
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Dermatology Service (continued)

Lee M, Wakefield P, Konzelman J Jr, James W. Oral
insertable prosthetic device as an aid in treating oral

Malane S, Sau P, Benson P. Epithelioid hemangioendothelioma
associated with reflex sympathetic dystrophy. J Am Acad


O'Donnell B, Sperling L, James W. Loose anagen hair syndrome.

Saad R, Domloge-Hultsch N, Yancey K, Benson P, James W.
Childhood localized vulvar pemphigoid is a true variant of

Sau P, Solivan G, Johnson F. Cutaneous reaction from a broken

Sperling L. Hair anatomy for the clinician. J Am Acad Dermatol

Sperling L. Inflammatory tinea capitis (kerion) mimicking
dissecting cellulitis. Occurrence in two adolescents.

Sperling L. Mohs surgery and the reconstructive surgeon: the
interdisciplinary approach for treating difficult cutaneous
malignancies of the head and neck. Ear Nose Throat J

Sperling L, Sau P. The follicular degeneration syndrome in
black patients. "Hot comb alopecia" revisited and revised.

* P = publication, Ab = abstract

130
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Dermatology Service (continued)


DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service


DEPARTMENT OF MEDICINE
Gastroenterology Service


* P = publication, Ab = abstract

131
## ADDENDUM

PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

<table>
<thead>
<tr>
<th>DEPARTMENT OF MEDICINE</th>
<th>TYPE*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastroenterology Service (continued)</strong></td>
<td></td>
</tr>
<tr>
<td>Shay S. Benign structural lesions of the esophagus.</td>
<td>P</td>
</tr>
<tr>
<td>Truesdale R Jr, Wong R. Complications of esophageal variceal sclerotherapy.</td>
<td>P</td>
</tr>
<tr>
<td><strong>Hematology-Oncology Service</strong></td>
<td></td>
</tr>
<tr>
<td>Diehl L. Radiation and chemotherapy in the treatment of esophageal cancer.</td>
<td>P</td>
</tr>
<tr>
<td><strong>Infectious Disease Service</strong></td>
<td></td>
</tr>
<tr>
<td>Artenstein A, Hicks C, Goodwin B Jr, Hilliard J. Human infection with B virus following a needlestick injury.</td>
<td>P</td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION TYPE*

DEPARTMENT OF MEDICINE
Infectious Disease Service (continued)


DEPARTMENT OF MEDICINE
Internal Medicine Service


* P = publication, Ab = abstract
CITATION

DEPARTMENT OF MEDICINE
Nephrology Service


DEPARTMENT OF MEDICINE
Pulmonary Disease Service


DEPARTMENT OF MEDICINE
Rheumatology Service


NEUROLOGY SERVICE


* P = publication, Ab = abstract
CITATION

NEUROCICLY SERVICE (continued)


* P = publication, Ab = abstract

135
**CITATION**

<table>
<thead>
<tr>
<th>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES</th>
</tr>
</thead>
</table>

*P* - publication, *Ab* - abstract
<table>
<thead>
<tr>
<th>CITATION</th>
<th>TYPE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF PEDIATRICS</td>
<td></td>
</tr>
<tr>
<td>Bilello J, O'Hair K, Kirby W, Moore J. Intraosseous infusion</td>
<td>P</td>
</tr>
<tr>
<td>the cytotoxic effect of cyclopentenylcytosine by its primary metabolite,</td>
<td></td>
</tr>
<tr>
<td>Blaney S, Balis F, Poplack D. Current pharmacological treatment</td>
<td>P</td>
</tr>
<tr>
<td>Blaney S, Balis F, Poplack D. Pharmacologic approaches to the</td>
<td>P</td>
</tr>
<tr>
<td>Filling-Katz M, Levin S, Patronas N, Katz N. Terminal transverse limb</td>
<td>P</td>
</tr>
<tr>
<td>defects associated with familial cavernous angiomatosis. Am J Med Genet</td>
<td></td>
</tr>
<tr>
<td>Hartman K, Triche T, Kinsella T, Miser J. Prognostic value of</td>
<td>P</td>
</tr>
<tr>
<td>histopathology in Ewing's sarcoma. Long-term follow-up of distal</td>
<td></td>
</tr>
<tr>
<td>Perry J, Jelinek J. Isolated central nervous system relapse of</td>
<td>P</td>
</tr>
<tr>
<td>Swanson S III, Skoog S, Garcia V, Wahl R. Pseudoadrenal mass: unusual</td>
<td>P</td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract
ADDITIONAL PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF PEDIATRICS (continued)


PHARMACY SERVICE


PHYSICAL MEDICINE AND REHABILITATION SERVICE


DEPARTMENT OF PSYCHIATRY


* P = publication. Ab = abstract
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF PSYCHIATRY (continued)


DEPARTMENT OF RADIOLOGY


* P = publication, Ab = abstract

139
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF RADIOLOGY (continued)


* P = publication, Ab = abstract
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Anesthesia-Operative Service


DEPARTMENT OF SURGERY
Army Audiology and Speech Center


DEPARTMENT OF SURGERY
General Surgery Service


* P = publication, Ab = abstract
A D D E N D U M
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Neurosurgery Service


DEPARTMENT OF SURGERY
Ophthalmology Service


DEPARTMENT OF SURGERY
Orthopaedic Surgery Service


* P - publication, Ab - abstract

142
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Orthopaedic Surgery Service (continued)


DEPARTMENT OF SURGERY
Otolaryngology-Head and Neck Surgery Service


* P - publication, Ab - abstract
ADDENDUM
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Plastic Surgery Service


DEPARTMENT OF SURGERY
Thoracic Surgery Service


DEPARTMENT OF SURGERY
Urology Service


* P = publication, Ab = abstract
CITATION TYPE*

DEPARTMENT OF SURGERY
Urology Service (continued)


* P = publication, Ab = abstract
DEPARTMENT OF SURGERY
Urology Service (continued)


* P = publication, Ab = abstract

146
CITATION

DENTAL CLINIC


DEPARTMENT OF MEDICINE
Dermatology Service


CITATION

DEPARTMENT OF MEDICINE
Dermatology Service (continued)


DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service


CITATION

DEPARTMENT OF MEDICINE
Gastroenterology Service


DEPARTMENT OF MEDICINE
Hematology-Oncology Service


DEPARTMENT OF MEDICINE
Infectious Disease Service


ADDENDUM
PUBLICATIONS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

DATA PROVIDED BY THE WRAMC MEDICAL LIBRARY - BIBLIOGRAPHY OF WALTER REED ARMY MEDICAL STAFF PUBLICATIONS 1990-1992

CITATION

DEPARTMENT OF MEDICINE

Infectious Disease Service (continued)


DEPARTMENT OF MEDICINE

Internal Medicine Service


DEPARTMENT OF MEDICINE

Pulmonary Disease Service


CITATION

DEPARTMENT OF MEDICINE

Pulmonary Disease Service (continued)


NEUROLOGY SERVICE


DEPARTMENT OF NURSING


ADDENDUM
PUBLICATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

DATA PROVIDED BY THE WRAMC MEDICAL LIBRARY - BIBLIOGRAPHY
OF WALTER REED ARMY MEDICAL STAFF PUBLICATIONS 1990-1992

CITATION

DEPARTMENT OF NURSING (continued)


Reeder J. Perioperative nurses showed courage and commitment in meeting the challenges of Operation Desert Storm. AORN J 1991;53(5):1134,36.


DEPARTMENT OF OBSTETRICS AND GYNECOLOGY


DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES

CITATION

DEPARTMENT OF PEDIATRICS


PHARMACY SERVICE


PHYSICAL MEDICINE AND REHABILITATION SERVICE


DEPARTMENT OF PSYCHIATRY

CITATION

DEPARTMENT OF PSYCHIATRY (continued)


DEPARTMENT OF SURGERY
Anesthesia-Operative Service


DEPARTMENT OF SURGERY
Army Audiology and Speech Center


DEPARTMENT OF SURGERY
Neurosurgery Service

CITATION

DEPARTMENT OF SURGERY
Ophthalmology Service


DEPARTMENT OF SURGERY
Organ Transplant Service


DEPARTMENT OF SURGERY
Orthopaedic Surgery Service


DEPARTMENT OF SURGERY
Otolaryngology-Head and Neck Surgery Service


ADDENDUM
PUBLICATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

DATA PROVIDED BY THE WRAMC MEDICAL LIBRARY - BIBLIOGRAPHY
OF WALTER REED ARMY MEDICAL STAFF PUBLICATIONS 1990-1992

CITATION

DEPARTMENT OF SURGERY
Otolaryngology-Head and Neck Surgery Service (continued)


DEPARTMENT OF SURGERY
Perivascular Surgery Service


DEPARTMENT OF SURGERY
Thoracic Surgery Service


DEPARTMENT OF SURGERY
Urology Service


CITATION

DEPARTMENT OF SURGERY
Urology Service (continued)


<table>
<thead>
<tr>
<th>Author</th>
<th>Volume I Pages</th>
<th>Volume II Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-Rahim M</td>
<td>96, 112</td>
<td>165, 337</td>
</tr>
<tr>
<td>Abreu S</td>
<td>103</td>
<td>196</td>
</tr>
<tr>
<td>Adamo D</td>
<td>104</td>
<td>208</td>
</tr>
<tr>
<td>Adrianza M</td>
<td>95</td>
<td>131</td>
</tr>
<tr>
<td>Agostinelli D</td>
<td>79, 80</td>
<td>4</td>
</tr>
<tr>
<td>Allen R</td>
<td>111</td>
<td>295</td>
</tr>
<tr>
<td>Ammann A</td>
<td>82</td>
<td>76</td>
</tr>
<tr>
<td>Anderson D</td>
<td>82</td>
<td>55</td>
</tr>
<tr>
<td>Andron L</td>
<td>85</td>
<td>74</td>
</tr>
<tr>
<td>Angritt P</td>
<td>91, 92</td>
<td>69</td>
</tr>
<tr>
<td>Arduino J</td>
<td>84</td>
<td>74</td>
</tr>
<tr>
<td>Armstrong J</td>
<td>109</td>
<td>268</td>
</tr>
<tr>
<td>Aronson N</td>
<td>82</td>
<td>76</td>
</tr>
<tr>
<td>Artenstein A</td>
<td>105</td>
<td>234</td>
</tr>
<tr>
<td>Ascher D</td>
<td>82, 89, 112</td>
<td>56, 57, 353</td>
</tr>
<tr>
<td>Atkins F</td>
<td>105</td>
<td>236</td>
</tr>
<tr>
<td>Azarow K</td>
<td>117</td>
<td>477</td>
</tr>
<tr>
<td>Bacchetti P</td>
<td>87</td>
<td>60</td>
</tr>
<tr>
<td>Baehm D</td>
<td>114</td>
<td>428</td>
</tr>
<tr>
<td>Baker J</td>
<td>96</td>
<td>165</td>
</tr>
<tr>
<td>Baker W</td>
<td>104, 112</td>
<td>220, 347</td>
</tr>
<tr>
<td>Bale A</td>
<td>97</td>
<td>165</td>
</tr>
<tr>
<td>Balfour H</td>
<td>87</td>
<td>74</td>
</tr>
<tr>
<td>Banks A</td>
<td>94, 95</td>
<td>116, 123</td>
</tr>
<tr>
<td>Barekman C</td>
<td>111</td>
<td>333</td>
</tr>
<tr>
<td>Barrett T</td>
<td>91, 92</td>
<td>69</td>
</tr>
<tr>
<td>Bartoszek D</td>
<td>79, 109</td>
<td>14, 29, 278</td>
</tr>
<tr>
<td>Baska R</td>
<td>102</td>
<td>204</td>
</tr>
<tr>
<td>Beam T</td>
<td>115</td>
<td>445</td>
</tr>
<tr>
<td>Beauchesne R</td>
<td>118</td>
<td>503</td>
</tr>
<tr>
<td>Becker R</td>
<td>119</td>
<td>528</td>
</tr>
<tr>
<td>Beckett L</td>
<td>84, 85</td>
<td>74</td>
</tr>
<tr>
<td>Belandres P</td>
<td>114</td>
<td>430</td>
</tr>
<tr>
<td>Bennett C</td>
<td>78</td>
<td>32</td>
</tr>
<tr>
<td>Benson P</td>
<td>95</td>
<td>131</td>
</tr>
<tr>
<td>Bent R</td>
<td>112</td>
<td>349</td>
</tr>
<tr>
<td>Berg B</td>
<td>105, 106</td>
<td>251</td>
</tr>
<tr>
<td>Berger T</td>
<td>79, 81</td>
<td>14, 29, 31, 37</td>
</tr>
<tr>
<td>Berman P</td>
<td>82</td>
<td>76</td>
</tr>
<tr>
<td>Bettencourt J</td>
<td>115</td>
<td>449</td>
</tr>
<tr>
<td>Betz J</td>
<td>112</td>
<td>355</td>
</tr>
<tr>
<td>Bilello K</td>
<td>107</td>
<td>259</td>
</tr>
<tr>
<td>Billups L</td>
<td>78, 79, 81</td>
<td>31, 32, 37</td>
</tr>
<tr>
<td>Birx D</td>
<td>80, 82, 83, 88, 89</td>
<td>2, 62, 65, 76</td>
</tr>
<tr>
<td>Bjornson D</td>
<td>83, 113, 114</td>
<td>70, 71, 425</td>
</tr>
<tr>
<td>Blake S</td>
<td>83, 89, 90, 93</td>
<td>60</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volumes I & II.
### AUTHOR INDEX*

<table>
<thead>
<tr>
<th>Author</th>
<th>Volume I Page(s)</th>
<th>Volume II Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boggi J</td>
<td>104</td>
<td>205</td>
</tr>
<tr>
<td>Bowen P</td>
<td>101, 103</td>
<td>189, 195</td>
</tr>
<tr>
<td>Bowman W</td>
<td>113</td>
<td>383</td>
</tr>
<tr>
<td>Bradford B</td>
<td>81</td>
<td>48</td>
</tr>
<tr>
<td>Braid L</td>
<td>116</td>
<td>458</td>
</tr>
<tr>
<td>Brandt U</td>
<td>83</td>
<td>60</td>
</tr>
<tr>
<td>Braunwald E</td>
<td>95</td>
<td>126</td>
</tr>
<tr>
<td>Braverman S</td>
<td>79, 114</td>
<td>29, 427, 430</td>
</tr>
<tr>
<td>Brewer T</td>
<td>102</td>
<td>185</td>
</tr>
<tr>
<td>Brewster L</td>
<td>104, 105</td>
<td>208</td>
</tr>
<tr>
<td>Brisker J</td>
<td>108</td>
<td>267</td>
</tr>
<tr>
<td>Brodine S</td>
<td>89</td>
<td>62</td>
</tr>
<tr>
<td>Brown G</td>
<td>83, 84, 85, 87, 89, 94</td>
<td>60</td>
</tr>
<tr>
<td>Brown L</td>
<td>95</td>
<td>126</td>
</tr>
<tr>
<td>Brunside J</td>
<td>97</td>
<td>170</td>
</tr>
<tr>
<td>Bryant P</td>
<td>114</td>
<td>427</td>
</tr>
<tr>
<td>Buchanan G</td>
<td>113</td>
<td>383</td>
</tr>
<tr>
<td>Burch H</td>
<td>95, 96, 99</td>
<td>165</td>
</tr>
<tr>
<td>Burgess L</td>
<td>80, 81, 108</td>
<td>34, 247</td>
</tr>
<tr>
<td>Burgess M</td>
<td>101</td>
<td>195</td>
</tr>
<tr>
<td>Burke D</td>
<td>82, 85, 86, 87, 88, 89</td>
<td>65, 74, 76</td>
</tr>
<tr>
<td>Burman K</td>
<td>95, 96, 97, 98, 99, 100</td>
<td>139, 143, 145, 154, 165, 172, 173</td>
</tr>
<tr>
<td>Burns T</td>
<td>98</td>
<td>165, 172</td>
</tr>
<tr>
<td>Burrell L</td>
<td>104, 112</td>
<td>220, 347</td>
</tr>
<tr>
<td>Cai W</td>
<td>96</td>
<td>165</td>
</tr>
<tr>
<td>Calabro M</td>
<td>94</td>
<td>62</td>
</tr>
<tr>
<td>Callaghan J</td>
<td>118</td>
<td>488</td>
</tr>
<tr>
<td>Carlson H</td>
<td>98</td>
<td>165, 172</td>
</tr>
<tr>
<td>Carome M</td>
<td>105</td>
<td>243, 245</td>
</tr>
<tr>
<td>Carpenter G</td>
<td>78, 79, 80</td>
<td>2, 4, 22, 30</td>
</tr>
<tr>
<td>Carr F</td>
<td>95, 96, 97, 98, 99, 100</td>
<td>123, 149, 165, 170</td>
</tr>
<tr>
<td>Carter A</td>
<td>95</td>
<td>123, 125</td>
</tr>
<tr>
<td>Cavallaro B</td>
<td>117</td>
<td>480</td>
</tr>
<tr>
<td>Chamberlain C</td>
<td>103</td>
<td>181</td>
</tr>
<tr>
<td>Chan J</td>
<td>99</td>
<td>170</td>
</tr>
<tr>
<td>Chandler J</td>
<td>83</td>
<td>60</td>
</tr>
<tr>
<td>Chang A</td>
<td>112</td>
<td>349</td>
</tr>
<tr>
<td>Chang E</td>
<td>119, 120</td>
<td>527, 528</td>
</tr>
<tr>
<td>Childers E</td>
<td>117</td>
<td>487</td>
</tr>
<tr>
<td>Chin W</td>
<td>97</td>
<td>170</td>
</tr>
<tr>
<td>Chin Y</td>
<td>95</td>
<td>125</td>
</tr>
<tr>
<td>Christian M</td>
<td>104, 105</td>
<td>208</td>
</tr>
<tr>
<td>Chung R</td>
<td>84, 86, 108</td>
<td>50, 74, 267</td>
</tr>
<tr>
<td>Clasby S</td>
<td>85</td>
<td>60</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volumes I & II.
<table>
<thead>
<tr>
<th>Author</th>
<th>Reference</th>
<th>Volume(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coak E</td>
<td>114, 428</td>
<td>(I)</td>
</tr>
<tr>
<td>Cohen A</td>
<td>117, 477</td>
<td>(I)</td>
</tr>
<tr>
<td>Cole T</td>
<td>95, 126</td>
<td>(I)</td>
</tr>
<tr>
<td>Colon C</td>
<td>82, 56</td>
<td>(II)</td>
</tr>
<tr>
<td>Cook E</td>
<td>114, 428</td>
<td>(II)</td>
</tr>
<tr>
<td>Cooley J</td>
<td>89, 57</td>
<td>(II)</td>
</tr>
<tr>
<td>Cooper C</td>
<td>91, 69</td>
<td>(II)</td>
</tr>
<tr>
<td>Cord M</td>
<td>115, 455</td>
<td>(II)</td>
</tr>
<tr>
<td>Cortese L</td>
<td>83, 71</td>
<td>(I)</td>
</tr>
<tr>
<td>Coyle C</td>
<td>83, 84, 60</td>
<td>(II)</td>
</tr>
<tr>
<td>Craig T</td>
<td>78, 80, 30</td>
<td>(II)</td>
</tr>
<tr>
<td>Cross A</td>
<td>105, 234</td>
<td>(II)</td>
</tr>
<tr>
<td>Croll F</td>
<td>115, 452</td>
<td>(II)</td>
</tr>
<tr>
<td>Crumpacker C</td>
<td>84, 85, 87</td>
<td>(II) 74</td>
</tr>
<tr>
<td>Cryz S</td>
<td>105, 234</td>
<td>(II)</td>
</tr>
<tr>
<td>Culpepper W</td>
<td>108, 247</td>
<td>(II)</td>
</tr>
<tr>
<td>Curley M</td>
<td>112, 355</td>
<td>(II)</td>
</tr>
<tr>
<td>Currier D</td>
<td>85, 60</td>
<td>(II)</td>
</tr>
<tr>
<td>Curry E</td>
<td>82, 87, 56</td>
<td>(II)</td>
</tr>
<tr>
<td>Curtis J</td>
<td>112, 356</td>
<td>(II)</td>
</tr>
<tr>
<td>Czege J</td>
<td>115, 445</td>
<td>(II)</td>
</tr>
<tr>
<td>D'Aquila R</td>
<td>84, 85, 74</td>
<td>(II)</td>
</tr>
<tr>
<td>D'Avvis J</td>
<td>96, 98, 99, 100</td>
<td>(II) 154, 165, 173</td>
</tr>
<tr>
<td>Dachman A</td>
<td>115, 445</td>
<td>(II)</td>
</tr>
<tr>
<td>Darling D</td>
<td>97, 170</td>
<td>(II)</td>
</tr>
<tr>
<td>Davis C</td>
<td>88, 89, 91</td>
<td>(II) 65, 69</td>
</tr>
<tr>
<td>Davis F</td>
<td>103, 195</td>
<td>(II)</td>
</tr>
<tr>
<td>Davis J</td>
<td>81, 40</td>
<td>(II)</td>
</tr>
<tr>
<td>Davis P</td>
<td>104, 105, 208</td>
<td>(II)</td>
</tr>
<tr>
<td>Davis W</td>
<td>78, 79, 80</td>
<td>(II) 14, 22, 29, 30</td>
</tr>
<tr>
<td>DeMarkles M</td>
<td>101, 186</td>
<td>(II)</td>
</tr>
<tr>
<td>Decker R</td>
<td>101, 192</td>
<td>(II)</td>
</tr>
<tr>
<td>Deftos L</td>
<td>98, 165, 172</td>
<td>(II)</td>
</tr>
<tr>
<td>Derderian S</td>
<td>80, 81, 108, 34, 247</td>
<td></td>
</tr>
<tr>
<td>Deuster P</td>
<td>102, 204</td>
<td>(II)</td>
</tr>
<tr>
<td>Dhillon G</td>
<td>96, 170</td>
<td>(II)</td>
</tr>
<tr>
<td>DiBenedetto M</td>
<td>114, 427</td>
<td>(II)</td>
</tr>
<tr>
<td>Dickerman J</td>
<td>113, 383</td>
<td>(II)</td>
</tr>
<tr>
<td>Dietli T</td>
<td>113, 383</td>
<td>(II)</td>
</tr>
<tr>
<td>Dillard T</td>
<td>105, 106, 107, 251, 259, 261</td>
<td>(II)</td>
</tr>
<tr>
<td>Dillingham T</td>
<td>114, 430</td>
<td>(II)</td>
</tr>
<tr>
<td>Dilworth S</td>
<td>85, 74</td>
<td>(II)</td>
</tr>
<tr>
<td>Djuh Y</td>
<td>96, 97, 165</td>
<td>(II)</td>
</tr>
<tr>
<td>Drabick J</td>
<td>84, 50</td>
<td>(II)</td>
</tr>
<tr>
<td>Dubowy R</td>
<td>113, 383</td>
<td>(II)</td>
</tr>
<tr>
<td>Dykstra K</td>
<td>112, 337</td>
<td>(II)</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Edmond C, (I) 81, 108, 116; (II) 34, 247, 457
Edwards B, (I) 95; (II) 131
Edwards F, (I) 117; (II) 477
Edwards G, (I) 104, 112; (II) 220, 347
Eliasson A, (I) 108; (II) 260
Elliot S, (I) 105; (II) 243
Engler R, (I) 78, 79, 80; (II) 2, 14, 22, 29, 30
Erice A, (I) 87; (II) 74
Feely B, (I) 85; (II) 64
Fein H, (I) 96, 97, 98, 99; (II) 149, 165, 170
Fischer G, (I) 82, 87, 89, 112; (II) 56, 57, 353
Fisher C, (I) 96; (II) 149, 170
Flynn F, (I) 114; (II) 435
Foley J, (I) 119; (II) 528
Foss R, (I) 117; (II) 487
Fowler A, (I) 85, 86, 94; (II) 62, 74
Francis G, (I) 112, 113; (II) 337, 345
Fredeking T, (I) 105; (II) 234
Friedrichs P, (I) 119; (II) 527
Frissman D, (I) 92; (II) 69
Fugimoto R, (I) 114; (II) 427
Furer E, (I) 105; (II) 234
Galloway R, (I) 96, 97, 98; (II) 149, 170
Gardner L, (I) 86; (II) 74
Garra B, (I) 115; (II) 445
Geyer C, (I) 118; (II) 501
Giblin W, (I) 92; (II) 69
Gilliland J, (I) 98; (II) 176
Glass A, (I) 98, 101; (II) 162, 189
Goel R, (I) 78; (II) 30
Goethe E, (I) 85; (II) 60
Goldstein R, (I) 95; (II) 123
Gonzalez C, (I) 80, 116; (II) 34, 457
Gouge S, (I) 105; (II) 236
Grabski W, (I) 95; (II) 131
Grafman J, (I) 109; (II) 283
Grant K, (I) 116; (II) 458
Greathouse D, (I) 114; (II) 428
Gregory T, (I) 82; (II) 76
Griffin J, (I) 119; (II) 528
Grimes J, (I) 81; (II) 40
Guill M, (I) 95; (II) 131
Guin J, (I) 95; (II) 131
Gurevich-Uvena J, (I) 116; (II) 457
Gurney C, (I) 110; (II) 289
Guzzi L, (I) 115; (II) 451

* Reference is to page numbers in Volumes I & II.

161
AUTHOR INDEX*

Hagemeister B, (I) 115; (II) 451
Hahn (I) 115; (II) 449
Haibach H, (I) 98; (II) 165, 172
Hakami N, (I) 113; (II) 383
Hall D Jr, (I) 114; (II) 438
Hamdallah M, (I) 94; (II) 62
Hamilton J, (I) 84; (II) 61
Hamm P, (I) 95; (II) 126
Hammer S, (I) 87; (II) 74
Hanna T, (I) 116; (II) 463
Hansen D, (I) 114; (II) 428
Harrison S, (I) 85, 87; (II) 74
Hartigan P, (I) 84; (II) 61
Hartman A, (I) 95; (II) 131
Haviland J, (I) 88; (II) 60
Hawkes C, (I) 84; (II) 61
Hawkins C, (I) 95; (II) 126
Heekin R, (I) 118; (II) 488
Hegenerich P, (I) 87; (II) 62
Henley M, (I) 113; (II) 351
Herbers J, (I) 104; (II) 205, 207
Hershey B, (I) 80; (II) 2
Hershey J, (I) 78, 79, 80; (II) 4, 22, 30
Hicks C, (I) 86; (II) 74
Hiner W, (I) 113; (II) 425
Hirscher P, (I) 105; (II) 236
Hitchcock C, (I) 119; (II) 528
Hnatiuk O, (I) 106, 107; (II) 261
Hoffman M, (I) 117; (II) 477
Holland T, (I) 84; (II) 69
Hollifield R, (I) 117; (II) 480
Holmes K, (I) 79; (II) 31
Hopkinson W, (I) 118; (II) 488
Huh M, (I) 79; (II) 14, 29
Hull R, (I) 95; (II) 123, 125
Humphrey M, (I) 98; (II) 145
Huss K, (I) 79, 80; (II) 4
Huss R, (I) 79, 80; (II) 4
Hyams K, (I) 89; (II) 62
Jabbari B, (I) 109, 118; (II) 278, 282, 501
Jackson S, (I) 98, 99, 100; (II) 154, 173
James W, (I) 91, 92; (II) 69
Japour A, (I) 84, 85, 87; (II) 74
Jenkins P, (I) 83; (II) 60
Jenkins R, (I) 83, 84, 85, 87, 93; (II) 60
Johnson C, (I) 83; (II) 60

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Johnson F, (I) 91; (II) 69
Johnson S, (I) 82, 88, 89; (II) 65, 76
Johnson V, (I) 85; (II) 74
Jonas B, (I) 109, 114; (II) 283, 427
Kahlter D, (I) 91; (II) 69
Kaplan K, (I) 96; (II) 143
Kaseem L, (I) 96, 97; (II) 170
Katzenstein D, (I) 84; (II) 74
Kendall S, (I) 83, 84, 85, 94; (II) 60
Kern J, (I) 107; (II) 259, 265
Ketter N, (I) 88, 89; (II) 65
Kikendall J, (I) 101, 103; (II) 189, 191, 195
Kim J, (I) 82; (II) 76
Kleinman D, (I) 93; (II) 64
Kline M, (I) 115; (II) 451, 452
Knezevich S, (I) 118; (II) 503
Knoll S, (I) 111; (II) 332
Kohn E, (I) 104, 105; (II) 208
Koldovsky O, (I) 81; (II) 40
Konzelman J, (I) 85, 93; (II) 64
Kozjak J, (I) 84; (II) 60
Kratochvil F, (I) 117; (II) 487
Krischer J, (I) 113; (II) 383
Kroenke K, (I) 104; (II) 205, 206, 207
Kroll R, (I) 117; (II) 461
Kuhn E, (I) 119, 120; (II) 527, 533
Kukita Y, (I) 119; (II) 503
Kuritzkes D, (I) 85; (II) 74
Kyle K, (I) 89; (II) 60
Lado L, (I) 85; (II) 60
Lahiri S, (I) 96, 98, 99, 100; (II) 154, 165, 173, 176
Laird J, (I) 94, 95; (II) 116, 123
La R, (I) 89; (II) 62
Lance R, (I) 119; (II) 527
Landes T, (I) 101, 102; (II) 181, 183
Lane J, (I) 86, 87; (II) 74
Larsen B, (I) 101, 102; (II) 181, 185
Lauver J, (I) 113; (II) 383
Law W, (I) 85; (II) 60
Ledsky R, (I) 83, 89, 90, 93; (II) 60
Leek M, (I) 116, 117; (II) 456, 463, 465
Leighton K, (I) 85; (II) 60
Lenhart M, (I) 118; (II) 497
Link C, (I) 104, 105; (II) 208
Lippert L, (I) 78, 79, 81; (II) 31, 32, 37
Loftus N, (I) 117; (II) 461

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Lombardo F, (I) 80, 85, 104, 105; (II) 16, 64, 208
Loomis L, (I) 82; (II) 62
Lucas C, (I) 82, 104; (II) 76, 205
Lucey D, (I) 82; (II) 76
Luk G, (I) 103; (II) 179
Lukes Y, (I) 96; (II) 165
Lupton C, (I) 91, 92; (II) 69
MacNeil D, (I) 82; (II) 56
Maggio M, (I) 120; (II) 533
Magruder C, (I) 85; (II) 60
Mapou R, (I) 85; (II) 60
Marks C, (I) 85; (II) 74
Marlowe S, (I) 82; (II) 49
Marshall L, (I) 116; (II) 463
Maybee D, (I) 113; (II) 383
Maydonovitch C, (I) 101, 102, 103; (II) 179, 181, 183, 186, 191, 192, 195
Mayers D, (I) 84, 85, 86, 87; (II) 74
McAdams M, (I) 95; (II) 131
McCardle P, (I) 87; (II) 56
McCleary M, (I) 116, 117; (II) 457, 461
McClintock W, (I) 82; (II) 56
McCumber T, (I) 107; (II) 259
McCutchan F, (I) 85, 86, 87; (II) 62, 74
McHale K, (I) 118; (II) 496, 497
McKay D, (I) 118; (II) 496
McLeod G, (I) 87; (II) 74
McManis S, (I) 83, 84, 94; (II) 60
McMillan V, (I) 109; (II) 268
McNally P, (I) 102, 103; (II) 199
Mehm W, (I) 105, 106; (II) 251
Meiser D, (I) 104, 112; (II) 220, 347
Mellette J, (I) 95; (II) 131
Menon P, (I) 95; (II) 131
Merritt L, (I) 85, 86; (II) 74
Michael N, (I) 82, 89; (II) 57, 76
Mitra R, (I) 89; (II) 62
Mobarham S, (I) 101; (II) 195
Moellman J, (I) 119; (II) 528
Molina R, (I) 109; (II) 268
Mooradian A, (I) 99; (II) 170
Moore J, (I) 105; (II) 236, 245
Moore R, (I) 81; (II) 37
Moores L, (I) 107; (II) 259
Moriarty R, (I) 82; (II) 56
Morin G, (I) 80; (II) 34

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Moses F, (I) 102; (II) 185, 204
Moss A, (I) 87; (II) 60
Moul J, (I) 119, 120; (II) 527, 528
Moulton J, (I) 87, 93; (II) 60
Moye L, (I) 95; (II) 126
Murphy J, (I) 102, 103; (II) 191, 199
Nagy E, (I) 95, 99; (II) 143, 165
Nannis E, (I) 85, 87, 93; (II) 56, 60
Nelson B, (I) 83; (II) 71
Nelson R, (I) 101, 103; (II) 195
Newby J, (I) 87, 88; (II) 60
Newman R, (I) 113; (II) 345
Newton T, (I) 88; (II) 60
Nguyen T, (I) 101; (II) 192
Nicely E, (I) 120; (II) 533
Nickels D, (I) 112; (II) 355
Nowlin J, (I) 116; (II) 457
O’Connor D, (I) 111; (II) 294
O’Connor F, (I) 82; (II) 49
O’Leary A, (I) 88; (II) 60
O’Neill J, (I) 112; (II) 356
Obieski J, (I) 82; (II) 76
Olaje F, (I) 114; (II) 430
Oster C, (I) 83, 84, 88, 89, 94; (II) 61, 62, 65, 71
Pace J, (I) 83; (II) 60
Page C, (I) 87; (II) 74
Pargament K, (I) 84; (II) 60
Patterson T, (I) 83, 87; (II) 60
Payne M, (I) 112; (II) 337
Pearl R, (I) 117; (II) 477
Peck G, (I) 95; (II) 131
Peele K, (I) 117; (II) 480
Peller P, (I) 101, 102, 103; (II) 186, 199
Peller T, (I) 101; (II) 192
Perry E, (I) 81; (II) 37
Perry J, (I) 104, 112; (II) 220, 347
Peten E, (I) 105; (II) 243
Peter E, (I) 105; (II) 243, 245
Peters M, (I) 99; (II) 165
Petrov J, (I) 110; (II) 287
Pettett P, (I) 112; (II) 356
Peura D, (I) 101, 102, 103; (II) 181, 204
Pfeffer M, (I) 95; (II) 126
Phillips R, (I) 103; (II) 179
Phillips Y, (I) 107, 108; (II) 255, 259, 260
Polly S, (I) 80; (II) 2

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Polonis V, (I) 88, 89; (II) 65
Poropatic R, (I) 107, 108, 109; (II) 255, 264, 267
Poth M, (I) 99, 112, 113; (II) 173, 345, 355
Potyk R, (I) 113; (II) 425
Price R, (I) 104; (II) 206
Que J, (I) 105; (II) 234
Rajagopal K, (I) 81, 105, 108; (II) 34, 247, 251
Redfield R, (I) 82, 88, 89, 94; (II) 57, 62, 65, 76
Reed E, (I) 104, 105; (II) 208
Reeder J, (I) 110, 111; (II) 288
Reichelderfer P, (I) 85; (II) 74
Reid A, (I) 96, 97; (II) 149, 170
Renn R, (I) 116; (II) 458
Reynolds P, (I) 115; (II) 449, 451
Rhooms P, (I) 96; (II) 165
Rich I, (I) 110; (II) 285
Richman D, (I) 85; (II) 74
Ringel M, (I) 99; (II) 165
Riordon G, (I) 117; (II) 487
Roach J, (I) 108; (II) 260
Robb M, (I) 82, 89; (II) 56, 57, 76
Roberts C, (I) 85, 86, 87, 89; (II) 62, 74
Robier T, (I) 82; (II) 56
Robinson J, (I) 95; (II) 131
Robinson M, (I) 114; (II) 427
Roller T, (I) 85; (II) 60
Romanoski A, (I) 114; (II) 438
Romney J, (I) 99; (II) 170
Rosenberg A, (I) 106; (II) 251
Rosenberg M, (I) 104; (II) 205
Roy M, (I) 104; (II) 207
Ruderman J, (I) 89; (II) 57
Ruiz N, (I) 86; (II) 74
Rundell J, (I) 83, 85, 87, 89, 90, 93; (II) 60
Sacks F, (I) 95; (II) 126
Sadoff J, (I) 105, 108; (II) 234, 267
Salasche S, (I) 95; (II) 131
Salata K, (I) 78, 79, 80, 81; (II) 4, 14, 22, 29, 30, 31, 32, 37
Salazar A, (I) 109; (II) 283
Salerno M, (I) 79; (II) 4
Samloff M, (I) 103; (II) 181
Sanders E, (I) 114; (II) 428
Sanders G, (I) 114; (II) 428
Sanders-Buell E, (I) 85, 87; (II) 74
Sarosy G, (I) 104, 105; (II) 208

* Reference is to page numbers in Volumes I & II.
<table>
<thead>
<tr>
<th>Author</th>
<th>Volume I Page(s)</th>
<th>Volume II Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Savory C</td>
<td>118</td>
<td>488</td>
</tr>
<tr>
<td>Schaaf M</td>
<td>103</td>
<td>191</td>
</tr>
<tr>
<td>Schaudies P</td>
<td>81</td>
<td>40</td>
</tr>
<tr>
<td>Schaudies R</td>
<td>111</td>
<td>294</td>
</tr>
<tr>
<td>Scherokman B</td>
<td>104</td>
<td>205</td>
</tr>
<tr>
<td>Scully T</td>
<td>114</td>
<td>427</td>
</tr>
<tr>
<td>Seal G</td>
<td>83</td>
<td>60</td>
</tr>
<tr>
<td>Selitti D</td>
<td>95</td>
<td>123, 165</td>
</tr>
<tr>
<td>Sesterhenn I</td>
<td>119</td>
<td>527, 528</td>
</tr>
<tr>
<td>Shah R</td>
<td>102</td>
<td>185</td>
</tr>
<tr>
<td>Sharp E</td>
<td>83, 89, 90, 93</td>
<td>60</td>
</tr>
<tr>
<td>Shaver T</td>
<td>117</td>
<td>487</td>
</tr>
<tr>
<td>Shay S</td>
<td>102, 103, 115</td>
<td>196, 199, 445</td>
</tr>
<tr>
<td>Shockner A</td>
<td>85</td>
<td>60</td>
</tr>
<tr>
<td>Simberkoff M</td>
<td>84</td>
<td>61</td>
</tr>
<tr>
<td>Sing H</td>
<td>114</td>
<td>438</td>
</tr>
<tr>
<td>Singh A</td>
<td>102</td>
<td>204</td>
</tr>
<tr>
<td>Sjogren R</td>
<td>101</td>
<td>186</td>
</tr>
<tr>
<td>Skelton H</td>
<td>84, 85, 91, 92, 93, 94; 64, 69</td>
<td></td>
</tr>
<tr>
<td>Smallridge R</td>
<td>96, 97, 98, 99; 149, 165, 170</td>
<td></td>
</tr>
<tr>
<td>Smith G</td>
<td>88, 89</td>
<td>65</td>
</tr>
<tr>
<td>Smith K</td>
<td>84, 91, 92, 93, 94; 69</td>
<td></td>
</tr>
<tr>
<td>Smith L</td>
<td>78, 79, 80, 85; 14, 22, 29, 64</td>
<td></td>
</tr>
<tr>
<td>Smith M</td>
<td>93, 101, 102; 60, 181</td>
<td></td>
</tr>
<tr>
<td>Smith R</td>
<td>87</td>
<td>56</td>
</tr>
<tr>
<td>Sobin L</td>
<td>101</td>
<td>189</td>
</tr>
<tr>
<td>Solomon B</td>
<td>100</td>
<td>139</td>
</tr>
<tr>
<td>Spector J</td>
<td>114</td>
<td>435</td>
</tr>
<tr>
<td>Spellman N</td>
<td>114</td>
<td>430</td>
</tr>
<tr>
<td>Squire E</td>
<td>79, 80</td>
<td>4, 16</td>
</tr>
<tr>
<td>Stamatos J</td>
<td>115</td>
<td>449, 452</td>
</tr>
<tr>
<td>Stamm C</td>
<td>102</td>
<td>185</td>
</tr>
<tr>
<td>Stempel R</td>
<td>87</td>
<td>60</td>
</tr>
<tr>
<td>Stetler-Stevenson W</td>
<td>105; 243, 245</td>
<td></td>
</tr>
<tr>
<td>Steuber P</td>
<td>113</td>
<td>383</td>
</tr>
<tr>
<td>Stevens W</td>
<td>118</td>
<td>501</td>
</tr>
<tr>
<td>Stoll H</td>
<td>95</td>
<td>131</td>
</tr>
<tr>
<td>Stoltzfus D</td>
<td>115</td>
<td>451</td>
</tr>
<tr>
<td>Striker C</td>
<td>105</td>
<td>243, 245</td>
</tr>
<tr>
<td>Striker L</td>
<td>105</td>
<td>243, 245</td>
</tr>
<tr>
<td>Summers W</td>
<td>116, 117; 456, 465</td>
<td></td>
</tr>
<tr>
<td>Sun W</td>
<td>84, 108</td>
<td>50, 267</td>
</tr>
<tr>
<td>Suthers K</td>
<td>118</td>
<td>503</td>
</tr>
<tr>
<td>Sutter E</td>
<td>103</td>
<td>195</td>
</tr>
<tr>
<td>Swango P</td>
<td>85, 93</td>
<td>64</td>
</tr>
<tr>
<td>Swartz A</td>
<td>111</td>
<td>288</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volumes I & II.
<table>
<thead>
<tr>
<th>Author</th>
<th>Volume I Page(s)</th>
<th>Volume II Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swartz J</td>
<td>(I) 95; (II) 125</td>
<td></td>
</tr>
<tr>
<td>Sweeney J</td>
<td>(I) 114; (II) 428</td>
<td></td>
</tr>
<tr>
<td>Tang D</td>
<td>(I) 84; (II) 50</td>
<td></td>
</tr>
<tr>
<td>Tangrea J</td>
<td>(I) 95; (II) 131</td>
<td></td>
</tr>
<tr>
<td>Taylor P</td>
<td>(I) 95; (II) 131</td>
<td></td>
</tr>
<tr>
<td>Temoshok K</td>
<td>(I) 87; (II) 60</td>
<td></td>
</tr>
<tr>
<td>Temoshok L</td>
<td>(I) 83, 84, 85, 87, 88, 89, 90, 93, 94; (II) 60</td>
<td></td>
</tr>
<tr>
<td>Tenuta J</td>
<td>(I) 118; (II) 496</td>
<td></td>
</tr>
<tr>
<td>Tesar J</td>
<td>(I) 109; (II) 268</td>
<td></td>
</tr>
<tr>
<td>Theune S</td>
<td>(I) 119, 120; (II) 527, 528</td>
<td></td>
</tr>
<tr>
<td>Thomasen J</td>
<td>(I) 89; (II) 60</td>
<td></td>
</tr>
<tr>
<td>Thornton-Vogel M</td>
<td>(I) 114; (II) 430</td>
<td></td>
</tr>
<tr>
<td>Toledano S</td>
<td>(I) 113; (II) 383</td>
<td></td>
</tr>
<tr>
<td>Torrington K</td>
<td>(I) 107, 108, 109; (II) 255, 264, 265</td>
<td></td>
</tr>
<tr>
<td>Tosi L</td>
<td>(I) 118; (II) 496</td>
<td></td>
</tr>
<tr>
<td>Troche V</td>
<td>(I) 98, 111; (II) 176, 294</td>
<td></td>
</tr>
<tr>
<td>Truesdale R</td>
<td>(I) 101, 102, 103; (II) 181</td>
<td></td>
</tr>
<tr>
<td>Tseng Y</td>
<td>(I) 98, 99, 100; (II) 154, 173, 176</td>
<td></td>
</tr>
<tr>
<td>Tsuchida A</td>
<td>(I) 103; (II) 196</td>
<td></td>
</tr>
<tr>
<td>Twaddell T</td>
<td>(I) 82; (II) 76</td>
<td></td>
</tr>
<tr>
<td>Ungar B</td>
<td>(I) 87; (II) 62</td>
<td></td>
</tr>
<tr>
<td>Usala S</td>
<td>(I) 97; (II) 165</td>
<td></td>
</tr>
<tr>
<td>Vahey M</td>
<td>(I) 89; (II) 57</td>
<td></td>
</tr>
<tr>
<td>Van Cott T</td>
<td>(I) 82; (II) 62</td>
<td></td>
</tr>
<tr>
<td>Van De Merwe W</td>
<td>(I) 115; (II) 445</td>
<td></td>
</tr>
<tr>
<td>Van Vranken E</td>
<td>(I) 87; (II) 56</td>
<td></td>
</tr>
<tr>
<td>Virmani R</td>
<td>(I) 82; (II) 55</td>
<td></td>
</tr>
<tr>
<td>Vukelja S</td>
<td>(I) 104, 112; (II) 220, 347</td>
<td></td>
</tr>
<tr>
<td>Waecker N</td>
<td>(I) 82, 89; (II) 56, 57</td>
<td></td>
</tr>
<tr>
<td>Wages J Jr</td>
<td>(I) 94; (II) 62</td>
<td></td>
</tr>
<tr>
<td>Wagner K</td>
<td>(I) 86, 91, 92; (II) 69, 74</td>
<td></td>
</tr>
<tr>
<td>Ward F</td>
<td>(I) 115; (II) 445</td>
<td></td>
</tr>
<tr>
<td>Ward T</td>
<td>(I) 117; (II) 480</td>
<td></td>
</tr>
<tr>
<td>Warden D</td>
<td>(I) 114; (II) 435</td>
<td></td>
</tr>
<tr>
<td>Wartofsky L</td>
<td>(I) 96, 98, 99, 100; (II) 154, 157, 165, 173, 176</td>
<td></td>
</tr>
<tr>
<td>Watson M</td>
<td>(I) 113; (II) 345</td>
<td></td>
</tr>
<tr>
<td>Wehrle P</td>
<td>(I) 104; (II) 205</td>
<td></td>
</tr>
<tr>
<td>Weidner S</td>
<td>(I) 107; (II) 265</td>
<td></td>
</tr>
<tr>
<td>Weintraub B</td>
<td>(I) 97; (II) 165</td>
<td></td>
</tr>
<tr>
<td>Weir L</td>
<td>(I) 115; (II) 434</td>
<td></td>
</tr>
<tr>
<td>Weiss R</td>
<td>(I) 104, 105; (II) 208</td>
<td></td>
</tr>
<tr>
<td>Wertz F</td>
<td>(I) 117; (II) 480</td>
<td></td>
</tr>
<tr>
<td>Wessendorf M</td>
<td>(I) 96; (II) 170</td>
<td></td>
</tr>
<tr>
<td>Weston L</td>
<td>(I) 95; (II) 125</td>
<td></td>
</tr>
<tr>
<td>White C</td>
<td>(I) 112; (II) 353</td>
<td></td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Wilkinson R, (I) 113; (II) 383
Williams W, (I) 84; (II) 50
Winton G, (I) 95; (II) 131
Wiswell T, (I) 112, 113; (II) 349, 351
Wong N, (I) 97, 99, 100; (II) 170
Wong R, (I) 101, 102, 103; (II) 179, 181, 183, 186, 191, 192
Wortham D, (I) 95; (II) 123
Wray H, (I) 81; (II) 40
Xenos J, (I) 118; (II) 488
Yeager J, (I) 91, 92, 93, 94; (II) 69
Yoder C, (I) 109; (II) 282
Yoshida M, (I) 114; (II) 427
Zachary R, (I) 83, 84, 94; (II) 60
Zatjchuk J, (I) 80; (II) 34
Zbick C, (I) 112; (II) 353
Zeigler D, (I) 114; (II) 430
Zurcher R, (I) 117; (II) 477
van Dam B, (I) 118; (II) 501

* Reference is to page numbers in Volumes I & II.
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-92

Abbrecht P, (I) 124
Argyros G, (I) 124, 125
Baker J, (I) 121, 125
Bartoszek D, (I) 125
Belandres P, (I) 126
Bennett L, (I) 125
Berard J, (I) 122
Bradley W, (I) 122
Braverman S, (I) 126
Brennan M, (I) 121
Burch H, (I) 121, 122
Burke D, (I) 124
Burman K, (I) 121, 122
Butler V, (I) 121
Cai W, (I) 121
Calvert R, (I) 121
Carey R, (I) 123
Carome M, (I) 124
Citrin C, (I) 125
Clamon G, (I) 123
Costanza M, (I) 123
Cowsar J Jr, (I) 124
Coyne P, (I) 124
Curtis J, (I) 126
Damato J, (I) 124
D’Avis J, (I) 122
Davis W, (I) 126
Dawson N, (I) 121, 123
Diehl L, (I) 123
Dillard T, (I) 124, 125
Djuh Y, (I) 121, 122
Dobek A, (I) 126
Dolman L, (I) 126
Drabick J, (I) 124
Duncan W, (I) 121, 122
Eliasson A, (I) 124
Fabry D, (I) 126
Fein H, (I) 121, 122
Fernandez-Bueno C, (I) 127
Frank J, (I) 123
Fuller S, (I) 124

* Reference is to page number(s) in Volume I

170
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-92

Gelmann E, (I) 123
Gemski P, (I) 122
Glass A, (I) 122
Clinoer D, (I) 122
Gordin F, (I) 124
Gunderson C, (I) 125
Hamilton J, (I) 124
Hansen K, (I) 125
Hartigan P, (I) 124
Henkin R, (I) 123
Horning V, (I) 124
Howard R, (I) 124
Jabbari B, (I) 125
Jackson S, (I) 122
Jacob J, (I) 123
James W, (I) 121
Kadakia S, (I) 123
Kevin K, (I) 126
Klein T, (I) 125
Knight R, (I) 124
Korzn A, (I) 123
Kruse R, (I) 127
Kyle R, (I) 124
Lagasse R, (I) 122
Lahir S, (I) 122
Landry F, (I) 123, 125
Leek M, (I) 126
Lennox J, (I) 124
Linehan W, (I) 123
Lombardo M, (I) 125
Lukes Y, (I) 121, 122
Maydonovitch C, (I) 123
McLean M, (I) 126
McLeod D, (I) 123
Miller F, (I) 121
Mitchell M, (I) 125
Mundie T, (I) 125
Myers C, (I) 121, 123
Nagatoki S, (I) 122
Nagayama Y, (I) 122
Nagy E, (I) 121, 122

* Reference is to page number(s) in Volume I

171
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-92

Nelson N, (I) 123
Nicholson D, (I) 121, 122
Nieman L, (I) 125
Norton L, (I) 123
Oddson B, (I) 126
O'Donnell B, (I) 121
Opsahl M, (I) 125
Oster C, (I) 124
Parker J, (I) 125
Pearl R, (I) 127
Peters M, (I) 122
Phillips Y, (I) 124, 125
Pike J, (I) 125
Pollak M, (I) 123
Radke A, (I) 126
Rajagopal K, (I) 124, 125
Reed W, (I) 123
Rhooms P, (I) 121
Ritchie E, (I) 126
Robie D, (I) 127
Robier T, (I) 126
Ross B, (I) 126
Satchithanandam S, (I) 121
Schaudies R, (I) 121
Sherman J, (I) 125
Simberkoff M, (I) 124
Solomon B, (I) 122
South-Paul J, (I) 125
Stajduhar K, (I) 124
Stein C, (I) 123
Steinberg A, (I) 121
Summers W, (I) 126
Surr R, (I) 126
Sweeney J, (I) 121
Tellis C, (I) 125
Temple H, (I) 127
Tenholder M, (I) 125
Thomas-Stonell N, (I) 126
Tseng Y, (I) 122
Usala S, (I) 122
van Dam B, (I) 127

* Reference is to page number(s) in Volume I

172
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-92

Van Nostrand D, (I) 125
Vogelzang N, (I) 123
Wartofsky L, (I) 121, 122
Weiss R, (I) 121, 123
Wilding G, (I) 123
Wiswell T, (I) 126
Wong R, (I) 123
Wray H, (I) 121, 122
Zierdt C, (I) 126

* Reference is to page number(s) in Volume I

173
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Adamson M, (I) 137
Adamson P, (I) 137
Agar J, (I) 128
Alving B, (I) 156
Anderson D, (I) 132
Anderson J, (I) 132, 140
Andriko J, (I) 136
Angel M, (I) 143
Angritt P, (I) 152
Antoine J, (I) 141
Armonda R, (I) 142
Armstrong D, (I) 152
Artenstein A, (I) 132, 149
Ascher D, (I) 153
Azarow K, (I) 141
Bach D, (I) 155
Bain M, (I) 137
Baker W, (I) 132
Balis F, (I) 137
Bandy D, (I) 128
Banks A, (I) 128, 129
Barker K, (I) 138
Barnhill D, (I) 136, 152
Bass B, (I) 156
Bauer F, (I) 152
Belandres P, (I) 138, 153
Bellamy R, (I) 144, 156
Belman A, (I) 146
Benedikt R, (I) 139, 140
Benjamin J, (I) 138, 153
Benson P, (I) 130
Bernton E, (I) 136, 148
Betageri R, (I) 133
Bettencourt J, (I) 141
Biedlingmaier J, (I) 140
Bierner S, (I) 134, 154
Bilello J, (I) 137
Bishoff J, (I) 156
Bishop J, (I) 144
Blaney S, (I) 137
Blauer K, (I) 136, 148

* Reference is to page number(s) in Volume 1
ADDENDUM

AUTHOR INDEX*
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Blumenstein B, (I) 145
Bolan C, (I) 149
Boslego J, (I) 133
Bosshcer J, (I) 136, 152
Brancaccio R, (I) 129
Branscum D, (I) 134
Brantone M, (I) 133
Brauner G, (I) 129
Bregman D, (I) 142
Brinton C Jr, (I) 133
Brooke J, (I) 133
Brown C, (I) 145
Brown D, (I) 139, 140
Bryant P, (I) 153
Buchanan T, (I) 138
Burch H, (I) 131, 148
Burge J, (I) 139, 144
Burge R, (I) 156
Burgess L, (I) 143, 155, 156
Burman K, (I) 131,
Burton D, (I) 143, 155
Cабellon S Jr, (I) 141
Calabro M, (I) 150
Caldwell J, (I) 147
Callaghan J, (I) 155
Cambier P, (I) 128, 140
Canning D, (I) 146
Canoso J, (I) 134
Caplow M, (I) 150
Caravalho J Jr, (I) 147
Carome M, (I) 134
Carpenter G, (I) 128
Carpenter M, (I) 142
Casler J, (I) 143
Chapman C, (I) 136
Chatham-Showalter P, (I) 138
Chulay J, (I) 133, 149, 150
Chung R, (I) 133
Cieslak T, (I) 153
Clemence E, (I) 155
Clement S, (I) 131, 148

* Reference is to page number(s) in Volume I
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Coffey J, (I) 145
Cohen A, (I) 141, 144
Cohen B, (I) 151
Cohen L, (I) 134, 154
Cohen M, (I) 151
Cole D, (I) 137
Colón E, (I) 140
Conley J, (I) 143
Cooper G, (I) 150
Corbett D, (I) 155
Costabile R, (I) 144, 145, 146
Cotter F, (I) 142
Covelli H, (I) 134
Coyne P, (I) 129
Cozza K, (I) 138
Craig B, (I) 153
Craig T, (I) 128
Crawford E, (I) 145
Cross G, (I) 153
Crowl F, (I) 141
Crutchfield K, (I) 134
Danesi R, (I) 132
Davidson M, (I) 136
Dawson N, (I) 132
Deal C, (I) 133
Derderian S, (I) 155
Derkay C, (I) 143
Diehl L, (I) 132, 149
Dillard T, (I) 134
Dillingham T, (I) 138, 153
Doering D, (I) 152
Domloge-Hultsch N, (I) 130
Dorr F, (I) 145
Doughty R, (I) 153
Drabick J, (I) 150
Dubinsky R, (I) 134, 154
Duncan M, (I) 135
Dunning D, (I) 149
Dysart S, (I) 142, 155
Ecklund J, (I) 142
Edwards F., (I) 136, 137, 141, 144

* Reference is to page number(s) in Volume I
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Eisenberger M, (I) 145
Eliasson A, (I) 129
Ellenbogen R, (I) 142
Engler R, (I) 128
Evans C, (I) 146
Farley J, (I) 152
Feldman A, (I) 147
Filling-Katz M, (I) 137
Fistel S, (I) 136
Fitzpatrick T, (I) 134, 150
Foley J, (I) 145
Fowler A, (I) 150
Francis G, (I) 137
Gachihi G, (I) 149
Gaither N, (I) 128, 129
Garcia V, (I) 137, 155
Gasser R Jr, (I) 133, 149
Gay N (I) 148
Geissele A, (I) 143
George E, (I) 142
Geyer C, (I) 139
Ghaed V, (I) 139, 140
Giblin W, (I) 147
Gibson J, (I) 138
Giguere J, (I) 149
Glass A, (I) 143
Goldman D, (I) 149
Gomez E, (I) 156
Gonzalez C, (I) 143, 155, 156
Goodman Z, (I) 136
Goodwin B Jr, (I) 132
Gorman P, (I) 129
Gormley T, (I) 144, 145
Grabenstein J, (I) 138
Graeber G, (I) 144
Granger E, (I) 149
Green M, (I) 132
Green W, (I) 142
Grem J, (I) 137
Griffin J, (I) 146
Grogl M, (I) 133

* Reference is to page number(s) in Volume 1
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Guess H, (I) 138
Guilford W, (I) 143
Gunderson C, (I) 135
Gurney C, (I) 152
Gutierrez M, (I) 140
Guzzi L, (I) 141
Hachey W, (I) 153
Hahn M, (I) 136, 141, 144
Hale D, (I) 141, 144
Hales R, (I) 138
Hall D Jr, (I) 139, 154
Hallett M, (I) 134
Hamdallah M, (I) 150
Hanna T, (I) 141
Hardy M, (I) 145, 146
Hargis J, (I) 132
Hartman D, (I) 146
Hartman K, (I) 137
Hartz J, (I) 137
Hartzema A, (I) 138
Harvey J, (I) 150
Hasbargen J, (I) 133
Hayward I, (I) 146
Heekin R, (I) 155
Heffner D, (I) 143
Heimer W II, (I) 129
Hemler D, (I) 153
Herbers J Jr, (I) 150
Hetzler N, (I) 144
Hicks C, (I) 132
Hilliard J, (I) 132
Hiner W Jr, (I) 153
Hinson R, (I) 144
Hirsch D, (I) 151
Hitchcock C, (I) 146
Hnatiuk O, (I) 134
Ho M, (I) 133
Ho V, (I) 139
Hodges T, (I) 142
Hoffman M, (I) 141
Hogans W III, (I) 128

* Reference is to page number(s) in Volume I

178
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Holland T, (I) 147
Hollinger J, (I) 144, 155
Hopkinson W, (I) 155
Hopper K, (I) 149
Hull R, (I) 128, 129
Ishak K, (I) 136
Jabbari B, (I) 134, 135
Jabs A, (I) 144
James W, (I) 129, 130, 131, 147, 148
Jamieson G, (I) 133
Januskiewicz A, (I) 151
Jelinek J, (I) 128, 132, 139, 140, 149
Jiang B, (I) 138
John P, (I) 135
Johnson A, (I) 151
Johnson F, (I) 130
Johnson S, (I) 133
Johnston W, (I) 138
Juarbe C, (I) 143
Kao G, (I) 136
Karstetter K, (I) 153
Katz N, (I) 137, 155
Kavolius J, (I) 141
Kenyon M, (I) 138
Kikendall J, (I) 131
Kim C, (I) 139
Kinsella T, (I) 137
Kirby W, (I) 128, 129, 137
Klotz F, (I) 133
Konzelman J Jr, (I) 130
Kransdorf M, (I) 139, 140
Kroenke K, (I) 150
Kryzer T, (I) 143, 156
Kutcher T, (I) 140
Labutta R, (I) 135
Lampe R, (I) 153
Lance R, (I) 156
Lande R, (I) 139, 154
Landry F, (I) 131, 148, 150
La Piana F, (I) 142
La Rocca R, (I) 132

* Reference is to page number(s) in Volume I
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Lauer C, (I) 156
Lederman D, (I) 134
Lee M, (I) 130, 147
Leek M, (I) 141, 146
Leek M, (I) 135
Lehmann C, (I) 135
Lehmann J, (I) 138, 153
Leiderman D, (I) 154
Lennox J, (I) 148
Lesar M, (I) 149
Levin S, (I) 137
Li S, (I) 153
Ling G, (I) 135
Lo S, (I) 152
Lovett E, (I) 129
Lowry M, (I) 136
Lupton G, (I) 147
Lynch S, (I) 138
Madigan W, (I) 155
Maggio M, (I) 145, 146
Magill A, (I) 132, 149
Malane S, (I) 130
Marak G Jr, (I) 142
Marin P, (I) 138
Marks J Jr, (I) 129
Marshall L, (I) 141
Martell J Jr, (I) 142
Mason D, (I) 155
Maurer P, (I) 140, 142
Max M, (I) 138, 153
McCarrney J, (I) 147
McCLean M, (I) 154
McCrea W, (I) 141
McFarland D, (I) 140
McGill A, (I) 133
McHale K, (I) 137, 142, 143, 155
McLean I, (I) 142
McLeod D, (I) 144, 145, 157
McManigle J, (I) 134
McNeil J, (I) 139
Meer J, (I) 134, 154
Meglin A, (I) 140

* Reference is to page number(s) in Volume I

180
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Mellen P, (I) 136
Meltzer M, (I) 131
Meyer C, (I) 140
Mirvis S, (I) 140
Miser J, (I) 137
Mitchell D, (I) 136
Mitchell D, (I) 136
Molloy M, (I) 141
Moore J, (I) 128, 129, 134, 136, 137
Morin C, (I) 143, 155
Morrison P, (I) 151
Moser R Jr, (I) 139, 140
Moses F, (I) 131
Moul J, (I) 144, 145, 146, 156, 157
Muigai R, (I) 149
Muir J, (I) 138
Nash J, (I) 152
Nicely E, (I) 145, 146
Noel G, (I) 150
Northam R, (I) 135
Nyakundi P, (I) 149
Ockenhouse C, (I) 133
O'Connor D, (I) 136, 152
O'Donnell B, (I) 130, 147
O'Hair K, (I) 137
Olaje F, (I) 153
Omori D, (I) 150
Ondra S, (I) 142
O'Neill J, (I) 129
Oster C, (I) 133, 148, 149, 150
Pangaro L, (I) 150
Park R, (I) 136, 152
Parker M, (I) 136
Patow C, (I) 143, 156
Patronas N, (I) 137
Paul J, (I) 135
Paulson D, (I) 157
Pearl R, (I) 141
Pearson R, (I) 138
Peller P, (I) 140
Penny S, (I) 135

* Reference is to page number(s) in Volume I

181
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Peppas D, (I) 144, 145, 146
Perlik P, (I) 143
Perry J, (I) 132, 137, 149
Pezzella A, (I) 144
Phillips R, (I) 131
Phillips W, (I) 154
Phillips Y, (I) 134, 150, 151
Pierson J, (I) 153
Pina J, (I) 147
Polly D, (I) 155
Poplack D, (I) 137
Poropatich R, (I) 134
Poth M, (I) 136, 148
Potyk R, (I) 150
Prewitt K, (I) 129
Price R, (I) 138, 153
Prier R, (I) 139
Propert K, (I) 132
Provost T, (I) 140
Quigley N, (I) 155
Redmond J III, (I) 132, 149
Reeder J, (I) 151, 152
Reid T III, (I) 149
Remmenga S, (I) 136, 152
Reynolds P, (I) 141
Richardson D, (I) 128
Richmond D, (I) 150, 151
Ripple G, (I) 134, 151
Ritchie E, (I) 139
Rittenhouse B, (I) 138
Roach J, (I) 134
Robinowitz M, (I) 136
Rogan K, (I) 128, 129, 144
Rogers W, (I) 136, 148
Romanoski A, (I) 139
Rosenberg M, (I) 135
Rosenthal L, (I) 129

* Reference is to page number(s) in Volume I

182
**ADDENDUM**

**AUTHOR INDEX**

PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Roth M, (I) 139  
Roth R, (I) 147  
Rowe J, (I) 147  
Rubin S, (I) 145  
Rueda-Pedraza E, (I) 136  
Saad R, (I) 130  
Sadoff J, (I) 133  
Samlaska C, (I) 131, 147  
Sanes J, (I) 134  
Sargent L, (I) 144  
Sarnecky M, (I) 152  
Sau P, (I) 130, 147, 148  
Savory C, (I) 155  
Sayles J, (I) 141  
Schaefer P, (I) 134, 139  
Scherokman K, (I) 135  
Schultz T, (I) 153, 154  
Seyfer A, (I) 144  
Shank E, (I) 143  
Sharpnack D, (I) 151  
Shaves M, (I) 136  
Shaw S, (I) 133  
Shay S, (I) 132  
Sherman J, (I) 140  
Sherwood J, (I) 150  
Snoaf S, (I) 153  
Shonnard K, (I) 140  
Shotkin J, (I) 151  
Sidell F, (I) 135  
Sihelnik S, (I) 144  
Simonds G, (I) 142  
Sing H, (I) 139  
Singer H, (I) 135  
Sinoff S, (I) 135  
Skelton H III, (I) 147  
Skoog S, (I) 137, 145, 146, 155  
Smith A, (I) 143  
Smith K, (I) 147  
Smolin M, (I) 129  
Snyder S, (I) 151

* Reference is to page number(s) in Volume I
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Sokol M, (I) 131, 148
Solis J, (I) 148
Solivan G, (I) 130
Solla J, (I) 141
Sowray P, (I) 132
Spellman N, (I) 138
Sperling L, (I) 130, 131, 147, 148
Springer T, (I) 133
Stajduhar K, (I) 128
Stamatos J, (I) 141
Stamm C, (I) 149
Starck T, (I) 141
Staunton D, (I) 133
Stith J, (I) 155
Strickland R, (I) 134
Stuhmiller J, (I) 151
Sullivan C, (I) 137
Sun W, (I) 133
Swanson S III, (I) 137, 155
Swengel R, (I) 142
Tandon N, (I) 133
Tang D, (I) 156
Tarkka I, (I) 134, 154
Taylor A, (I) 129, 144
Teneriello M, (I) 136, 152
Tenholder M, (I) 134, 150
Thach A, (I) 142
Theberge D, (I) 128
Theune S, (I) 156
Thompson L, (I) 144
Thompson R, (I) 140
Thornton-Vogel M, (I) 153
Thwaites B, (I) 141
Torrington K, (I) 151
Tramont E, (I) 128, 133, 148, 149
Triche T, (I) 137
Truesdale R Jr, (I) 132
Truwit J, (I) 151
van Dam B, (I) 135, 142
Van Echo D, (I) 132
Van Seventer G, (I) 133

* Reference is to page number(s) in Volume I

18/
ADDENDUM

AUTHOR INDEX
PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Vaughan T, (I) 131
Venbrux A, (I) 140
Verma A, (I) 151
Vernalis M, (I) 128, 136, 141
Virmani R, (I) 129, 136, 144
Vukelja S, (I) 132, 134
Wages J Jr, (I) 150
Wahl R, (I) 137, 155
Wakefield P, (I) 130, 131
Ward F, (I) 132
Ward W, (I) 153
Wartofsky L, (I) 131, 148
Wathne J, (I) 143
Wear D, (I) 152
Weber C, (I) 147
Webster H, (I) 133
Weedn V, (I) 136
Weiss J, (I) 153
Weiss R, (I) 132
Were J, (I) 149
Weston L, (I) 144
Whitaker M, (I) 140
White N, (I) 133
White R, (I) 139
Whitsitt T, (I) 128
Wind G, (I) 145
Wiswell T, (I) 138, 153
Wohlgethan J, (I) 134
Wohlhieter J, (I) 128
Wolf A, (I) 140
Wong R, (I) 131
Wood S, (I) 133
Woosley R, (I) 129
Wortham D, (I) 128, 129
Wortzel C, (I) 135
Wright D, (I) 148
Yancey K, (I) 130
Yang E, (I) 128
Yost W, (I) 128
Young S, (I) 154
Zajtchuk J, (I) 151, 155

* Reference is to page number(s) in Volume I
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/ABSTRACTS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Zeigler D, (I) 138, 153
Zislis T, (I) 155
Zurcher R, (I) 141

* Reference is to page number(s) in Volume I

186
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adair, C</td>
<td>333</td>
</tr>
<tr>
<td>Adams, J</td>
<td>213</td>
</tr>
<tr>
<td>Allen, R</td>
<td>295</td>
</tr>
<tr>
<td>Alving, B</td>
<td>216, 225</td>
</tr>
<tr>
<td>Anderson, D</td>
<td>55</td>
</tr>
<tr>
<td>Anderson, J</td>
<td>441, 442, 443</td>
</tr>
<tr>
<td>Anderson, M</td>
<td>435</td>
</tr>
<tr>
<td>Andreosen, P</td>
<td>262</td>
</tr>
<tr>
<td>Antoine, G</td>
<td>517</td>
</tr>
<tr>
<td>Artenstein, A</td>
<td>234, 235</td>
</tr>
<tr>
<td>Ascher, L</td>
<td>57</td>
</tr>
<tr>
<td>Asplund, L</td>
<td>499</td>
</tr>
<tr>
<td>Atack, R</td>
<td>455</td>
</tr>
<tr>
<td>Azarow, K</td>
<td>474, 477, 478</td>
</tr>
<tr>
<td>Bagg, M</td>
<td>493</td>
</tr>
<tr>
<td>Baker, J</td>
<td>159, 165, 166, 172, 177</td>
</tr>
<tr>
<td>Baum, A</td>
<td>450</td>
</tr>
<tr>
<td>Beachy, J</td>
<td>343</td>
</tr>
<tr>
<td>Beam, T</td>
<td>474</td>
</tr>
<tr>
<td>Beauchesne, R</td>
<td>503</td>
</tr>
<tr>
<td>Becker, G</td>
<td>253</td>
</tr>
<tr>
<td>Bednarek, J</td>
<td>222</td>
</tr>
<tr>
<td>Belandres, P</td>
<td>432</td>
</tr>
<tr>
<td>Bennett, C</td>
<td>32</td>
</tr>
<tr>
<td>Benson, P</td>
<td>131</td>
</tr>
<tr>
<td>Bent, R</td>
<td>349</td>
</tr>
<tr>
<td>Berg, B</td>
<td>251, 266</td>
</tr>
<tr>
<td>Berger, T</td>
<td>7, 9, 10, 11, 14, 15, 17, 18, 19, 22, 23, 24, 26, 27, 28, 30</td>
</tr>
<tr>
<td>Berrey, H</td>
<td>490, 494</td>
</tr>
<tr>
<td>Bigham, P</td>
<td>117</td>
</tr>
<tr>
<td>Billups, L</td>
<td>31, 32</td>
</tr>
<tr>
<td>Billups, L</td>
<td>31, 32</td>
</tr>
<tr>
<td>Birx, D</td>
<td>54, 65, 75, 76</td>
</tr>
<tr>
<td>Biskey, V</td>
<td>285, 290</td>
</tr>
<tr>
<td>Bjornson, D</td>
<td>66, 70, 71, 425</td>
</tr>
<tr>
<td>Blair, S</td>
<td>434</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Bley, J, 341, 516
Bohen, E, 246
Bolt, J, 280
Bombaugh, M, 67
Boscher, J, 316, 327, 328, 329, 330
Bowen, P, 195
Bowes, J, 472
Bradford, B, 48
Brammer, R, 506, 507
Brandt, U, 60
Braverman, S, 20, 432
Brown, M, 502
Bryant, P, 427
Buchanan, T, 424
Bueno, C, 486
Burgess, L, 510
Burgess, M, 195
Burke, D, 57
Burrell, L, 214, 219, 220, 226
Busey, J, 498
Callahan, S, 509
Cambier, P, 119
Carome, M, 243
Carpenter, G, 8
Carr, F, 149, 170, 171, 172, 175
Carregal, V, 3
Carter, A, 123, 128
Cavallaro, B, 480, 481
Cheney, C, 181
Childers, E, 487
Choyce, R, 535
Chung, R, 50, 63, 232
Clark, G, 55
Clay, J, 462
Clement, S, 151, 155
Coats, M, 435
Cobb, P, 215
Coffey, L, 43, 137, 142
Compton, A, 440
Condon, B, 453
Cord, M, 455, 460, 462
Cox, K, 482
Crespo, I, 181

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Cross, A, 229, 231, 234, 235
Crowl, F, 454
Cukier, A, 509
Culpepper, W, 34, 44
Curtis, J, 356
Dachman, A, 221, 444, 445
Davies, W, 426
Davis, W, 20, 25, 29
Dawson, N, 221
DeMarkles, M, 186
Derderian, S, 34, 38, 39, 41, 247, 248, 250, 254
Deuster, P, 161
Diehl, L, 210
Dillard, T, 248, 249, 251, 256, 261, 266
Dillingham, T, 430
Dobek, A, 45
Dolev, E, 161
Doyle, J, 263
Drabick, J, 51
Duncan, W, 144, 160, 167, 169, 229
Dutta, S, 201
Edmonds, C, 457
Edwards, E, 339, 347, 363, 364, 365, 366, 367, 369,
370, 371, 372, 373, 375, 376, 377, 379, 380, 382,
383, 385, 386, 387, 388, 389, 390, 392, 395, 396,
399, 400, 401, 402, 403, 404, 405, 407, 408, 409,
411, 412, 414, 415, 419, 420, 421, 422
Edwards, P, 518, 519
Eliasson, A, 257, 258, 260
Engler, R, 1, 2, 3, 4, 12, 21, 25
Fein, H, 175
Fernandez, C, 484, 485
Fischer, G, 56, 57, 334
Fisher, C, 149
Fisher, L, 33
Foley, J, 528
Forlaw, L, 284
Foss, R, 487
Francis, G, 337, 344, 345, 346
Francis, T, 156, 178
Fujimoto, R, 427
Furukawa, K, 450
Gaither, N, 122
Gasser, R, 230
Glass, A, 140, 147, 158, 162, 163, 164, 171, 229
Gomez, E, 511

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Gorman, P, 118, 126
Gorski, D, 81
Gouge, S, 169, 236
Grant, K, 458, 460, 462
Gurevich-Uvina, J, 457
Gurney, C, 289, 290
Guzzi, L, 451
Hachey, W, 354
Hahn, M, 449, 450
Hall, D, 438
Hargis, J, 218
Harper, M, 280
Hartman, K, 212, 273
Hawkes, C, 61
Hayda, R, 560
Hayes, D, 508
Hendrix, R, 77
Henley, M, 351
Hershey, J, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 22, 23, 24, 26, 27, 28, 30
Hicks, C, 50, 53, 73, 217
Hiner, W, 70, 425
Hitchcock, C, 528
Hnatiuk, O, 249, 261, 263, 468
Hollinger, J, 514, 515, 516
Holmes, K, 31
Hoover, D, 52
Hopkinson, W, 488, 489
Hudak, C, 130
Huh, M, 29
Hull, R, 120, 127
Humphrey, M, 134, 137, 145, 147, 150, 152, 178
Huss, K, 4
Jabbari, B, 275, 278, 281, 282
Jackson, S, 154
James, W, 132, 133, 134, 174
Jaques, D, 476
Jesse, S, 338
Johnson, J, 237
Johnson, S, 65, 73, 75, 76
Jones, F, 440
Joslin, S, 433
Kalter, C, 52
Kapur, J, 33
Karan, S, 446, 448
Kark, J, 217

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Kern, J, 265
Kiandoli, L, 244
Kikendall, J, 1, 188, 189, 195, 200
Kim, C, 495
Kirk, K, 431
Kishbaugh, D, 431
Klein, T, 292, 294
Kline, M, 451
Klipple, G, 270, 271, 272, 273
Knight, R, 213, 218
Knoll, S, 332
Kohanski, P, 444
Konzelman, J, 64
Kramer, K, 479
Kroenke, K, 205, 206
Kuhn, E, 527
Kumke, K, 261
Kuzma, P, 470
La Russa, V, 228
Laird, J, 116
Landes, T, 183
Lane, B, 475
Lauer, C, 511
Lee, N, 214
Leek, M, 456, 463, 464, 465, 467
Leone, L, 281
Levin, L, 67
Lippert, L, 33, 35, 36, 37, 42
Livermore, G, 505, 510
Lockard, J, 238
Lombardo, F, 16, 66, 210, 213, 215, 223
Lupkas, R, 447
MacNeil, D, 466
Magill, A, 230, 233
Marin, R, 431
Marlowe, S, 49
Martinez, M, 1
Mateski, D, 188
May, E, 122

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Maydonovitch, C, 179, 182, 183, 191, 192, 197, 201, 203
Mayer, M, 514, 515, 516
Mayers, D, 74
McClean, M, 457, 459, 461
McCormack, E, 3, 12, 21
McEvoy, P, 45
McFarland, J, 393, 406
McHale, K, 491, 496, 497
McKee, M, 81
McLeod, D, 520, 521, 522, 523, 524, 525, 526, 529, 532, 534
McNeil, J, 72, 478
Mecredy, T, 194
Mewshaw, B, 270, 271, 272
Mohr, L, 250
Molina, R, 268
Moore, J, 169, 236, 237, 238, 239, 240, 241, 243, 244, 245
Moores, L, 259
Moses, F, 180, 185, 193, 204
Mosijczuk, A, 529, 530, 360, 374, 384, 391, 395, 397, 399, 410, 411, 414, 416, 417, 419, 421, 422, 423
Mouer, T, 535
Moul, J, 527, 528, 530, 534
Moyer, J, 6
Muldoon, S, 446
Mulvaney, M, 133
Murphy, J, 179, 187, 188, 191, 197, 199, 202
Nagy, E, 143
Nannis, E, 60
Nelson, B, 424
Neutze, J, 135
Nicely, E, 533
Nickels, D, 355
O'Connor, F, 49
O'Donnell, B, 133
Oleshansky, M, 439
Oster, C, 50, 53, 62, 70, 71, 74, 78, 79, 230
Pacicco, T, 202
Pamnani, M, 241
Park, S, 66
Patterson, A, 47

* Reference is to page numbers in Volume II.
<table>
<thead>
<tr>
<th>Investigator</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patterson, R</td>
<td>291</td>
</tr>
<tr>
<td>Payne, M</td>
<td>356</td>
</tr>
<tr>
<td>Peele, M</td>
<td>166</td>
</tr>
<tr>
<td>Peller, P</td>
<td>199</td>
</tr>
<tr>
<td>Peller, T</td>
<td>185, 197</td>
</tr>
<tr>
<td>Perry, J</td>
<td>214</td>
</tr>
<tr>
<td>Petrov, J</td>
<td>287</td>
</tr>
<tr>
<td>Petett, G</td>
<td>56, 58</td>
</tr>
<tr>
<td>Petett, P</td>
<td>59, 356</td>
</tr>
<tr>
<td>Phillips, Y</td>
<td>41, 255, 259, 260, 262, 266</td>
</tr>
<tr>
<td>Phillips-Dawkins, J</td>
<td>358</td>
</tr>
<tr>
<td>Philopena, A</td>
<td>43</td>
</tr>
<tr>
<td>Pickett, B</td>
<td>507, 510</td>
</tr>
<tr>
<td>Pierce, J</td>
<td>357</td>
</tr>
<tr>
<td>Poillon, W</td>
<td>217</td>
</tr>
<tr>
<td>Polly, S</td>
<td>25</td>
</tr>
<tr>
<td>Poropatich, R</td>
<td>255, 264, 267, 473</td>
</tr>
<tr>
<td>Poth, M</td>
<td>335, 336, 337, 355</td>
</tr>
<tr>
<td>Potyk, R</td>
<td>425</td>
</tr>
<tr>
<td>Prewitt, J</td>
<td>116, 124</td>
</tr>
<tr>
<td>Radcliffe, E</td>
<td>436</td>
</tr>
<tr>
<td>Rajagopal, K</td>
<td>34, 41, 247, 252, 253</td>
</tr>
<tr>
<td>Redfield, R</td>
<td>65, 75, 76</td>
</tr>
<tr>
<td>Reeder, J</td>
<td>287, 288</td>
</tr>
<tr>
<td>Reid, T</td>
<td>223</td>
</tr>
<tr>
<td>Restuccia, R</td>
<td>341</td>
</tr>
<tr>
<td>Riordan, K</td>
<td>269</td>
</tr>
<tr>
<td>Roach, J</td>
<td>260</td>
</tr>
<tr>
<td>Roberts, C</td>
<td>62</td>
</tr>
<tr>
<td>Robie, D</td>
<td>512</td>
</tr>
<tr>
<td>Robinson, M</td>
<td>427</td>
</tr>
<tr>
<td>Rogan, K</td>
<td>118, 120</td>
</tr>
<tr>
<td>Rosenberg, M</td>
<td>205</td>
</tr>
<tr>
<td>Rothman, S</td>
<td>45</td>
</tr>
<tr>
<td>Rowe, J</td>
<td>134</td>
</tr>
<tr>
<td>Roy, M</td>
<td>207</td>
</tr>
<tr>
<td>Rundell, J</td>
<td>60</td>
</tr>
<tr>
<td>Salata, K</td>
<td>2, 4, 5, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 22, 23, 24, 26, 27, 28, 30, 31, 32</td>
</tr>
<tr>
<td>Salazar, A</td>
<td>274, 276, 277, 279, 283</td>
</tr>
<tr>
<td>Salvado, A</td>
<td>228</td>
</tr>
<tr>
<td>Sandman, L</td>
<td>436</td>
</tr>
<tr>
<td>Sarnecky, M</td>
<td>284, 286, 290</td>
</tr>
<tr>
<td>Schaaf, M</td>
<td>148, 191</td>
</tr>
<tr>
<td>Schaudies, P</td>
<td>40, 294, 512</td>
</tr>
<tr>
<td>Schoenfeld, P</td>
<td>504</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Scott, R, 56
Sesterhenn, I, 527
Shaver, T, 483, 485, 486, 487
Shay, S, 190, 196, 203
Sihelnik, S, 531
Sinnott, M, 429
Sinoff, S, 280
Sjogren, M, 187
Sjogren, R, 186, 190
Skillman, D, 80
Smallridge, R, 149, 175
Smith, A, 493
Smith, C, 513
Smith, K, 68, 69
Smith, L, 12
Smith, M, 198
Solla, J, 478
Solomon, B, 136, 139, 142, 153, 168
Sperling, L, 131
Squire, E, 2, 4, 6, 16
Stajduhar, K, 127
Stamatos, J, 448, 449, 452
Stamm, C, 184
Stevens, W, 501
Stoltzfus, D, 451, 470, 471, 473
Strickland, R, 240, 269, 270, 271, 272
Striker, L, 243
Summers, W, 456, 467
Swango, P, 64
Swartz, A, 288
Sweeney, J, 428
Tenuta, J, 496, 499
Tesar, J, 268
Theberge, D, 48
Tijerina, M, 288
Torrington, K, 262, 263, 264, 265
Tramont, E, 73
Tseng, Y, 146, 173, 176, 239
Turnicky, R, 55
Tzikas, T, 507
Villavicencio, L, 511
Wagner, K, 74
Wain, H, 436
Walden, B, 455
Ward, F, 210, 215, 221, 222, 223, 228
Ward, T, 480, 481

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Warden, D, 435  
Wartofsky, L, 136, 139, 146, 157, 165, 168, 173, 176, 177, 433  
Wehrle, A, 205  
Weidner, S, 265  
Weir, L, 437  
Weisman, L, 338, 350, 358  
Welch, P, 238, 240  
Wertz, F, 480, 481  
Weston, L, 121, 125, 127  
White, A, 46  
Wiley, T, 129  
Wiswell, T, 351  
Wong, R, 179, 182, 183, 186, 192, 198, 200, 201  
Wortham, D, 116, 117, 120  
Wray, H, 167  
Wright, D, 212, 218, 222, 227, 273  
Wynder, S, 493  
Yowler, C, 469  
Yuan, C, 241, 242, 244  
Zawadsky, P, 340, 342, 352, 353  
vander Dam, B, 492  

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

1,25-dihydroxyvitamin, 167
1,25-Dihydroxyvitamin D, 160
2,3-DPG, 217
24 hr pH monitoring, 183
5-alpha-reductase, 337
5-fluorouracil, 215, 221, 316, 326
5FU, 325
5FU/leucovorin, 224
ACE-inhibitor, 120
acetabular components, 503
achalasia, 182
acoustics, 457
acromegaly, 191
activation, 13
acuity, 434
acute leukemia, 100
acute myelocytic leukemia, 386
adaptation, 290
adenocarcinoma, 314, 329
adenocarcinoma/prostate, 524
adjuvant, 111, 114
adjuvant chemotherapy, 209
adjuvant radiotherapy, 530
adjuvant therapy, 98
adrenal imaging, 441
advanced, 303, 304, 317
advanced liquid diet, 291
adverse reactions, 12
Aethoxysklerol, 511
AHH, 42
AIDS, 53, 57, 62, 63, 78, 79
airway hyperreactivity, 260
ALL, 106, 107, 411, 412, 413
allergens, 5, 7, 11, 27
allergy, 8, 15
allergy immunotherapy, 12
alpha-interferon, 101
altitude, 266
ambivalence, 285
aminothiadiazole, 299
AML, 87, 91, 93
AML/CML, 92
amonafide, 110, 318
amphotericin B, 79, 232, 471
analgesia, 450
anaphylaxis, 22

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

androgen, 337
androgen blockage, 534
angioplasty, 123
ANLL, 392
ANP, 146, 173, 176, 239, 242
anti-hormones, 83
anti-idiotypic, 177
anti-inflammatory drugs, 201
anti-lymphocyte, 486
anti-neutrophil, 212
Anti-Ro/SSA, La/SSB, 268
antiarrhythmic therapy, 121
antibiotic, 513
antibiotic therapy, 342
antibody, 258, 485
antigen, 109, 178
antimony trisulfide, 442
aortic arch, 477
aortic stenosis, 116
Ara-C, 103, 391
ARC, 61
arrhythmia, 257
arthroscopic, 489
articulation index, 462
asphyxia, 343
aspirin, 506
assay, 45
asthma, 6, 16, 260
atrial natriuretic, 241
audiometric testing, 506
auditory models, 464
auditory-visual, 458
autoantibodies, 212, 268, 273
autoimmunity, 175, 269
autologous, 219, 220, 347
autologous bone marrow, 386
azathioprine, 483
AZT resistance, 74
B-adrenergic, 482
B-cell leukemia, 371
back pain, 491
bacteremia, 340
bacterial vaccines, 235
balloon, 123
Barrett's esophagus, 179
basal cell, 131

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

BEP, 523
bet'4 endorphine, 38
beta-carotene, 195, 200
beta-interferon, 276
biology, 165, 399
bird, 30
bladder cancer, 521
bleomycin, 313
blockers, 482
blood donors, 187
blood loss, 499
blood transfusion, 37
bone, 502, 514, 515
bone ingrowth, 495
bone marrow, 219, 220
bone mineral, 169
BPH, 525, 529
BPH dilator, 525
brain irradiation, 372
brain stem glioma, 418
brain tumors, 375, 381, 402
breast, 104
breast cancer, 83, 97, 98, 109, 114
breast milk, 3
bronchial epithelial, 518
bronchoalveolar, 333
bronchodilators, 252
bronchogenic carcinoma, 265
Brown dermatome, 133
BTOPS, 531
burnout, 429
bursitis, 272
c-ErbB-2, 527
c-reactive protein, 348
c. difficile, 45
Ca channel, 259
CA15-3 antigens, 85
calcium channel blocker, 278
calyceal stones, 533
cancer, 104, 135, 142, 215, 309, 526, 527
cancer pain, 449
candidiasis, 471
capnography, 470
capsaicin, 280
carbocyanine (DIO), 24
carbohydrate, 5

* Reference is to page numbers in Volume II.

198
carbonate, 186
carboplatin, 400
carcinoma, 150, 223, 293, 302, 303, 308, 311, 312, 333, 416
cardioplatin antibody, 216, 225
carotenoids, 189
carpal tunnel, 493
catheter, 125, 468, 469
cats, 341
causal models, 289, 290
cause of death, 55
CCNU, 277
CD69, 24, 31
ceftriaxone, 340
central venous catheter, 342
cervix, 293, 302, 317, 324
chemotherapy, 102, 104, 105, 111, 115, 219, 220, 363, 387, 392, 394, 413, 415, 417, 422, 423
chest radiography, 263
childhood, 387, 393, 395, 398, 412, 418, 419, 420, 421
childhood cancer, 406
childhood leukemia, 364
childhood tumor, 390
children, 389, 399, 400, 401, 402, 405, 408, 411, 422, 423
chlorambucil, 88
cholangitis, 185
cholesterol, 126
cholestyramine, 136
chondroplasty, 489
CHOPE, 112
chronic phosphate, 312
chromosome 10, 156
chronic myloid, 383
chronic stress, 339
CIDP, 20
cimetidine, 204
ciprofloxacin, 233
circadian function, 44
cirrhosis, 39
cis-platinum, 297, 320, 361, 362
cisapride, 190, 203
cisplatin, 246, 313, 316, 321, 325, 330, 391, 410, 418, 521
claudication, 117
clinical pharmacist, 425

* Reference is to page numbers in Volume II.
clinical reasoning, 429
clomiphene, 140
CML, 96
CNS relapse, 409
cobra catheters, 533
cognition, 274
cold, 141
colitis, 180
collagen, 47, 245
colloid, 442
colon cancer, 111, 200
colon mucosa, 518
colon polyps, 188, 195
colonic adenomas, 189
colonic neoplasia, 191
colorectal cancer, 224
combat injury, 288
combined therapy, 90
companion study, 96
compliance, 71
complications, 295
compressive nonlinearity, 465
computer, 519
concentration-controlled, 439
condylar measurements, 48
congenital anomaly, 477
conjugated Hib saccharide, 357
conjunctival monitor, 250
conscious sedatives, 454
continuity of care, 207
continuous infusion, 215
contrast sensitivity, 81
contrasuppressor, 17
conventional staging, 214
COPD, 248, 249, 251, 256, 259, 262
coping, 290
cornea, 479
coronary, 127
coronary vascular injury, 128
CRH, 38
critically ill, 470
cross reactivity, 9
crossover therapy, 88
cryoprecipitate, 35
cryopreservation, 334
cultures, 57

* Reference is to page numbers in Volume II.
SUBJECT INDEX

culturing, 468
Cushing's syndrome, 148
cutaneous microflora, 68
cyanooacrylate, 481
cyclooxygenase inhibition, 475
cyclophosphamide, 320
cyclophosphamide, 320
cyclosporin A, 244
cyclosporine, 157
cystectomy, 521
cytogenetics, 100, 403, 404
cytokines, 232
cytosine arabinoside, 396
cytotoxicity, 14
D. farinae, 4
D. pteronyssinus, 4
dacarbazine, 319
data base, 70
depression, 438, 439
dermatology, 69
Desert Shield, 428
diabetes, 144, 147, 155, 355
diabetes mellitus, 151, 229
diabetic gastroparesis, 190
diabetic patients, 498
diagnosis, 57, 406, 440
dialysis, 236, 237
diaminedichloroplatinum, 297
diarrhea, 1
Didemnin B, 323
differentiation, 228
diffuse, 368
diffuse liver disease, 193
diffusion, 513
digoxin, 120
dihydroxyanthracenedione, 298
dilated cardiomyopathy, 120
DIO, 13
disease progression, 50
dissociation, 436
diving reflex, 281
dizziness, 205
DNA, 327, 328, 329
down regulation, 23
doxorubicin, 321, 522
drug, 213
drug use, 70

* Reference is to page numbers in Volume II.
SUBJECT INDEX

DTH, 54
dural puncture, 448
dust mite, 7
E. coli, 234
ear canal SPL, 466
early HIV disease, 60
echinomycin, 310
echocardiography, 122
ectopic, 26
EDTA, 117
efficacy, 349
EGF, 40, 173, 294, 512
EGF-R, 174
electrocardiogram, 281
electrocardiograms, 129
electroencephalography, 282
electrophysiology, 435
ELISA, 27
embolism, 122
embryonal tumor, 419
emphysema, 251, 256, 266
endocrine, 160
endometrial, 311, 314, 321
endometrium, 176, 294, 303, 308
endothelial cells, 479
endothelin, 154, 244, 246
endotracheal, 341, 356
energy, 138
energy balance, 163
enteral absorption, 338
ependymomas, 363
epidemiology, 50, 56, 58, 64, 206, 393
epidermal growth factor, 174, 201
epidural, 449
epidural catheter, 448
epilepsy, 282
epitopes, 5
Epstein-Barr virus, 487
esophagitis, 197, 198
esophagus, 444
esophageal pressure, 254
estrogen, 176
ESWL, 533
etiology, 205
etoposide, 319
evoked potentials, 501

* Reference is to page numbers in Volume II.
SUBJECT INDEX

Ewing's sarcoma, 390
exercise, 248, 249, 253, 256
exophthalmos, 157
expenditures (costs), 426
extensor indicus proprius, 427
extracorporeal, 484
F wave response, 427
factor VIII, 35
family coping, 288
fat, 188
Fazarabine, 331
fetal HIV infection, 59
fever, 352
fiber, 188
fiberoptic bronchoscopy, 264, 265
fibrillation, 129
fibrinogen, 35
fibrosis, 247
first relapse, 388
fixation, 516
flow cytometry, 13, 14, 17, 18, 23, 28, 31, 32, 36,
    37, 84, 327, 328, 329, 528
fludarabine, 88
fludarabine phosphate, 226
fluorescence, 10
fluoxetine, 439
flutamide, 520, 529
FMOC-Leu, 28
foot length, 354
foot ulcerations, 498
Foscarnet, 78
fractures, 139
free radicals, 335
frequency resolution, 456, 464, 467
frontal lobe, 274
full liquid diet, 291
GABA, 39
gallium nitrate, 315
gas exchange, 259
gastric emptying, 184, 186
gastritis, 181, 192
gastroesophageal reflux, 179, 183, 194
gelatinase, 243
gene, 143, 149, 170
genetics, 402
GERD, 198

* Reference is to page numbers in Volume II.
germ cell, 307
gestation, 26
gestational age, 354
gestational diabetes, 138
GI blood loss, 204
glaucoma, 482
glipizide GITS, 151
glomerulonephritis, 245
glomerulosclerosis, 243
glucose, 171
glutathione, 479
glycosylated, 155
GM-CSF, 210
GME, 432
gonad, 345
gonadotropins, 158
gpl20, 76
gram-negative, 235
granulocytes, 222
Graves' disease, 157, 177
group, 296
group B streptococcal, 343
growth factor priming, 92
growth factors, 91, 517
growth hormone, 336, 355
guinea pig, 338
gynecologic, 296
gynecologic cancer, 297
H2 antagonists, 184
hairy cell leukemia, 101
halothane/caffeine, 446
hardiness, 284
harmonics, 463
headache, 448, 453
hearing aids, 466
hearing loss, 464
hearing-impaired, 455, 456, 458, 467
heart, 519
heart failure, 121
heart rate, 281
Helicobacter pylori, 181
hemodynamic responses, 451
hemoglobin S, 217
hemophilia A, 33
hepatitis C antibody, 187
hepatoblastoma, 401

* Reference is to page numbers in Volume II.
hepatocellular carcinoma, 401
heterosexual, 67
high-dose, 112
Hispanic, 440
histocompatibility, 33
histology, 55
HIV, 50, 51, 52, 61, 62, 63, 64, 67, 69, 71, 72, 73, 74, 145
HIV infection, 65, 75, 76, 80
HIV risk behaviors, 60
HIV-negative, 77
HIV-positive, 77
HLA, 162
hoarseness, 197
Hodgkin's disease, 115, 365, 385, 387, 393, 395
Holter monitor, 119, 124
homoharringtonine, 380
hormone refractory, 532
house dust mites, 4
human, 51, 154
human thyroid, 173
hydroxyurea, 319, 324
hymenoptera, 2
hypercalcemia, 164
hypercortisolemia, 148
hypersensitivity, 30
hyperthyroidism, 163, 168
hypnosis, 436
hypocalcemia, 474
hypocortisolemia, 148
hypogammaglobulinemia, 1
hypothyroidism, 168
hypoxia, 251, 266
I-131 MIBG, 443
I-131 NP-59, 441
ibuprofen, 192
ICAM-1, 19
ifosfamide, 223, 305, 306, 322, 373, 407
ifosfamide/VP-16, 378
IgE, 15
IgG subclasses, 2
IL-1, 504
immunization, 25
immunodeficiency, 21, 56
immunoglobulin, 1, 3, 20, 30, 107, 231, 338
immunohistochemical stain, 68

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

immunologic, 26
immunological changes, 29
immunology, 94, 108, 159
immunosuppression, 24
immunotherapy, 2, 11, 17, 65
implant, 513
impotence, 147
IND, 213, 230
indomethacin, 202
induction study, 92
infant, 352, 415, 466
infant brain tumor, 372
infant leukemia, 409
infection, 342, 469
inhaled bronchodilators, 262
inhibitor, 33
injuries, 428
inspiration, 252
insulin, 155
integrins, 273
intensive post remission, 93
interferon, 80, 224, 375, 383, 397
interleukin-1, 19
interleukin-2, 87
intervention, 287, 425
intolerant, 53
intracoronary, 125
intracoronary stents, 128
intramedullary fixation, 496
intraocular, 480
intravenous, 20
intubated, 509
intubation, 341
iodine 131, 152
iodine restriction, 142
iontophoresis, 270, 271, 272
irradiated blood, 332
irradiator, 31
irritable bowel syndrome, 203
ischemia, 127
isotretinoin, 131
IV immunoglobulin, 177
IVIG, 29, 350
job satisfaction, 289
ketoconazole, 158, 164
kidney, 238, 239, 241, 242

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

Klebsiella, 231, 258
knowledge, 287
kyphoscoliosis, 41
L5, 431
laboratory analysis, 411
laceration, 481
Langerhans' cells, 52
laparoscopy, 295
large cell, 370
laryngeal dysfunction, 6
laryngeal dyskinesia, 6
laryngotracheoplasty, 457
laser, 445
laser Doppler, 202
latex agglutination tests, 357
leishmaniasis, 230
leucovorin, 221
leukotriene B4, 23
leuprolide, 520
limited chemotherapy, 89
linden, 9
lipid, 358
lithium, 186, 433
lithotripsy, 454, 502
liver, 160, 167, 221, 445
liver failure, 484
localized, 379, 408
long bone, 496
long-term effects, 395
low back pain, 49
low-dose, 471
lubricants, 292
lung, 102
lung cancer, 82
lung mechanics, 253
lupus, 240
lupus anticoagulant, 216, 225
lupus nephritis, 240
lymph node positive, 99
lymphoblastic, 382
lymphoblastic leukemia, 384
lymphocyte, 10, 94, 334
lymphocytic leukemia, 226, 364
lymphoma, 112, 368, 370, 371

* Reference is to page numbers in Volume II.

207
SUBJECT INDEX*

lymphoscintigraphy, 442
macrophages, 52
magnesium, 161
magnetic, 275
malignancies, 318, 323, 326, 331
malignancy, 301, 306, 397
malignant, 300
malignant germ cell tumor, 405, 408
malignant glioma, 419
malignant hyperthermia, 446
malignant otitis externa, 132
mandibular movement, 48
manometry, 196, 199
mapping, 125
marathon running, 204
marksmanship, 81
marrow transplantation, 347
masking, 467
mast cell, 22
materials, 514, 515
maturation, 222
maxillary sinusitis, 509
mechanical ventilation, 262, 473
mechanics, 252
meconium, 349, 351
medical history, 286
medulloblastoma, 372, 410
MEN II, 156
meningitis, 79
Mesna, 305, 306
messenger RNA, 166
metastatic, 83
metastatic breast cancer, 85
metastatic neuroblastoma, 373
methotrexate, 16, 19, 185, 364, 376, 381, 495, 522
microbial flora, 132
microbiology, 55
microscopic/collagenous, 180
midazolam, 452
military, 430
military performance, 60
milk, 40
mitral stenosis, 116
MLC, 18
mls phenotype, 42
modeling, 519

* Reference is to page numbers in Volume II.
SUBJECT INDEX

moderate head injury, 279
molecular, 165
molecular biology, 171
monoclonal, 15, 51, 485
MOPP/ABVD, 365, 385
morale, 429
mortality, 425
motility, 292
motor evoked potentials, 275
motor system, 275
movement disorder, 278
MRI, 214, 494, 501
mucosal, 218
mucosal immunity, 21
mucosal injury, 192
multinodular goiter, 152
multiple sclerosis, 276
multitest, 54
myelodysplasia, 84, 113
myeloperoxidase, 229
myocardial infarction, 118, 124, 451
myocardial ischemia, 451
narcotics, 449
nasal CPAP, 254
nasopharyngeal, 416
natural history, 58, 63
natural killer cells, 14
neonatal, 346
neonate, 335, 343, 350, 354
nephroblastoma, 367
nephropathy, 355
neuroblastoma, 361, 373, 404, 414
neuromotor, 461
neuropsychological, 283
neuropsychology, 435
neutropenia, 212, 218
neutrophil, 28, 218, 229, 358
newborn infant, 351
nimodipine, 278
nocturnal, 183
nocturnal oxygenation, 41
nodal radiation, 385
node negative, 114
node positive, 97, 98
noise, 455
non-compliance, 424

* Reference is to page numbers in Volume II.
non-Hodgkin's lymphoma, 379
non-lymphoblastic, 380
non-small cell, 82
non-ulcer dyspepsia, 190, 203
normal-hearing, 460, 462
normovolemic, 472
nutrition, 43, 171
nutritional status, 284
obese, 153
obstruction, 238
obstructive sleep apnea, 34
occult, 340
ocular eye, 480
oligospermia, 140
oncogenes, 113, 172, 175
oncology, 108, 296
optic pathway tumors, 399, 400
oral diseases, 64
oral hairy leukoplakia, 487
orchiectomy, 524, 526
ornithine decarboxylase, 167
orofacial, 461
osteitis, 47
osteoarthritis, 269, 271, 489
osteogenesis imperfecta, 496
osteosarcoma, 369, 377
ovarian, 307, 309, 312
ovarian carcinoma, 316, 327, 330
ovarian tumors, 328
ovary, 300, 320
over age 60, 91
oxygen, 250
oxygen consumption (VO2), 473
p53, 150
pacing, 127
Paget's, 478
pain, 280, 287, 447
papillary, 308
pathologic Stage C, 530
patient satisfaction, 207
patient-controlled, 450
PCA, 500
PCP, 71
PDCF, 490
pediatric, 56, 414, 416, 452
pediatric tumors, 359

* Reference is to page numbers in Volume II.
PEG L-asparaginase, 389
pelvic, 301, 318, 323, 326, 331
pelvic malignancies, 298, 299, 310, 315
penetrating head injury, 283
pentamidine, 257
Pentostam, 230
pentostatin, 101
peptic ulcer, 181
perceptions, 432
performance, 43
perianal, 478
perinatal HIV, 58
pH monitoring, 199
pharmacodynamics, 110
pharmacoepidemiology, 70
pharmacokinetics, 66, 90, 103, 208
phase, 465
Phase I, 208
phenotype, 32
phenotypic changes, 29
pseudocytoma, 443
Philadelphia chromosome, 106
physical medicine, 432
physical therapy, 428
pneumocytomal, 134
pilot study, 44
pituitary, 344
pityriasis rosea, 134
platelets, 517
pleural fluids, 518
pleural pressure, 254
plugs, 47
pneumatic dilation, 182
pneumococcal, 25
pneumocytes, 333
POG, 376
polar, 141
pollen, 9
poly-ICLC, 277
polycarbonate, 480
polymerase chain reaction, 134, 267
polysaccharide, 25, 234
polysomnography, 34
poor prognosis, 209
poor risk, 413
poor risk Hodgkin's, 89

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

porcine, 166
porous, 488
positive relationship, 505
post dural puncture, 453
post traumatic epilepsy, 283
post-op radiation, 209
postmenopausal, 99, 139
potassium, 332
potency, 7
potential, 300
pravastatine, 126
predictors, 433
predisposing factor, 129
pregnancy, 491
pregnancy attitudes, 285
preoperative, 452
preoperative evaluation, 119
preparations, 486
prescription, 424, 426
pretransplant, 483
prevention, 49, 131
primary, 377
primary care, 207
primitive neuroectodermal, 390
probes, 137
processing, 512
prognosis, 205
progressive adenopathy, 226
prolactic, 346
proliferation, 10, 179, 200
promotion, 153
propofol, 454
prosody, 460
prostacyclin, 244, 246
prostate, 526, 527, 531
prostate cancer, 520, 530, 532, 534
prosthesis, 488
Pseudomonas, 231, 258
psychiatric, 206
psychosocial adaptation, 86
Puerto Rican, 440
pulmonary disease, 261
pulmonary function, 447
pulmonary function test, 261
pulmonary hypertension, 356
PWB spine system, 492

* Reference is to page numbers in Volume II.

212
SUBJECT INDEX*

pyridostigmine, 260, 336
pyridoxine, 493
rabies, 535
radial nerve, 427
radiation, 102, 314, 324, 325, 365
radiation therapy, 420
radiculopathy, 431
radiocontrast, 236
radioreceptor, 294
radiotherapy, 362, 410
randomized, 309
rare tumors, 359
RAS, 113
rat, 40
rats, 507
reactions to stress, 339
receptor positive, 97, 99
rectosigmoid, 202
recurrent, 377, 414
recurrent brain tumor, 407
recurrent disease, 494
recurrent sarcoma, 421
recurrent/refractory, 396
red cell antigens, 36
red cells, 32
reflex, 431
reflux, 196, 197
refractory disease, 392
regulator, 222
rehabilitation, 430
relapsed ALL, 389
renal failure, 169, 237
renal tumor, 367
repair, 514, 515
requirement, 138
residual clubfoot, 497
resolution, 463
respiratory control, 38, 39, 247
reticulocyte, 36, 37
retinitis, 78
retrospective analysis, 211
retroviral, 145
RFB, 264
rgpl60, 65, 75
rhabdomyosarcoma, 362, 376, 394, 398, 422, 423
rheumatoid arthritis, 270, 273, 444

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

rigid, 516
risk, 72
risk factors, 189
RNA, 143
rodent, 170
RSV, 350
salicylate, 506
saliva, 201
sarcoidosis, 255
sarcoma, 105, 304, 305, 322, 490
scans, 135
scar tensile strength, 505
schizophrenia, 434, 435
scintigraphy, 193, 196, 199
scleral, 481
sclerosant, 511
sclerosing, 185
scoliosis, 501
second induction, 417
second remission, 87
seizure, 282
self-care, 144
self-efficacy, 144
sense of coherence, 284
septic shock, 472, 475
sero-negative lupus, 268
seroconversion, 72
serum antibiotic levels, 499
severity, 459
sexual intercourse, 124
sexual maturation, 163
shock, 241, 242
shockwaves, 502
short stature, 336
sickle cell, 217
sickle cell disease, 348
silent ischemia, 118
sinusitis, 21
skeletal, 516
skeletal muscle, 446
skin test, 8, 11, 54
sleep, 41, 247
sleep apnea, 44, 250
sleep stage distribution, 77
small cell carcinoma, 214
smoking, 49

* Reference is to page numbers in Volume II.

214
soft tissue sarcoma, 366, 494
soldiers, 43
solid malignancy, 347
solid tumors, 378, 396
solitary pulmonary, 265
somatomedin C, 337
spectral, 463
spectral contrast, 465
speech kinematics, 459
speech perception, 455, 458, 460, 462
sperm, 292
spermatozoa, 162
spinal fusion, 492
spleen, 334
Sprotte needle, 453
squamous cell carcinoma, 317
stability, 27
Stage B2, 534
Stage I, 528
Stage II, 109
Stage III breast cancer, 90
Stage IV-S, 361
standard liquid diet, 291
status, 161
stem cells, 228
STHT system, 508
stomatococcus, 353
stress response, 450
stroke, 122
stuttering, 459, 461
suboptimal, 302
substernal goiter, 152
subtotal nodal radiation, 89
suction, 349
sulfasalazine, 180
suppressor, 13
supratentorial malignancy, 391
supratentorial tumor, 420
surgery, 474
survival, 121
survivors, 86
suspected malignancy, 264
symptom distress, 285
symptom onset, 406
symptoms, 206
synovial cell sarcoma, 366

* Reference is to page numbers in Volume II.
SUBJECT INDEX

syphilis, 73
T-cell, 374, 397
T-cell receptor, 107
T-lymphoblastic leukemia, 388
T-non-Hodgkin's lymphoma, 388
tamoxifen, 140, 311
tattoo, 133
Taxol, 330, 532
temporal resolution, 456
tendinitis, 272
teniposide, 301
tensile strength, 507, 510
tension, 510
testicular cancer, 523, 528
testosterone, 158
Tetraplatin, 208
therapy, 126, 255
thermogenic, 153
third trimester, 194
thoracentesis, 263
thoracotomy, 447
thyroid, 135, 136, 137, 141, 142, 143, 145, 146, 150, 154, 161, 165, 172, 178, 433, 474
thyroid disease, 159
thyroid glands, 166
thyroid hormone, 139, 239
thyroiditis, 175
thyrotoxicosis, 136
thyroxine, 237
TIMP, 245
TIMP-1, 243
tissue blocks, 211
TNF, 123, 344, 345
tolazoline, 356
tongue epithelium, 487
total joint, 488
total joint arthroplasty, 499
toxicity, 66
toxin B, 45
TPN, 469
transfusions, 483
transitional cell, 223
transmission, 67
transplant, 386
transplantation, 162, 485, 486
transport, 236, 470

* Reference is to page numbers in Volume II.

216
SUBJECT INDEX*

traumatic brain injury, 279
  treatment, 73, 151
  treatment complications, 360
TRH, 149
tri-modality, 82
triamcinolone acetonide, 255
tryptase, 22
TSH, 146, 149, 170
tuberculosis, 267
tumor marker, 490
tumor necrosis factor, 232, 240, 475
tumors, 307, 359, 363
turnover, 289
TURP, 531
ultradian rhythms, 438
ultrasound, 238, 445
ultraviolet light, 8
uncemented 503
undifferentiated, 368
unstable angina, 118
untreated, 93
untreated CML, 95
upper airway, 253
ureter, 295
uterine, 322
uterus, 304
utilization, 426
uvulopalatopharyngoplasty, 34
V-beta T cell receptor, 42
vaccine, 234
vaccine therapy, 75, 76
validation, 468
valvuloplasty, 116
varicose veins, 511
vascular ring, 477
vascular surgery, 119
venom immunotherapy, 12
ventilation, 248, 249
vinblastine, 522
VIP, 523
viral, 178
virus, 137
virus culture, 62, 74
vision, 434
vitamin A, 195
vitamin B6, 493

* Reference is to page numbers in Volume II.

217
SUBJECT INDEX*

vitamin D, 164
vitamin E, 335
voice, 457
VP-16, 313
Walter Reed stage, 69
war, 430
Wilms' tumor, 360, 367, 403
work of breathing, 473
wound, 517
wound closing tension, 505
wound healing, 504, 510
wounds, 507
WRAMC, 286
YAC, 156
yohimbine, 147
Zacopride Hydrochloride, 213
zidovudine, 53, 61, 66
zinc, 168, 198
zoladex, 524

* Reference is to page numbers in Volume II.